这是用户在 2024-10-8 22:23 为 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948217/ 保存的双语快照页面,由 沉浸式翻译 提供双语支持。了解如何保存?
Skip to main content 跳转到主要内容
美国国旗

美国政府的官方网站

访问键 NCBI 主页 MyNCBI 主页 事由 主导航
2022 年 3 月 24 日在线发布。 doi:10.1038/s41392-022-00934-y 假设:40.8 Q1
PMCID:PMC8948217 假设:40.8 Q1
PMCID:PMC8948217假设:40.8Q1

Notch 信号通路:结构、疾病和治疗

关联数据

补充材料

抽象

NOTCH 基因大约在 110 年前被发现。经典研究表明,NOTCH 信号转导是一种进化上保守的通路。NOTCH 受体经历 3 次切割并转位到细胞核中以调节靶基因的转录。NOTCH 信号转导深度参与多个组织和器官的发育和稳态,其畸变导致癌性和非癌性疾病。然而,最近的研究表明,NOTCH 信号转导的结果是多变的,并且高度依赖于环境。在癌症方面,NOTCH 信号转导可以促进和抑制各种类型癌症的肿瘤发展。NOTCH 靶向疗法在临床试验中的整体性能未能达到预期。此外,NOTCH 突变已被提议作为许多癌症免疫检查点阻断治疗的预测生物标志物。总的来说,需要用新的视角对 NOTCH 途径进行综合评估,以激发发现和应用。在这篇综述中,我们重点介绍了与 NOTCH 信号传导相关的经典和最新发现,以说明 NOTCH 通路的历史、结构、调节机制、对生理发育的贡献、相关疾病和治疗应用。还强调了 NOTCH 信号转导对肿瘤免疫微环境和癌症免疫治疗的贡献。我们希望这篇综述不仅能帮助初学者,也能帮助专家系统、彻底地了解 NOTCH 信号通路。

主题词: 药物开发, 靶标鉴定, 癌症微环境, 分化, 神经发生

介绍

NOTCH 基因在 1910 年代对具有缺口翅膀的黑腹果蝇的研究中首次命名.然后在多个后生动物中鉴定出 NOTCH 的同源物,所有这些 NOTCH 同源物具有相似的结构和信号转导成分.在古代人类中也发现了 NOTCH 变体,并被发现与大脑大小控制有关.通常,NOTCH 被认为是一种古老且高度保守的信号通路。NOTCH 信号转导参与跨物种的各种生物过程,例如器官形成、组织功能和组织修复;因此,异常的 NOTCH 信号传导可能会导致病理后果。

在过去的二十年里,各种靶向 NOTCH 信号转导的药物已在临床前和临床环境中进行了测试,但没有药物获得批准。最近的研究表明,NOTCH 通路比以前认为的要广泛和复杂得多。随着免疫疗法彻底改变了癌症治疗,NOTCH 信号转导及其与抗肿瘤免疫的关系引起了科学家的关注。

本文旨在阐明 NOTCH 信号通路的历史、结构、调节机制、与健康和疾病的关系以及治疗应用。关于 NOTCH 信号通路的特定行为,我们试图专注于哺乳动物的研究,而不是其他动物的研究。我们希望这篇综述不仅能帮助初学者,也能帮助专家系统、彻底地了解 NOTCH 信号通路。

Notch 信号转导简史

NOTCH 基因在 1910 年代对具有缺口翅膀的黑腹果蝇突变体的研究中首次被描述.NOTCH 的单倍体不足导致黑腹果蝇的翅膀末端有缺口,而完全不足是致命的。这种表型的发现激发了后来提出的命名法。然后分离黑腹果蝇 NOTCH 基因和 sequenced在 1980 年代,发现推定的 NOTCH 蛋白跨越膜并包含许多表皮生长因子 (EGF) 样重复序列.然后,对黑腹果蝇中 NOTCH 信号传导的研究增加,引起对整个信号通路的注意。1988 年和 1989 年,LIN-12 和 GLP-1 被鉴定为秀丽隐杆线虫中的 NOTCH 同源物,似乎与秀丽隐杆线虫的发育有关.1990 年,在非洲爪蟾中发现了 XOTCH(黑腹果蝇 NOTCH 的同源物),并克隆了哺乳动物 NOTCH 基因的 cDNA.从那时起,对其他动物的 NOTCH 的研究越来越受欢迎。NOTCH 信号转导的更多细节已经阐明,因此,NOTCH 已被公认为一种古老且高度保守的后生动物信号转导通路.

1991 年,NOTCH 基因首次与人 T 细胞急性淋巴细胞白血病 (T-ALL) 有关。1997 年,发现 Alagille 综合征 (AGS) 是由编码 NOTCH1 配体的 JAG1 突变引起的.AGS 是一种非癌性常染色体显性遗传病,其特征是多个器官发育异常。自这些发现以来,NOTCH 与人类健康和疾病的关系得到了广泛的研究。此外,还进行了转化研究。2006 年启动了第一个涉及 NOTCH 信号传导的临床试验,使用 γ-分泌酶抑制剂治疗 T-ALL 或其他白血病患者.由于严重腹泻而停止,但结果在很大程度上促进了 NOTCH 信号传导的治疗靶向。在临床前和临床环境中,已经探索了靶向 NOTCH 信号转导其他成分的各种药物和抗体,但尚未获得批准。近年来,出现了许多新的研究,例如详细的结构分析、复杂调控机制分析,以及健康和疾病中的多种功能分析,突出了 NOTCH 信号传导的一些未探索领域。NOTCH 信号转导的简史如图 2 所示。图 1.1.需要对 NOTCH 信号转导有深入的了解;因此,需要付出更多的努力。

包含图片、插图等的外部文件。
对象名称为 41392_2022_934_Fig1_HTML.jpg

NOTCH 信号通路的简史。T-ALL,T 细胞急性淋巴细胞白血病;AGS,Alagille 综合征;GSI,γ-分泌酶抑制剂

Notch 信号的架构

NOTCH 信号通路具有某些特征。由 G 蛋白偶联受体 (GPCR) 介导的经典信号通路和酶联受体,在膜受体和核效应子之间具有多个中间体。然而,经典的 NOTCH 信号通路没有中间通路,受体在三次切割后直接转位到细胞核中21,41,42 元(图 .(图 2)。2).此外,NOTCH 受体的 S2 切割是由与相邻细胞上表达的配体的相互作用触发的,表明 NOTCH 信号转导的范围相当狭窄。NOTCH 信号传导参与后生动物生活的多个方面,包括细胞命运决定、胚胎和组织发育、组织功能和修复,以及非癌性和癌性疾病。因此,了解 NOTCH 信号通路的结构是必要的。

包含图片、插图等的外部文件。
对象名称为 41392_2022_934_Fig2_HTML.jpg

Overview of the NOTCH signaling pathway and therapeutic targets. In signal-receiving cells, NOTCH receptors are first generated in the ER and then trafficked to the Golgi apparatus. During trafficking, NOTCH receptors are glycosylated at the EGF-like repeat domain (red curves). Then, in the Golgi apparatus, NOTCH receptors are cleaved into heterodimers (S1 cleavage) and transported to the cell membrane. With the help of ubiquitin ligases, some of the NOTCH receptors on the cell membrane are endocytosed into endosomes. Endosomes contain an acidic environment with ADAMs and γ-secretase. The NOTCH receptors in endosomes can be recycled to the cell membrane, cleaved into NICD, or transported into lysosomes for degradation. In signal-sending cells, NOTCH ligands are distributed on the cell membrane and can bind to NOTCH receptors on signal-receiving cells. However, the ligands are inactive before ubiquitylation by Neur or Mib. After ubiquitylation, ligands can be endocytosed, thus producing a pulling force for the binding receptors. Without the pulling force, the S2 site (red marks) of NOTCH receptors is hidden by the NRR domain, and thus, the NOTCH receptors are resistant to cleavage by ADAMs. With the pulling force, the NRR domain is extended, therefore exposing the S2 site for cleavage. ADAMs and the pulling force are both necessary for S2 cleavage. After S2 cleavage, the remaining part of the NOTCH receptor is called NEXT. NEXT can be further cleaved on the cell membrane by γ-secretase or endocytosed into endosomes. In the former mode, NICD is released on the cell membrane. In the latter mode, NEXT can be cleaved into NICD or transported into lysosomes for degradation. In total, there are three approaches to generate NICD, classified as ligand-independent activation, ligand-dependent endocytosis-independent activation, and ligand-dependent endocytic activation. NICD can be translocated into the nucleus or remain in the cytoplasm to crosstalk with other signaling pathways, such as NFκB, mTORC2, AKT, and Wnt. The classical model proposes that, in the absence of NICD, CSL binds with corepressors to inhibit the transcription of target genes. Once NICD enters the nucleus, it can bind with CSL and recruit MAMLs, releasing corepressors, recruiting coactivators, and thus promoting the transcription of NOTCH target genes. There are two main approaches to inhibit NOTCH signaling for therapy. One is designing inhibitors of the key components of the pathways, including the enzymes that participate in S1 cleavage, ADAMs, γ-secretase, and MAML. The other one is producing antibody-drug conjugates against NOTCH receptors and ligands. The protein structures of NOTCH ligands and receptors are shown in the top left corner. NICD, NOTCH intracellular domain; ADAM, a disintegrin and metalloproteinase domain-containing protein; Neur, Neuralized; Mib, Mindbomb; NRR, negative regulatory region; NEXT, NOTCH extracellular truncation; CSL, CBF-1/suppressor of hairless/Lag1; MAMLs, Mastermind-like proteins; TM, transmembrane domain; RAM, RBPJ association module; ANK, ankyrin repeats; PEST, proline/glutamic acid/serine/threonine-rich motifs; NLS, nuclear localization sequence; CoR, corepressor; CoA, coactivator; ub, ubiquitin
NOTCH信号通路和治疗靶点概述。在信号接收细胞中,NOTCH受体首先在ER中产生,然后被运输到高尔基体。在运输过程中,NOTCH受体在EGF样重复结构域被糖基化(红色曲线)。然后,在高尔基体中,NOTCH受体被切割成异源二聚体(S1切割)并运输到细胞膜。在泛素连接酶的帮助下,细胞膜上的一些NOTCH受体被内吞到内体中。内体含有酸性环境,含有亚当斯和γ-分泌酶。内体中的NOTCH受体可以再循环到细胞膜,裂解成NICD,或转运到溶酶体中进行降解。在信号发送细胞中,NOTCH配体分布在细胞膜上,并可与信号接收细胞上的NOTCH受体结合。然而,配体在被Neur或Mib泛素化之前是无活性的。 在泛素化之后,配体可以被内吞,从而对结合受体产生拉力。在没有拉力的情况下,NOTCH受体的S2位点(红色标记)被NRR结构域隐藏,因此,NOTCH受体对亚当斯的切割具有抗性。在拉力的作用下,NRR结构域延伸,因此暴露S2位点进行切割。S2断裂需要亚当斯和拉力。S2裂解后,NOTCH受体的剩余部分称为NEXT。NEXT可以在细胞膜上被γ-分泌酶进一步切割或内吞到内体中。在前一种模式中,NICD在细胞膜上释放。在后一种模式中,NEXT可以被切割成NICD或转运到溶酶体中进行降解。总的来说,有三种方法来产生NICD,分为配体非依赖性激活、配体依赖性内吞非依赖性激活和配体依赖性内吞激活。 NICD可以被转移到细胞核中或保留在细胞质中以与其他信号传导途径如NFκB、mTORC 2、AKT和Wnt交叉。经典模型认为,在NICD缺失的情况下,CSL与辅阻遏物结合以抑制靶基因的转录。一旦NICD进入细胞核,它可以与CSL结合并募集MAML,释放辅阻遏物,募集辅激活物,从而促进NOTCH靶基因的转录。抑制NOTCH信号传导用于治疗有两种主要方法。其中之一是设计该途径关键组分的抑制剂,包括参与S1切割的酶、亚当斯、γ-分泌酶和MAML。另一个是生产针对NOTCH受体和配体的抗体-药物缀合物。NOTCH配体和受体的蛋白质结构显示在左上角。 NICD,NOTCH胞内结构域; ADAM,一种含有去整合素和金属蛋白酶结构域的蛋白; Neur,神经化; Mib,Mindbomb; NRR,负调控区; NEXT,NOTCH胞外截短; CSL,CBF-1/无毛抑制因子/Lag 1; MAML,Mastermind样蛋白; TM,跨膜结构域; RAM,RBPJ关联模块; ANK,锚蛋白重复序列; PEST,富含脯氨酸/谷氨酸/丝氨酸/苏氨酸的基序; NLS,核定位序列; CoR,辅阻遏物; CoA,辅激活物; ub,泛素

The receptors and ligands of NOTCH signaling
NOTCH信号的受体和配体

D. melanogaster has only one NOTCH receptor. C. elegans has two redundant NOTCH receptors, LIN-12 and GLP-1. Mammals have four NOTCH paralogs, NOTCH1, NOTCH2, NOTCH3, and NOTCH4, showing both redundant and unique functions. In humans, NOTCH1, NOTCH2, NOTCH3, and NOTCH4 are located on chromosomes 9, 1, 19, and 6, respectively. After transcription and translation, NOTCH precursors are generated in the endoplasmic reticulum (ER) and then translocated into the Golgi apparatus. In the ER, the NOTCH precursors are initially glycosylated at the EGF-like repeat domain. Glycosylations include O-fucosylation, O-glucosylation, and O-GlcNAcylation, which are catalyzed by the enzymes POFUT1, POGLUT1, and EOGT1, respectively. Subsequently, in the Golgi apparatus, O-fucose is extended by the Fringe family of GlcNAc transferases, while O-glucose is extended by the xylosyltransferases GXYLT1/2 and XXYLT1. The glycosylation of NOTCH is vital to its stability and function. Alteration of core glycosylation enzymes severely inhibits the activity of NOTCH signaling, making these enzymes vital for further research.
D.黑腹果蝇只有一个NOTCH受体C.线虫具有两个冗余的NOTCH受体,LIN-12和GLP-。哺乳动物有四个NOTCH旁系同源物,NOTCH 1,NOTCH 2,NOTCH 3和NOTCH 4,显示出冗余和独特的功能。在人类中,NOTCH 1、NOTCH 2、NOTCH 3和NOTCH 4分别位于染色体9、1、19和6上。在转录和翻译后,NOTCH前体在内质网(ER)中产生,然后易位到高尔基体中。在ER中,NOTCH前体最初在EGF样重复结构域处糖基化。糖基化包括O-岩藻糖基化、O-葡糖基化和O-GlcNAc酰化,其分别由酶POFUT 1、POGLUT 1和EOGT 1催化。 随后,在高尔基体中,0-岩藻糖通过GlcNAc转移酶的Fringe家族延伸,而0-葡萄糖通过木糖基转移酶GXYLT 1/2和XXYLT 1 - 。NOTCH的糖基化对它的稳定性和功能至关重要。核心糖基化酶的改变严重抑制NOTCH信号传导的活性 - ,使得这些酶对于进一步研究至关重要。

The glycosylated NOTCH precursors undergo S1 cleavage in the Golgi apparatus before being transported to the cell membrane. The cleavage always occurs at a conserved site (heterodimerization domain) and is catalyzed by a furin-like protease, cutting NOTCH into a heterodimer (mature form). Here, we take mouse NOTCH1 as an example to illustrate the structure of mature NOTCH on the cell membrane.
糖基化的NOTCH前体在被转运至细胞膜之前在高尔基体中经历S1裂解。切割总是发生在保守位点(异源二聚化结构域),并由弗林蛋白酶样蛋白酶催化,将NOTCH切割成异源二聚体(成熟形式)。在此,我们以小鼠NOTCH1为例来说明细胞膜上成熟NOTCH的结构。

The extracellular domain (N-terminal) contains 36 EGF-like repeats and a negative regulatory region (NRR). The 11th and 12th EGF-like repeats usually interact with ligands, although a new study found that many more motifs of the extracellular domain are involved in ligand binding. The NRR domain is composed of three cysteine-rich Lin12-NOTCH repeats (LNRs) and a heterodimerization region critical for S2 cleavage. Located after the membrane-spanning region, the intracellular RBPJ association module (RAM) domain is responsible for interacting with transcription factors in the nucleus, and seven ankyrin repeat (ANK) domains are observed in the RAM domain. Nuclear localization sequences are located on both sides of the ANK domains. At the end of the intracellular domain (C-terminus), there are conserved proline/glutamic acid/serine/threonine-rich motifs (PEST domains) that contain degradation signals and are thus critical for the stability of the NOTCH intracellular domain (NICD). Mammalian NOTCH2-4 have similar structures to NOTCH1, diverging mainly in the number of EGF-like repeats, the glycosylation level of the EGF-like repeats, and the length of the PEST domains. The level of NOTCH receptors on the cell membrane is controlled by constitutive endocytosis, which is promoted by ubiquitin ligases. An appreciable amount of NOTCH receptors are ubiquitinated and degraded in the proteosome, while the rest are expressed on the cell membrane to transmit signals.
细胞外结构域(N-末端)含有36个EGF样重复和一个负调控区(NRR)。第11和第12个EGF样重复序列通常与配体相互作用,尽管一项新的研究发现细胞外结构域的更多基序参与配体结合。NRR结构域由三个富含半胱氨酸的Lin 12-NOTCH重复序列(LNR)和一个对S2裂解至关重要的异源二聚化区组成。位于跨膜区之后的细胞内RBPJ结合模块(RAM)结构域负责与核内转录因子相互作用,在RAM结构域中观察到7个锚蛋白重复(ANK)结构域。核定位序列位于ANK结构域的两侧。 在胞内结构域的末端(C-末端),存在保守的富含脯氨酸/谷氨酸/丝氨酸/苏氨酸的基序(PEST结构域),其包含降解信号,因此对于NOTCH胞内结构域(NICD)的稳定性是关键的。哺乳动物的NOTCH 2 -4与NOTCH 1具有相似的结构,主要在EGF样重复序列的数量、EGF样重复序列的糖基化水平和PEST结构域的长度上不同。细胞膜上NOTCH受体的水平由组成性内吞作用控制,而组成性内吞作用由泛素连接酶促进。相当数量的NOTCH受体在蛋白体中被泛素化和降解,而其余的在细胞膜上表达以传递信号。

Humans and mice have five acknowledged NOTCH ligands,,: delta-like ligand 1 (DLL1), delta-like ligand 3 (DLL3), delta-like ligand 4 (DLL4), Jagged-1 (JAG1), and Jagged-2 (JAG2), all of which present redundant and unique functions. For instance, DLL1 governs cell differentiation and cell-to-cell communication, DLL3 suppresses cell growth by inducing apoptosis, DLL4 activates NF-κΒ signaling to enhance vascular endothelial factor (VEGF) secretion and tumor metastasis, JAG1 enhances angiogenesis, and JAG2 promotes cell survival and proliferation.
人类和小鼠具有五种公认的NOTCH配体:δ样配体1(DLL 1)、δ样配体3(DLL 3)、δ样配体4(DLL 4)、Jagged-1(JAG 1)和Jagged-2(JAG 2),所有这些都呈现冗余和独特的功能。例如,DLL 1支配细胞分化和细胞间通讯,DLL 3通过诱导细胞凋亡抑制细胞生长,DLL 4激活NF-κ B信号传导以增强血管内皮因子(VEGF)分泌和肿瘤转移,JAG 1增强血管生成,并且JAG 2促进细胞存活和增殖

The structures of the NOTCH ligands are partially similar to those of the receptors. The ligands are also transmembrane proteins, and the extracellular domains contain multiple EGF-like repeats, which determine the crosstalk with corresponding receptors. The levels and functions of the ligands are also controlled by ubiquitylation and endocytosis (discussed in the section “Ligand ubiquitylation”).
NOTCH配体的结构与受体的结构部分相似。配体也是跨膜蛋白,并且细胞外结构域包含多个EGF样重复,其决定与相应受体的串扰。配体的水平和功能也受泛素化和内吞作用控制(在“配体泛素化”部分讨论)。

The canonical NOTCH signaling pathway
经典的NOTCH信号通路

The mature NOTCH receptors on the cell membrane are heterodimers, with the heterodimerization domain being cleaved in the Golgi apparatus (S1 cleavage). Generally, binding to extracellular domains of NOTCH receptors allows ligands to initiate endocytosis. Such endocytosis induces receptors to change their conformation, exposing the enzymatic site for S2 cleavage. Receptors then experience S3 cleavage, changing into the effector form: NOTCH intracellular domain (NICD). NICD is degraded in the cytoplasm or transported into the nucleus to regulate the transcription of target genes (Fig. (Fig.22).
细胞膜上的成熟NOTCH受体是异源二聚体,其中异源二聚化结构域在高尔基体中被切割(S1切割)。通常,与NOTCH受体的细胞外结构域的结合允许配体引发内吞作用。这种内吞作用诱导受体改变其构象,暴露酶促位点用于S2裂解。然后受体经历S3裂解,转变为效应物形式:NOTCH胞内结构域(NICD)。NICD在细胞质中降解或转运到细胞核中,调节靶基因的转录(图2 -2)。

S2 cleavage is the only ligand-binding step and is thus vital for signal initiation. The structural basis of S2 cleavage is illustrated in Fig. Fig.2.2. The S2 site (metalloprotease site) is hidden by the LNR domain in the silent phase, referred to as the “autoinhibited conformation”. Once bound with ligands, the receptor extends the LNR domain and exposes the S2 site for cleavage. The core enzymes for S2 cleavage include a disintegrin and metalloprotease 10 (ADAM 10) and its isoforms ADAM 17 and ADAMTS1, which are popular targets for drug discovery. The product of S2 cleavage (larger part) is composed of the transmembrane domain and the intracellular domain, which is also called NOTCH extracellular truncation (NEXT).
S2裂解是唯一的配体结合步骤,因此对于信号起始至关重要。S2裂解的结构基础如图2所示2.第一章S2位点(金属蛋白酶位点)在沉默期被LNR结构域隐藏,称为“自抑制构象”。一旦与配体结合,受体延伸LNR结构域并暴露S2位点用于切割 - 。S2裂解的核心酶包括解整合素和金属蛋白酶10(ADAM 10)及其同种型ADAM 17和ADAMTS - ,它们是药物发现的流行靶标。 S2裂解的产物(大部分)由跨膜结构域和胞内结构域组成,也称为NOTCH胞外截短(NEXT)

NEXT is further cleaved at the S3 site, releasing NICD, which can be translocated into the nucleus and function as a transcription factor. The enzyme responsible for S3 cleavage is γ-secretase, which contains the catalytic subunits presenilin1 or presenilin2 (PS1 or PS2),, APH-1, PEN-2, and nicastrin (NCT). However, the classical substrates for γ-secretase contain NOTCH receptors and amyloid precursor protein (APP), the successive cleavage of which is related to Alzheimer’s disease. The structural basis for γ-secretase to recognize NOTCH or APP had remained unclear until recently, when Yigong Shi’s team elucidated the structural basis,. In short, the transmembrane helix of NOTCH or APP closely interacts with the surrounding transmembrane helix of PS1 (the catalytic subunit of γ-secretase); thus, the hybrid β-sheet promotes substrate cleavages, although some differences exist between NOTCH and APP. Structural information would accelerate the discovery of substrate-specific inhibitors of NOTCH and APP. Additionally, S3 cleavage can occur both on the cell membrane and in the endosome after NEXT is endocytosed, termed the endocytosis-independent model and endocytic-activation model, respectively.
NEXT在S3位点进一步裂解,释放NICD,其可以易位到细胞核中并作为转录因子发挥作用。负责S3裂解的酶是γ-分泌酶,其含有催化亚基早老素1或早老素2(PS1或PS2)、APH-1、PEN-2和nicastrin(NCT)。然而,γ-分泌酶的经典底物含有NOTCH受体和淀粉样前体蛋白(APP),其连续裂解与阿尔茨海默病相关 - 。γ-分泌酶识别NOTCH或APP的结构基础一直不清楚,直到最近,Yigong Shi的团队阐明了结构基础。 简而言之,NOTCH或APP的跨膜螺旋与周围PS1的跨膜螺旋(γ-分泌酶的催化亚基)密切相互作用;因此,尽管NOTCH和APP 73之间存在一些差异,但杂合β-折叠促进底物裂解。结构信息将加速NOTCH和APP的底物特异性抑制剂的发现。此外,在NEXT被内吞后,S3裂解可以发生在细胞膜上和内体中,分别称为内吞作用独立模型和内吞激活模型74。

After release from the cell membrane, NICD is translocated into the nucleus to regulate gene transcription, the mechanism of which may be related to the nuclear localization sequences of NICD and importins alpha 3, 4, and 7. However, the details of this translocation remain unclear. CBF-1/suppressor of hairless/Lag1 (CSL, also called recombination signal binding protein-J, RBPJ) is a ubiquitous transcription factor (TF) that recruits other co-TFs to regulate gene expression,. The target genes of NOTCH signaling are largely determined by the Su (H) motif of CSL, which is responsible for DNA binding. The canonical NOTCH target gene families are Hairy/Enhancer of Split (HES) and Hairy/Enhancer of Split related to YRPW motif (HEY).
从细胞膜释放后,NICD易位到细胞核中以调节基因转录,其机制可能与NICD和导入素α 3、4和7的核定位序列有关。然而,这种易位的细节仍然不清楚。CBF-1/无毛抑制因子/Lag 1(CSL,也称为重组信号结合蛋白-J,RBPJ)是一种普遍存在的转录因子(TF),其募集其他co-TF来调节基因表达。NOTCH信号传导的靶基因主要由CSL的Su(H)基序决定,其负责DNA结合。典型的NOTCH靶基因家族是与YRPW基序(HEY)21相关的Hairy/裂解增强子(HES)和Hairy/裂解增强子

In the traditional model of NICD regulating gene transcription,,,, CSL recruits corepressor proteins and histone deacetylases (HDACs) to repress the transcription of target genes without NICD binding. NICD binding can change the conformation of the CSL-repressing complex, dissociating repressive proteins and recruiting activating partners to promote the transcription of target genes. The transcriptional coactivator Mastermind-like protein (MAML) is one of the core activating partners that can recognize the NICD/CSL interface, after which it recruits other activating partners. Drugs targeting MAML are under study.
在NICD调节基因转录的传统模型,CSL招募辅阻遏蛋白和组蛋白脱乙酰酶(HDAC)来抑制靶基因的转录,而无需NICD结合。NICD结合可改变CSL-阻遏复合物的构象,解离阻遏蛋白并募集激活配偶体以促进靶基因的转录。转录辅激活因子类主蛋白(MAML)是识别NICD/CSL界面的核心激活配偶体之一,在识别NICD/CSL界面后,MAML会招募其他激活配偶体。针对MAML的药物正在研究中。

Recently, Kimble et al. used single-molecule fluorescence in situ hybridization to study the NOTCH transcriptional program in germline stem cells of C. elegans and found that NICD dictated the probability of transcriptional firing and thus the number of nascent transcripts. However, NICD did not orchestrate a synchronous transcriptional response in the nucleus, in contrast to that seen in the classical model. Gomez-Lamarca et al. found similar results in D. melanogaster. NICD promoted the opening of chromatin and enhanced the recruitment of both the NICD-containing activating CSL complex and the NICD-free repressive CSL complex. Bray et al. proposed a new model to interpret their findings. In the NOTCH-off state, chromatin is compact, and only the NICD-free (repressing) CSL complex regulates transcription. In the NOTCH-on state, chromatin is loosened and bound to both NICD-containing (activating) and NICD-free (repressive) CSL complexes. Because the number of activating complexes is greater than that of repressive complexes after NICD enters the nucleus, NICD promotes the transcription of target genes. Bray et al. further reported that nucleosome turnover occurred frequently at NOTCH-responsive regions and depended on the Brahma SWI/SNF chromatin remodeling complex. Consistently, Kimble et al. found that NOTCH signaling regulated the duration of the transcriptional burst but not the intensity of signaling or the time between bursts. Oncogenic NOTCH is also considered to enhance repositioning to promote the transcription of genes, such as MYC. In general, the new model from Bray et al. helps explain the flexibility of NOTCH signaling, although the details still require further elucidation.
最近,Kimble等利用单分子荧光原位杂交技术研究了C. elegans,并发现NICD决定了转录触发的概率,从而决定了新生转录本的数量。然而,NICD并没有在细胞核中协调同步转录反应,这与经典模型中所见相反。Gomez-Lamarca等在D. . history of life NICD促进了染色质的开放,并增强了含NICD的激活CSL复合物和无NICD的抑制CSL复合物的募集。Bray等人提出了一个新的模型来解释他们的发现。在NOTCH关闭状态下,染色质是紧凑的,只有无NICD(抑制)的CSL复合物调节转录。 在NOTCH-on状态下,染色质松动并结合到含NICD(激活)和无NICD(抑制)的CSL复合物上。由于NICD进入细胞核后,激活复合物的数量大于抑制复合物的数量,因此NICD促进了靶基因的转录。Bray等人进一步报道,核小体更新频繁发生在NOTCH反应区,并依赖于Brahma SWI/SNF染色质重塑复合物。同样,Kimble等人发现NOTCH信号调节转录爆发的持续时间,但不调节信号的强度或爆发之间的时间。致癌性NOTCH也被认为增强重新定位以促进基因(如MYC 84)的转录。一般来说,来自Bray等人的新模型。 有助于解释NOTCH信令的灵活性,尽管细节仍需要进一步阐明。

The noncanonical NOTCH signaling pathway
非经典NOTCH信号通路

Pathways other than canonical signaling pathway are also able to initiate signaling, classified as noncanonical NOTCH signaling pathways. Although the mature NOTCH receptors on the cell membrane are capable of ligand binding, some are endocytosed for renewal. Endocytosed NOTCH receptors can return to the cell membrane, be degraded in lysosomes or activated in endosomes (ligand-independent activation),. Interestingly, endosome trafficking can also be regulated by NOTCH signaling. Endosomes have been proven to contain ADAM and γ-secretase. Ligand-independent activation of NOTCH signaling is vital to T cell development. One example of ligand-independent activation is T cell receptor (TCR)-mediated self-amplification. The activated TCR/CD3 complex can activate the signaling axis of LCK-ZAP70-PLCγ-PKC. PKC then activates ADAM and γ-secretase on the endosome to initiate S2 and S3 cleavage and thus NOTCH signaling. Activated NOTCH signaling can further upregulate immune-related genes to amplify the immune response.
除了规范信号传导途径之外的途径也能够启动信号传导,被分类为非规范NOTCH信号传导途径。尽管细胞膜上的成熟NOTCH受体能够与配体结合,但有些被内吞以进行更新。内吞的NOTCH受体可以返回到细胞膜,在溶酶体中降解或在内体中活化(配体非依赖性活化)。有趣的是,内体运输也可以通过NOTCH信号传导调节。已证实内体含有ADAM和γ-分泌酶。NOTCH信号传导的配体非依赖性激活对T细胞发育至关重要。配体非依赖性活化的一个实例是T细胞受体(TCR)介导的自身扩增。 活化的TCR/CD 3复合物可激活LCK-ZAP 70-PLCγ-PKC信号轴。然后PKC激活内体上的ADAM和γ-分泌酶以启动S2和S3切割,从而启动NOTCH信号传导。激活的NOTCH信号可以进一步上调免疫相关基因以放大免疫应答。

Independent of CSL, NICD can interact with the NF-κB, mTORC, PTEN, AKT, Wnt, Hippo, or TGF-β pathways at the cytoplasmic and/or nuclear level to regulate the transcription of target genes,. The crosstalk between NICD and NF-κB affects the malignant properties of cervical cancer, colorectal cancer, breast cancer, and small-cell lung cancer cells. Targeting the NF-κB pathway could be an effective way to block noncanonical NOTCH signaling.
独立于CSL,NICD可以在细胞质和/或细胞核水平上与NF-κB、mTORC、PTEN、AKT、Wnt、Hippo或TGF-β途径相互作用,以调节靶基因的转录 - 。NICD和NF-κB之间的串扰影响宫颈癌、结肠直肠癌、乳腺癌和小细胞肺癌细胞。靶向NF-κB通路可能是阻断非经典NOTCH信号传导的有效途径。

In addition to those mentioned above, there is a newly identified mechanism of noncanonical activation. In the classical model, S3 cleavage is necessary for NOTCH receptors to release NICD and thus regulate the transcription of target genes. However, membrane-tethered NOTCH may activate the PI3K-AKT pathway, promoting the transcription of interleukin-10 and interleukin-12. In blood flow-mediated NOTCH signaling, the transmembrane domain instead of NICD recruits other partners to promote the formation of an endothelial barrier. NOTCH3 itself can promote the apoptosis of tumor endothelial cells, independent of cleavage and transcription regulation. The JAG1 intracellular domain can promote tumor growth and epithelial–mesenchymal transition (EMT) without binding to NOTCH receptors. These noncanonical mechanisms provide this ancient signaling pathway with more unique functions while massively increasing its complexity.
除了上面提到的那些,还有一个新发现的非典型激活机制。在经典模型中,S3切割对于NOTCH受体释放NICD并因此调节靶基因的转录是必需的。然而,膜栓系的NOTCH可以激活PI 3 K-AKT通路,促进白细胞介素-10和白细胞介素-12 100的转录。在血流介导的NOTCH信号传导中,跨膜结构域而不是NICD募集其他配偶体以促进内皮屏障的形成。NOTCH 3本身可以促进肿瘤内皮细胞的凋亡,不依赖于切割和转录调节。JAG 1胞内结构域可以促进肿瘤生长和上皮-间质转化(EMT),而不结合NOTCH受体。 这些非经典机制为这个古老的信号通路提供了更多独特的功能,同时大大增加了它的复杂性。

The mechanisms regulating NOTCH signaling
调控NOTCH信号的机制

Glycosylation 基化

The glycosylation of NOTCH receptors on specific EGF-like repeats is crucial for the maturation of receptors, which also affects signaling output. First, O-fucosylation catalyzes the enzyme Pofut1 to affect ligand binding. Elimination of Pofut1 greatly influences the ligand binding of NOTCH signaling in embryonic stem cells, lymphoid cells, and angiogenic cells of mice. The aberration of fringe family proteins, which catalyzes the elongation of O-fucose, can also affect ligand binding. Second, O-glucose of NOTCH receptors is involved in S2 cleavage. Alteration of O-glucosylation damages the proteolysis of NOTCH receptors after ligand binding,. Third, the sites of O-glycosylation, such as EGF 12, are important regions for ligand binding, the loss of which decreases NOTCH signaling in T cells. Furthermore, EGF 28 might contribute to DLL1-mediated NOTCH1 signaling. Targeting glycosylation is also thought to effectively inhibit NOTCH signaling.
NOTCH受体在特定EGF样重复序列上的糖基化对于受体的成熟至关重要,这也影响信号输出。首先,O-岩藻糖基化催化酶Pofut 1影响配体结合。Pofut 1的消除极大地影响小鼠胚胎干细胞、淋巴样细胞和血管生成细胞中NOTCH信号传导的配体结合 - 。边缘家族蛋白的畸变(其催化0-岩藻糖的延伸)也可影响配体结合 - 。其次,NOTCH受体的O-葡萄糖参与S2裂解。O-葡糖基化的改变损害配体结合后NOTCH受体的蛋白水解。 第三,O-糖基化位点,如EGF 112,是配体结合的重要区域,其损失降低T细胞112中的NOTCH信号传导。此外,EGF 28可能有助于DLL 1介导的NOTCH 1信号传导。靶向糖基化也被认为有效抑制NOTCH信号传导

Receptor trafficking 受体运输

After S1 cleavage, most mature NOTCH proteins are transported to the cell membrane. However, reaching the membrane does not guarantee stability. NOTCH receptors are constitutively endocytosed through a process modulated by ubiquitin ligases such as FBXW, NUMB, ASB, DTX1, NEDD4, ITCH, and CBL,. Endocytosed NOTCH can be recycled to the cell membrane or trapped in the cytoplasm; thus, receptor trafficking can directly affect the level of NOTCH receptors on the cell membrane. Furthermore, the endocytosed NOTCH receptors in the cytoplasm can be degraded or activated. Degradation is usually initiated by the endosomal sorting complex required for transport (ESCRT) system, the failure of which also lays the foundation for receptor activation. However, the mechanism of ligand-independent activation remains clear. The balance between degradation and activation after endocytosis is closely related to downstream signaling. The specific distribution of receptors and ligands on the cell membrane can also influence the regional intensity of NOTCH signaling.
S1裂解后,大多数成熟的NOTCH蛋白被转运到细胞膜。然而,到达膜并不能保证稳定性。NOTCH受体通过由FBXW、NUMB、ASB、DTX 1、NEDD 4、ITCH和CBL 74、115 - 118等遍在蛋白连接酶调节的过程被组成性内吞。内吞的NOTCH可以再循环到细胞膜或被捕获在细胞质74中;因此,受体运输可以直接影响细胞膜上的NOTCH受体的水平。此外,细胞质中内吞的NOTCH受体可以被降解或活化。降解通常由转运所需的内体分选复合物(ESCRT)系统 - 启动,其失效也为受体活化奠定了基础。 然而,配体非依赖性激活的机制仍然清楚 - 。内吞作用后降解和活化之间的平衡与下游信号传导密切相关。受体和配体在细胞膜上的特异性分布也可以影响NOTCH信号传导的区域强度

Ligand ubiquitylation 配体泛素化

Unlike the ubiquitylation of NOTCH receptors, ubiquitylation of ligands (usually catalyzed by Neuralized (Neur) and Mindbomb (Mib)) in signal-sending cells is necessary for signaling activation. Without Neur or Mib, NOTCH signaling decreases significantly. One explanation is that the endocytosis of ligands promotes exposure of the NRR domain of the receptor for S2 cleavage,.
与NOTCH受体的泛素化不同,信号发送细胞中配体的泛素化(通常由Neuralized(Neur)和Mindbomb(Mib)催化)是信号激活所必需的。在没有Neur或Mib的情况下,NOTCH信号传导显著降低 - 。一种解释是配体的内吞作用促进受体的NRR结构域暴露于S2裂解

Cis-inhibition 顺式抑制

Receptors and ligands expressed on different cells can initiate signal transduction. However, receptors and ligands expressed on the same cell both inhibit and activate the whole signaling pathway, termed cis-inhibition and cis-activation,. DLL3 seems to operate only in cis-inhibition,. The loss of DLL3 increases NOTCH activity during T cell development in vivo. DLL1-NOTCH1 can function in both cis- and trans-activation. Thus, the balance between cis- and trans-interactions can be vital to signaling output.
在不同细胞上表达的受体和配体可以启动信号转导。然而,在同一细胞上表达的受体和配体都抑制和激活整个信号传导途径,称为顺式抑制和顺式激活。DLL 3似乎仅在顺式抑制中起作用。DLL 3的缺失增加体内T细胞发育期间的NOTCH活性。DLL 1-NOTCH 1可以在顺式和反式激活中起作用。因此,顺式和反式相互作用之间的平衡对信号输出至关重要。

Other regulatory mechanisms
其他调节机制

Various signals regulate the transcription of NOTCH receptors and thus the whole signaling pathway, such as AKT, RUNX1, SIRT6, CBFB, and DEC1. Many noncoding RNAs regulate the level of NOTCH receptors, such as microRNA-26a, microRNA-26b, microRNA-153, microRNA-182, and microRNA-34a. Nitric oxide regulates the activity of ADAM17 and USP9X and ultimately NOTCH signaling,. Calzado et al. found that dual-specificity tyrosine-regulated kinase 2 (DYRK2) phosphorylated the NOTCH1 intracellular domain to promote its degradation by FBXW7. In the classical model, NOTCH signaling is prompted through the interaction between receptors and ligands in extracellular domains. However Suckling et al. found that the interaction between the C2 domain of NOTCH ligands and the phospholipid membrane of receptor-containing cells modulated NOTCH signaling. This finding provides a possible explanation for the diversified consequences of NOTCH signaling mediated by different ligand–receptor interactions.
各种信号调节NOTCH受体的转录,从而调节整个信号传导途径,例如AKT、RUNX 1、SIRT 6、CBFB和DEC 1 - 。许多非编码RNA调节NOTCH受体的水平,例如microRNA-26 a、microRNA-26 b、microRNA-153、microRNA-182和microRNA-34 a - 。一氧化氮调节ADAM 17和USP 9 X的活性,并最终调节NOTCH信号传导。Calzado等人发现,双特异性酪氨酸调节激酶2(DYRK 2)磷酸化NOTCH 1胞内结构域以促进其被FBXW 7降解。在经典模型中,NOTCH信号传导通过细胞外结构域中受体和配体之间的相互作用来促进。然而,萨克林等人。 发现NOTCH配体的C2结构域与含受体细胞的磷脂膜之间的相互作用调节NOTCH信号传导。]这一发现为不同配体-受体相互作用介导的NOTCH信号传导的多样化结果提供了可能的解释。

Notch signaling in organ development and repair
Notch信号在器官发育和修复中的作用

As a highly conserved signaling pathway, NOTCH deficiency leads to serious embryonic lethality. NOTCH signaling is active in the early stage of embryonic development but is maintained at a low level in the mature stage of body development. It also increases rapidly under conditions of injury or stress and is indispensable for development and injury repair (Fig. (Fig.3).3). First, NOTCH signaling promotes the self-renewal and dedifferentiation of stem and progenitor cells, thus maintains progenitor stemness and the stem cell pool. Among these cells, neural stem cells and multipotent progenitor cells (MPCs), are classic representatives. Different combinations of NOTCH ligands and receptors promote stem cell proliferation and inhibit terminal differentiation. Second, NOTCH signaling is involved in the selection of cell fate. Based on temporal and spatial expression of NOTCH ligands, receptors, and cell-enriched transcription factors, NOTCH signaling induces fixed differentiation of progenitor cells, such as differentiation of cardiac progenitor cells into endocardial cells and hepatoblasts into bile duct lineage cells,. Furthermore, NOTCH signaling is vital to maintaining the homeostasis of the body in normal regeneration and damage repair. NOTCH signaling can rapidly regulate the dynamic transformation of cells to maintain physiological homeostasis, such as stem cells and tail cells in angiogenesis, through lateral inhibition. It also induces the differentiation and transformation of mature cells to promote damage repair, for example, in liver regeneration. Last, numerous ligands and receptors are involved in NOTCH signaling and have specified temporal and spatial expression in various organs and tissues, although the consequences are similar.
作为一种高度保守的信号通路,NOTCH缺陷导致严重的胚胎致死。NOTCH信号在胚胎发育的早期阶段是活跃的,但在身体发育的成熟阶段维持在低水平。在受伤或压力的情况下,它也会迅速增加,对发育和损伤修复是必不可少的(图3)。3)。首先,NOTCH信号促进干细胞和祖细胞的自我更新和去分化,从而维持祖细胞的干性和干细胞库。在这些细胞中,神经干细胞 - 和多能祖细胞(MPC)是经典的代表。 NOTCH配体和受体的不同组合促进干细胞增殖并抑制终末分化。其次,NOTCH信号转导参与细胞命运的选择。基于NOTCH配体、受体和富含细胞的转录因子的时间和空间表达,NOTCH信号传导诱导祖细胞的固定分化,例如心脏祖细胞分化成内皮细胞和成肝细胞分化成胆管谱系细胞。此外,NOTCH信号传导对于维持身体在正常再生和损伤修复中的稳态至关重要。NOTCH信号传导可以通过侧向抑制快速调节细胞的动态转化以维持生理稳态,例如血管生成中的干细胞和尾细胞 - 。 它还诱导成熟细胞的分化和转化以促进损伤修复,例如在肝再生中。最后,许多配体和受体参与NOTCH信号传导,并且在各种器官和组织中具有特定的时间和空间表达,尽管结果是相似的。

An external file that holds a picture, illustration, etc.
Object name is 41392_2022_934_Fig3_HTML.jpg

The role of NOTCH signaling in body development and damage repair. NOTCH signaling is involved in regulating the differentiation and function of stem cells, affecting organ production and damage repair. a NOTCH signaling promotes the self-renewal of stem cells, induces multipotent progenitors for lineage selection, and generates different terminal cells; when the organ is damaged, cell type A is damaged and destroyed, and the stimulated cell type B rapidly upregulates the expression of NOTCH signaling to promote their own proliferation, and is partially redifferentiated into cell type A. b Highly activated NOTCH induces the expression of bile duct cell-enriched transcription factors and promotes the differentiation of multipotent hepatocyte progenitors into bile duct epithelial cells. c In liver injury, BEC are damaged and destroyed. NOTCH signaling is highly expressed in hepatocytes, which are further transformed into biphenotypic cells, which manifests the biliary tract morphology, and finally generate new BEC (BEC’) to form small tubular structures. HPC, hematopoietic progenitor cell; BEC, bile duct epithelial cell; SOX9, SRY-related high-mobility group box 9; HNF, hepatocyte nuclear factor
NOTCH信号在身体发育和损伤修复中的作用。NOTCH信号参与调节干细胞的分化和功能,影响器官的产生和损伤修复。aNOTCH信号促进干细胞的自我更新,诱导多能祖细胞进行谱系选择,产生不同的终末细胞;当器官受损时,A型细胞被损伤破坏,受刺激的B型细胞迅速上调NOTCH信号的表达,促进自身增殖,并部分再分化为A型细胞。B高度活化的NOTCH诱导胆管细胞富集的转录因子的表达,并促进多能肝细胞祖细胞分化为胆管上皮细胞。c在肝损伤中,BEC被破坏和破坏。 NOTCH信号在肝细胞中高度表达,肝细胞进一步转化为双表型细胞,其表现出胆道形态,并最终产生新的BEC(BEC ')以形成小的管状结构。 HPC,造血祖细胞; BEC,胆管上皮细胞; SOX 9,SRY相关高迁移率族蛋白9; HNF,肝细胞核因子

NOTCH and somitogenesis NOTCH与体节发生

The somitogenesis of vertebrates occurs in a strict order and is regulated by the segmentation clock. It is closely related to the expression of oscillating genes regulated by NOTCH, Wnt and FGF signaling. NOTCH signaling triggers an excitatory signal, causing presomitic mesoderm (PSM) to transition into a self-sustaining cyclic oscillation state,. The gene oscillation period is consistent with the half-life of HES7 and induces lunatic fringe (Lfng) transcription. LFNG, as a glycosyl transferase that can modify the extracellular domain of NOTCH after translation and periodically blocks the cleavage of NOTCH receptors, causes the formation of cyclic NICD. PSM is a group of self-sustaining oscillating cells, but the synchronous oscillation between depends on the transmission of NOTCH signaling. LFNG inhibits the activation of NOTCH signaling in neighboring cells by regulating the function of DLL1,,. In Lfng-knockout mice, PMS oscillation fails to synchronize, but PMS oscillation amplitude and period remain unaffected. This finding further demonstrates that LFNG is a key coupling factor for synchronous oscillations between cells.
脊椎动物的体节发生有严格的顺序,并受到体节时钟的调控。它与由NOTCH、Wnt和FGF信号传导调节的振荡基因的表达密切相关 - 。NOTCH信号传导触发兴奋性信号,导致分裂前中胚层(PSM)转变成自持循环振荡状态。基因振荡周期与HES 7 165的半衰期一致,并诱导疯狂边缘(Lfng)转录。LFNG作为糖基转移酶,可以在翻译后修饰NOTCH的细胞外结构域并周期性地阻断NOTCH受体的切割,导致环状NICD - 。 PSM是一组自维持振荡小区,但是它们之间的同步振荡取决于NOTCH信令 - 。LFNG通过调节DLL 1的功能来抑制相邻细胞中NOTCH信号传导的激活。在Lfng敲除小鼠中,PMS振荡未能同步,但PMS振荡幅度和周期保持不受影响。这一发现进一步证明LFNG是细胞间同步振荡的关键耦合因子。

NOTCH and skeleton 缺口和骨架

In the growth and development of MPC, NOTCH signaling regulates and inhibits the production of osteoblasts, chondrocytes, and osteoclasts, through different ligands and receptors (NOTCH1, NOTCH2, JAG1, DLL1) as well as the downstream target gene (SRY-related high-mobility group box 9, SOX9). In addition, the latest research shows that inhibiting glucose metabolism can guide NOTCH to regulate MPC, proving the complex role of NOTCH signaling in the skeletal microenvironment. In the mouse model, the absence of NOTCH signaling leads to depletion of MPC and nonunion of fractures, consistent with the finding that activated JAG1-NOTCH signaling reduces MPC senescence and cell cycle arrest. Interestingly, using γ-secretase inhibitors intermittently and temporarily for fractures significantly promotes cartilage and bone callus formation, as well as superior strength. This indicates that NOTCH signaling exerts its function in a temporally and spatially dependent manner.
在MPC的生长和发育中,NOTCH信号通过不同的配体和受体(NOTCH 1、NOTCH 2、JAG 1、DLL 1)以及下游靶基因(SRY相关高迁移率族蛋白9,SOX 9)调节和抑制成骨细胞151、软骨细胞174 - 178和破骨细胞179、180的产生。此外,最新研究表明,抑制葡萄糖代谢可以引导NOTCH调节MPC,证明了NOTCH信号在骨骼微环境中的复杂作用。在小鼠模型中,NOTCH信号传导的缺乏导致MPC的消耗和骨折不愈合,这与活化的JAG 1-NOTCH信号传导减少MPC衰老和细胞周期停滞的发现一致。 有趣的是,间歇性和暂时性使用γ-分泌酶抑制剂治疗骨折可显著促进软骨和骨痂形成,以及上级强度。这表明NOTCH信号以时间和空间依赖的方式发挥其功能。

NOTCH and cardiomyogenesis
NOTCH与心肌发生

During heart wall formation, NOTCH signaling regulates the ratio of cardiomyocytes to noncardiomyocytes by inhibiting myogenesis, further promoting atrioventricular canal remodeling and maturation, EMT development and heart valve formation. In the endocardium layer, the DLL4-NOTCH1-mediated Hey1/2-Bmp2-Tbx2 signaling axis is a complex negative feedback regulation loop, where overexpressed Tbx2 can in turn inhibit upstream Hey expression. In embryos lacking key NOTCH signaling molecules such as Notch1, Rbpj, Hey1/Heyl, or Hey2, EMT development is hindered, and endocardial cells are activated but fail to scatter and invade heart glia. NOTCH signaling affects the expression of the cadherin 5 and the TGF-β family member bone morphogenetic protein 2 (BMP2),. In addition, by downregulating VEGFR2, a key negative regulator of EMT within atrioventricular canals (AVCs), NOTCH signaling further induces EMT. Studies have found that active NOTCH1 is most highly expressed in endocardial cells at the base of the trabecular membrane. Bone morphogenetic protein 10 (BMP10) and Neuregulin 1 (NRG1) are key molecules of NOTCH signaling that regulate the proliferation, differentiation, and correct folding of cardiomyocytes during trabecular development.
在心脏壁形成期间,NOTCH信号传导通过抑制肌生成来调节心肌细胞与非心肌细胞的比率,进一步促进房室管重塑和成熟、EMT发育和心脏瓣膜形成 - 。在内分泌层中,DLL 4-NOTCH 1介导的Hey 1/2-Bmp 2-Tbx 2信号传导轴是一个复杂的负反馈调节环,其中过表达的Tbx 2可以反过来抑制上游Hey表达 - 。在缺乏关键NOTCH信号分子如Notch 1RbpjHey 1/Hey 1Hey 2的胚胎中,EMT发育受阻,内皮细胞被激活,但不能分散和侵入心脏胶质细胞。 NOTCH信号传导影响钙粘蛋白5和TGF-β家族成员骨形态发生蛋白2(BMP 2)。此外,通过下调VEGFR 2(房室管(AVC)内EMT的关键负调节因子),NOTCH信号传导进一步诱导EMT。研究发现,活性NOTCH 1在小梁膜基底的内皮细胞中表达最高。骨形态发生蛋白10(BMP 10)和神经调节蛋白1(NRG 1)是NOTCH信号传导的关键分子,其在小梁发育期间调节心肌细胞的增殖、分化和正确折叠。

NOTCH and the vasculature
Notch和脉管系统

NOTCH4 and DLL4 are specifically expressed on vascular endothelial cells (ECs),. Deficiencies in NOTCH signaling result in serious defects in the vasculature of the embryo and yolk sac during embryonic development as well as abnormal development of multiple organs, such as the retinal vasculature, and uterine blood vessels in rats. At the cellular level, the vascular system mainly includes ECs, pericytes and vascular smooth muscle cells (VSMCs). Under stressors such as hypoxia, resting ECs quickly transform into a state of active growth and high plasticity and then dynamically transform between tip cells (TCs) and stalk cells (SCs) through lateral inhibition rather than direct lineage changes,. This cascade reaction between DLL4-mediated NOTCH signaling and VEGFA-VEGFR2 signaling induces ECs near dominant TCs to maintain a high level of NOTCH signaling, inhibiting their differentiation into TCs,. NOTCH signaling activates the Wnt pathway through feedback regulation to maintain the connection between ECs, promoting vascular stability. In addition, DLL4-NOTCH can maintain arterial blood–retinal barrier homeostasis by inhibiting transcytosis. NOTCH signaling is also important for the development of VSMCs,. Blocking Notch signaling in neural crest cells, especially NOTCH2 and NOTCH3, results in vascular dysplasia, aortic defects, and even bleeding,. The regulation of the downstream transcription factors PAX1, SCX, and SOX9 by NOTCH signaling is vital for regulating the differentiation of progenitor cells in the sclera toward VSMCs.

NOTCH signaling acts decisively in the arteriovenous differentiation of endothelial cells,. NOTCH signaling induces the expression of the arterial marker ephrin B2 and inhibits that of the venous marker EphB4, thereby regulating the number and diameter of arteriovenous vessels,. In mice with dysfunctional mutations of NOTCH signaling molecules such as Notch1, Dll4, Hey1, or Hey2, the arterial subregion is defective, while venous differentiation is hyperactive, leading to unexpected bleeding,,. Before blood perfusion, active NOTCH signaling on the arterial side can be detected. High levels of VEGF, ERK/MAP kinase and Wnt pathway components increase DLL4 expression,, and the transcription factors Fox1C and Fox2C promote DLL4 activation. Interestingly, ECs can sense and respond to laminar flow through NOTCH1, similar to the shear stress response, transforming the hemodynamic mechanical force into an intracellular signal, which is necessary for vascular balance,.
NOTCH信号传导在内皮细胞的动静脉分化中起决定性作用。NOTCH信号传导诱导动脉标志物肝配蛋白B2的表达并抑制静脉标志物EphB4的表达,从而调节动静脉血管210、211的数量和直径。在具有NOTCH信号分子如Notch 1Dll 4、Hey 1Hey 2的功能失调突变的小鼠中,动脉亚区是有缺陷的,而静脉分化是过度活跃的,导致意外出血。在血液灌注之前,可以检测到动脉侧的活性NOTCH信号传导。 高水平的VEGF、ERK/MAP激酶和Wnt途径组分增加DLL 4表达,并且转录因子Fox 1CFox 2C促进DLL 4活化。有趣的是,EC可以感测并响应通过NOTCH 1的层流,类似于剪切应力响应,将血液动力学机械力转化为血管平衡所必需的细胞内信号

NOTCH and the hemopoietic system
NOTCH与造血系统

NOTCH signaling is important in the differentiation, development, and function of hematopoietic system cells, both lymphocytes and myeloid cells. In early embryonic development, the hematopoietic endothelium forms hematopoietic stem cells through NOTCH-dependent endothelial-to-hematopoietic transition. NOTCH signaling is fundamental in maintaining the number and stemness of hematopoietic stem cells. In lymphocyte development, the absence of NOTCH1 or CSL in early hematopoietic progenitor cells (HPCs) leads to thymic T cell development retardation and B cell accumulation, with HES1 being the key mediator. Naïve thymocytes highly express NOTCH and immediately downregulate NOTCH1 expression once they successfully pass β-selection. Some scholars propose that NOTCH-mediated T cell development is initiated in the prethymic niche,. For example, bone mesenchymal cells outside the thymus can cross-link with HPCs through NOTCH ligands on the surface to promote the generation of T cell lineages,. Shreya S et al. induced the production of HSPC-derived CD7+ progenitor T cells with DLL4 and VCAM-1 in vitro engineering, and these cells further differentiated into mature T cells after thymus transplantation. Regarding B cells, the development of splenic marginal zone B (MZB) cells depends on DLL1-NOTCH2 signaling,. In addition, it was found that active NOTCH2 signaling can mediate the lineage conversion of follicular B cells into MZB cells so that mature B cell subpopulations can quickly and dynamically transform based on the needs of the immune system,. The development of innate lymphoid cells (ILCs) was recently found to be NOTCH-dependent, and the response of different subtypes of ILCs to NOTCH signaling is heterogeneous,. It is interesting that ILCs can activate MZB cells through DLL1 to enhance antibody production. Regarding myeloid cells, NOTCH signaling is significant in the development of macrophages,, dendritic cells,, granulocytes, etc.
NOTCH信号传导在造血系统细胞(淋巴细胞和骨髓细胞)的分化、发育和功能中是重要的。在早期胚胎发育中,造血内皮通过NOTCH依赖性内皮向造血转化形成造血干细胞。NOTCH信号传导在维持造血干细胞220的数量和干细胞性中是基本。在淋巴细胞发育中,早期造血祖细胞(HPC)中缺乏NOTCH 1或CSL导致胸腺T细胞发育迟缓和B细胞积累,其中HES 1是关键介体。幼稚胸腺细胞高度表达NOTCH,一旦它们成功通过β-选择,立即下调NOTCH 1表达。 一些学者提出NOTCH介导的T细胞发育起始于胸腺前龛222,223。例如,胸腺外的骨髓间充质细胞可以通过表面上的NOTCH配体与HPC交联以促进T细胞谱系的产生224、225。Shreya S等人用DLL4和VCAM-1体外工程诱导HSPC衍生的CD7+祖T细胞的产生,并且这些细胞在胸腺移植后进一步分化为成熟T细胞226。关于B细胞,脾边缘区B(MZ B)细胞的发育取决于DLL1-NOTCH 2信号传导227,228。 此外,发现主动NOTCH 2信号传导可以介导滤泡B细胞向MZ B细胞的谱系转化,使得成熟的B细胞亚群可以根据免疫系统的需要快速且动态地转化。最近发现先天性淋巴样细胞(ILC)的发育是NOTCH依赖性的 - ,并且不同亚型的ILC对NOTCH信号传导的应答是异质的。有趣的是,ILC可以通过DLL 1激活MZB细胞以增强抗体产生。 关于骨髓细胞,NOTCH信号传导在巨噬细胞、树突细胞、粒细胞等的发育中是重要的。

NOTCH and the liver

NOTCH signaling plays a key role in determining the fate of biliary tract cells and directing the correct morphogenesis of the biliary tree. Active NOTCH signaling, especially mediated by NOTCH2 and JAG1, promotes the expression of transcription factors enriched in bile duct cells, induces the differentiation of hepatocytes toward bile duct cells, and promotes the formation of the bile duct plates,. The expression of SOX9, a downstream molecule of NOTCH signaling, is synchronized with the asymmetric development of the bile duct,, with a mouse model of liver-specific deletion of Sox9 echoing this finding. Interestingly, delayed biliary tract development caused by liver-specific deletion of Sox9 eventually resolves in a spontaneous manner, proving that SOX9 plays a major role in timing regulation through the development of the biliary tract.

The liver has a strong compensatory regeneration ability, where NOTCH signaling responds quickly with significant upregulation, and the transformation of hepatocytes into bile duct-like cells can be observed (Fig. (Fig.3c).3c). Similarly, high levels of dual-phenotype hepatocytes can also be observed in liver slices of patients with early liver diseases. Additionally, in a mouse orthotopic liver transplantation model, a high level of NOTCH1 (NICD and HES1) signaling was found to have a protective effect on hepatocytes during ischemia–reperfusion injury, regulating macrophage immunity. In incomplete liver injury, NOTCH signaling mediates the proliferation and differentiation of facultative progenitor cells, thereby promoting biliary tract repair. Such damage repair can be induced mainly by NOTCH2,, consistent with the discovery of the role of NOTCH2 signaling in the differentiation and selection of liver progenitor cells during liver development.

NOTCH and the gastrointestinal tract

Studies have shown that NOTCH signaling prevents embryonic epithelial cells from differentiating into secretory lineages, with Hes1 being the main negative regulator. Highly activated NOTCH signaling promotes the differentiation of intestinal stem cells toward intestinal epithelial cells. Inhibiting NOTCH signaling increases the differentiation of secretory goblet cells. Additionally, the lateral inhibition of NOTCH/DLL1 and the synergy of the Wnt signaling pathway drive Paneth cell differentiation and subsequent crypt formation. NOTCH signaling is also essential in the lineage selection of gastric stem cells and necessary to maintain the homeostasis of gastric antral stem cells. Activated NOTCH signaling in differentiated mature gastric epithelial cells induces their dedifferentiation. NOTCH signaling is also vital to the proliferation of pancreatic progenitor cells and their correct differentiation into mature pancreatic cells,. DLL1 and DLL4 are specifically expressed in β cells, while JAG1 is expressed in α cells. The DLL1-NOTCH-HES1 signaling axis promotes the growth and fate selection of multipotent pancreatic progenitor cells, while JAG1 competes with DLL1 to induce opposite effects.

NOTCH and the nervous system

NOTCH signaling negatively regulates neurogenic phenotypes. Its absence induces differentiation of neural stem cells toward neurons at the cost of glial cell production, in both D. melanogaster and vertebrates. There are two mainstream models: the classic lateral inhibition model that is similar to vascular development and the model involving oscillatory expression of HES1, NEUROG2 and DLL1. In addition, NOTCH signaling promotes the differentiation of most glial cell subtypes, except for oligodendrocytes. In the peripheral nervous system, the interaction between NOTCH signaling and Hairy2 is vital for the development of neural crest cells, although the specific regulatory mechanism remains unclear. Active NOTCH signaling blocks the occurrence and stratification of the trigeminal nerve, leading to disorders of brain development. Furthermore, NOTCH signaling drives intestinal neural crest cells to develop into precocious glial cells in Hirschsprung disease,. These results indicate that NOTCH signaling participates in neural crest differentiation, but further exploration is required.

NOTCH and other organs or systems

NOTCH signaling functions throughout lung development and the damage repair process. Components of NOTCH signaling are highly expressed in various cells and tissues during lung development. Inhibition of NOTCH signaling or RBPJ deficiency causes defects in proximal airway differentiation, club-cell secretion inhibition, and excessive proliferation of ciliated cells and neuroendocrine cells. NOTCH2 is the main factor activating alveolar morphogenesis and maintaining airway epithelial integrity. NOTCH signaling mediates the balance between the proliferation and differentiation of basal cells. In damage repair, NOTCH2 in basal cells is activated, promoting the separation of cell lineages and producing secretory cells.

NOTCH signaling is important in cell lineage selection, epidermal homeostasis and skin function. NOTCH signaling in the skin promotes cell differentiation, while NOTCH in hair follicles inhibits cell differentiation, promotes proliferation and maintains stemness. Notch signaling is also closely related to cilia cell proliferation, differentiation and morphogenesis and may be involved in asymmetric cell division in the embryonic epidermis,. NOTCH signaling regulates sebaceous gland stem cells directly and indirectly. In Rbpj-deficient mice, the differentiation of sebaceous stem cells is inhibited, and the number of sebaceous glands (SGs) is reduced, with compensatory, enlarged SGs still existing. Many skin diseases have been found to have NOTCH signaling changes, such as hidradenitis suppurativa, psoriasis, and atopic dermatitis,.

Notch signaling in noncancerous diseases

As mentioned above, NOTCH signaling is essential for body development and homeostasis, indicating that NOTCH signaling is vital for the occurrence and development of diseases. Most genetic diseases caused by NOTCH mutations have a low incidence and lack effective treatment. For example, the first discovered related disorder, Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), has no effective treatment other than supportive treatment. The prognosis of only a few patients with AGS can be improved through liver transplantation, suggesting that further research is necessary. Most of the diseases caused by nonmutant NOTCH signaling abnormalities present corresponding developmental characteristics. New and interesting findings have appeared recently. For example, NOTCH signaling may be related to alcohol-associated preference, playing an important role in nonalcoholic fatty liver disease. We will now focus on the manifestations of NOTCH signaling abnormalities in diseases caused by congenital or nongenetic mutations (Table (Table11).

Table 1

NOTCH Signaling in Noncancerous diseases

Disease typeKey NOTCH componentsAffected organs/tissueMain manifestationsRef.
Diseases related to abnormal expression of NOTCH signaling factors caused by gene mutation
CADASILNOTCH3Arterioles of the brainParticulate osmophilic substances are deposited near VSMCs; arterial damage and brain damage,,,
Alagille syndromeNOTCH2, JAG1Multiple organs and systemsAbsence of bile ducts, cholestasis; peripheral arterial stenosis; specific facial features,,
Spondylocostal dysostosisDLL3, MESP2, HES7Vertebral columnMalformed ribs, asymmetrical rib cage, short trunk,
Hajdu-Cheney diseaseNOTCH2Skeletal tissueTruncated NOTCH2 proteins escape ubiquitylation and degradation, mediating active NOTCH2 signaling; osteoporosis, craniofacial anomalies
Left ventricle cardiomyopathyMIB1HeartPromotes the engulfment of NOTCH ligands, inhibits NOTCH signal transduction; hinders ventricular myocardium development,
Adams-Oliver syndromeNOTCH1, RBPJ, DLL4Skin, limbsScalp hypoplasia, terminal transverse limb defects,
Bicuspid aortic valve diseaseNOTCH1, RBPJ, JAG1Cardiac valvesRelated to valvular disorders of EMT and valve calcification
SchizophreniaNOTCH4BrainOne of the strongest candidate susceptibility genes for schizophrenia,
Diseases related to abnormal expression of NOTCH signaling factors caused by factors other than gene mutation
Pulmonary arterial hypertensionNOTCH1, NOTCH3Pulmonary vasculatureECs and VSMCs hyperproliferation and activation; vascular remodeling, pulmonary artery obstruction,,,
Nonalcoholic steatohepatitisNOTCH1, JAG1LiverAbnormal NOTCH signaling activation in liver cells promotes osteopontin expression and secretion,,
OsteoarthritisRBPJ, JAG1, HES1Articular cartilageAbnormally high expression of NOTCH factors in OA; NOTCH signaling plays a dual regulatory role, participating in both damage repair and progression of disease, with temporal and spatial specificity
Graft versus host diseaseNOTCH1, NOTCH2, JAG1, DLL1, DLL4Immune systemActivation and promotion the differentiation and function of T cells; increases the BCR responsiveness of patient B cells,,,
PancreatitisNOTCH1, JAG1, HES1PancreasAssociated with tissue regeneration and renewal after pancreatitis; contributes to the differentiation and proliferation of acinar cells
Multiple sclerosisJAG1Myelin sheathInhibition of oligodendrocyte maturation and differentiation and formation of the myelin sheath
Duchenne muscular dystrophyJAG1Skeletal muscleAssociated with the depletion and senescence of MPCs,
Klippel-Feil syndromeRIPPLY2VertebraRegulates the asymmetric development of embryos,
Alcohol associative preferenceNOTCH/Su(H)NeuronsAffects alcohol-related neuroplasticity in adults

CADASIL Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, VSMCs vascular smooth muscle cells, MESP2 mesoderm posterior 2, MIB1 mindbomb homolog 1, RBPJ recombination signal binding protein-J, EMT epithelial–mesenchymal transition, ECs endothelial cells, OA osteoarthritis, BCR B-cell receptor, MPCs multipotent progenitor cells, RIPPLY2 ripply transcriptional repressor 2, Su(H) suppressor of hairless

Diseases associated with abnormal expression of NOTCH signaling related to mutations

CADASIL

CADASIL syndrome, an arteriolar vascular disease mediated by dominant mutations in the NOTCH3 gene, is the most common hereditary cause of stroke and vascular dementia in adults,. NOTCH3 is mainly expressed in VSMCs and pericytes, especially arterioles. In a study of 50 unrelated CADASIL patients, 45 with NOTCH3 pathogenic mutations presented abnormal folding of NOTCH3 and deposition of osmophilic particles near VSMCs,, and cerebral arteries showed reduced lumen diameter unassociated with chronic hypertension. Notch3-knockout mice show obvious structural abnormalities of arterioles and loss of vascular smooth muscle, simulating some CADASIL vascular changes, but are insufficient to constitute a complete CADASIL pathological model. Attempts have been made to simulate the main pathological features of CADASIL regarding vascular damage and unique brain damage, such as introducing Notch3 pathogenic point mutations into large P1-derived artificial chromosomes (PACs) to construct transgenic mouse models with large genome fragments of Nothc3 pathogenic mutations and using patient-derived induced pluripotent stem cell modeling. Evidently, NOTCH3 is pathogenic when mutated, although its underlying mechanism remains unclear.

Alagille syndrome

AGS is an autosomal dominant genetic disease caused by abnormal NOTCH signaling, with JAG1 mutations being predominant (greater than 90%) and NOTCH2 mutations being second most common (5%),,. AGS affects multiple organs throughout the body, inducing, for example, abnormal development of the liver, heart, vasculature, bones, eyes, and maxillofacial dysplasia. Liver damage is the most prominent and is characterized by a lack of interlobular bile ducts and varying degrees of cholestasis, jaundice, and itching. AGS is one of the most important causes of chronic cholestasis in children. Symptoms ameliorate with age, yet there is still no effective treatment other than liver transplantation,. These findings are consistent with the roles of JAG1 and NOTCH2 in bile duct development and morphological maintenance mentioned above. Interestingly, according to statistics, JAG1 has more than 430 mutation sites outside of mutation hotspots. Similarly, its phenotype is highly variable, and a correlation between genotype and phenotype has not yet been found. Thus, it remains a mystery how changes in different NOTCH receptors and ligands affect the occurrence and development of AGS. There was no research model with the characteristics of AGS until the structural defect model of the biliary tree using biopsies from AGS patients was developed, and experiments have indicated that AGS liver organoids may be a good human 3D model of AGS. JAG1 homozygous mutations often lead to embryonic lethality in mice. Andersson et al. successfully constructed mice homozygous for a missense mutation (H268Q) in Jag1 (Jag1Ndr/Ndr), and these mice showed a decreased rate of embryonic lethality and recapitulation of all AGS features. Surviving mice presented with the classic absence of bile ducts and other features of AGS, including defects of the heart, vasculature, and eyes,. In the pathological tissues of patients and mouse models, Joshua et al. found that the expression level of SOX9 was negatively correlated with the severity of AGS liver damage, and overexpression of SOX9 could rescue bile duct loss in Jag1+/– mouse models. One explanation is that overexpressed SOX9 can be recruited to the NOTCH2 promoter to upregulate the expression of NOTCH2 in the liver, thereby compensating for the decreased expression of the JAG1 ligand. These new research models and related experimental data have promoted and informed further research on AGS.

Congenital scoliosis

Sporadic and familial congenital scoliosis (CS) refers to the lateral curvature of at least one spine segment caused by fetal spinal dysplasia. Studies have shown that CS is closely related to genetic factors, environmental factors, developmental abnormalities, and NOTCH signaling. Several key NOTCH genes involved in the segmentation clock mechanism may explain the features of a genetic model of a rare syndrome characterized mainly by CS-spondylocostal dysostosis (SCD),.

When analyzing genes in the families of SCD patients, multiple mutation sites in DLL3 are found, and the phenotype of pyramidal dysplasia in Dll3-free mice is similar to that of SCD patients. The genetic correlation between DLL3 mutation and spinal rib dysplasia has been reported, and DLL3 deletion alone is unable to induce a complete SCD phenotype. In addition, Mesp2 is a downstream gene of NOTCH in somite differentiation, and abnormal expression of its 4 pairs of base repeats are closely related to SCD. Mesp2-knockout mice have spinal chondrodysplasia and serve as the current main research model,. In mice, inactivation of Lfng or Hes7 can distort the development of the spine and ribs, with corresponding mutations also found in patients,. Furthermore, environmental damage to genetically susceptible mice affects the penetrance and severity of the CS phenotype, especially under hypoxic conditions, providing an explanation for the family phenotypic variation of SCD.

Diseases associated with abnormal expression of NOTCH signaling not related to mutations

Nonalcoholic steatohepatitis

There is almost no NOTCH activity in hepatocytes of healthy adults, while NOTCH activity is slightly elevated in hepatocytes of people with simple steatosis and highly elevated in the hepatocytes of nonalcoholic steatohepatitis (NASH)/fibrosis patients; NOTCH activity is positively correlated with the severity of the disease. In NASH patients or high-fat diet-induced NASH mouse models, the expression of NOTCH1, NOTCH2, and HES1 is highly elevated, which activates neoadipogenesis and increases liver steatosis. Such abnormal NOTCH activation may mainly be induced by JAG1/NOTCH signaling triggered by intercellular TLR4. NOTCH-active hepatocytes can upregulate the expression of SPP1 through the downstream transcription factor SOX9, promoting secretion of osteopontin (OPN) by hepatocytes and activating hepatic stellate cells (HSCs) to induce liver fibrosis.

Osteoarthritis

The expression level of NOTCH signaling components is low in the articular cartilage of healthy adults but higher in osteoarthritis (OA) biopsies,. After trauma, NOTCH signaling is abnormally activated in joint tissues, and its continuous activation can cause early and progressive OA-like lesions. However, transient NOTCH signaling activation helps synthesize cartilage matrix and promotes joint repair. Inhibition of NOTCH signaling was found to significantly reduce the proliferation of OA chondrocytes. However, the specific inhibition of cartilage NOTCH signaling and the decrease in MMP13 abundance in the joint can delay cartilage degeneration. Eventually, long-term loss of NOTCH signaling will cause cartilage homeostasis imbalance and bone destruction. The findings above suggest that Rbpj and Hes1 play a major mediating role. In summary, NOTCH signaling presents duality when regulating the physiology and pathology of articular cartilage, and its effects are depending on temporal and spatial factors.

Lung-related diseases

Allergic asthma is mainly driven by the Th2 immune response, where NOTCH signaling activates the expression of the key transcription factor Gata3,. Preclinical studies of γ-secretase inhibitor (GSI) have also proven that inhibiting NOTCH signaling reduces the asthma phenotype,. NOTCH signaling plays an important role in promoting Th2 cell lymph node regression and lung migration. NOTCH4 has been further proven to be vital in the occurrence of asthma. Repeated exposure to allergens can induce regulatory T cells (Tregs) to upregulate the expression of NOTCH4, dampening their immunoregulatory function and activating downstream Wnt and Hippo pathways. These factors turn Tregs into Th2 and Th17 cells, maintaining persistent allergic asthma,. In addition, upregulation of JAG1 expression is found in lung tissues of patients with interstitial pulmonary fibrosis. In chronic lung injury, repeated injury promotes continuous upregulation of JAG1 by inhibiting CXCR7, leading to the continuous activation of NOTCH in surrounding fibroblasts and inducing profibrotic responses. NOTCH3 is an important mediator of pulmonary artery remodeling in pulmonary arterial hypertension (PAH) that mediates the excessive proliferation and dedifferentiation of VSMCs. In addition, the regulation of NOTCH1 in endothelial cells also promotes the progression of PAH,. Chronic obstructive pulmonary disease (COPD) is a common lung disease associated with smoking. Studies have shown that smoking and PM2.5 exposure promote the activation of NOTCH signaling, leading to the imbalance of T cell subsets and immune disorders, thus aggravating COPD.

Other diseases

NOTCH signaling is a regulator of the CD4+ T cells that cause graft versus host disease (GVHD). Inhibition of NOTCH signaling reduces target organ injury and germinal center formation, significantly reducing the severity and mortality of GVHD,. Activated NOTCH signaling can directly activate reactive T cells and promote their function. The responsiveness of patients’ B cell receptors is also significantly enhanced by activated NOTCH signaling. NOTCH signaling is also involved in regulating the glomerular filtration barrier. Abnormal activation of NOTCH1 signaling in the glomerular endothelium inhibits the expression of VE-cadherin and induces albuminuria through the transcription factors Snai1 and Erg. In adult pancreatic β cells, the abnormal activation of NOTCH signaling, especially DLL1 and DLL4, can promote β cell proliferation. A large number of naïve, dysfunctional β-cells, which proliferate but are unable to secrete insulin normally, causes glucose intolerance,.
NOTCH信号传导是引起移植物抗宿主病(GVHD)的CD 4 + T细胞的调节剂。抑制NOTCH信号传导可减少靶器官损伤和生发中心形成,显著降低GVHD的严重程度和死亡率。激活的NOTCH信号传导可以直接激活反应性T细胞并促进其功能。患者的B细胞受体的反应性也通过活化的NOTCH信号传导340而显著增强。NOTCH信号传导也参与调节肾小球滤过屏障。肾小球内皮细胞中NOTCH 1信号的异常激活通过转录因子Snai 1和Erg 36抑制VE-钙粘蛋白的表达并诱导蛋白尿。 在成年胰腺β细胞中,NOTCH信号的异常激活,尤其是DLL1和DLL4,可促进β细胞增殖。大量幼稚、功能失调的β细胞增殖但不能正常分泌胰岛素,导致葡萄糖耐受不良

Notch signaling in cancers
癌症中的Notch信号传导

NOTCH as an oncogene in cancers
NOTCH作为癌症中的癌基因

NOTCH was first identified as an oncogene in T-ALL,. Subsequently, the alteration of NOTCH receptors was discovered in various cancers (Fig. (Fig.4).4). The activation of NOTCH in breast cancer, lung adenocarcinoma, hepatocellular cancer, ovarian cancer and colorectal cancer was determined to be oncogenic (Table (Table2).2). The pattern of NOTCH activation varies; for example, NOTCH can be activated by upstream signals or by structural alteration resulting from its internal mutations. Potential mechanisms of tumorigenesis include controlling the tumor-initiating cell phenotype, regulating known upstream or downstream tumor-associated signaling factors, such as MYC or P53, facilitating angiogenesis or tumor invasion, regulating the cell cycle, etc. These mechanisms will now be discussed based on cancer type.
NOTCH首先在T-ALL 342、343中被鉴定为癌基因。随后,在各种癌症中发现了NOTCH受体的改变(图4)。4)。乳腺癌、肺腺癌、肝细胞癌、卵巢癌和结肠直肠癌中NOTCH的活化被确定为致癌的(表2)。2)。NOTCH激活的模式各不相同;例如,NOTCH可以通过上游信号或通过其内部突变导致的结构改变来激活。 肿瘤发生的潜在机制包括控制肿瘤起始细胞表型,调节已知的上游或下游肿瘤相关信号传导因子,如MYC或P53,促进血管生成或肿瘤侵袭,调节细胞周期等。

An external file that holds a picture, illustration, etc.
Object name is 41392_2022_934_Fig4_HTML.jpg

Mutation frequencies of NOTCH receptors in different cancers. Data are obtained from cBioPortal (http://cbioportal.org). We included data from two studies: MSK-IMPACT Clinical Sequencing and TCGA PanCancer Atlas Studies, with a total of 21289 patients. And we only used samples with mutation information, including missense, truncating, inframe, splice, and structural variation/fusion. This figure shows the mutation frequency of the four receptors of NOTCH in different cancer types. EC, endometrial carcinoma; SCLC, small-cell lung cancer; ESCC, esophageal squamous cell carcinoma; HNSCC, head, and neck squamous cell carcinoma; SGC, salivary gland cancer; SAC, stomach adenocarcinoma; CRC, colorectal cancer; EAC, esophagogastric adenocarcinoma; CSCC, cervical squamous cell carcinoma; NSCLC, non-small-cell lung cancer; BUC, bladder urothelial carcinoma; HCC, hepatocellular carcinoma; BC, breast cancer; RCC, renal cell carcinoma; CCA, cholangiocarcinoma; OC, ovarian cancer; PAC, prostate adenocarcinoma
不同癌症中NOTCH受体的突变频率。数据来自cBioPortal(http://cbioportal.org)。我们纳入了两项研究的数据:MSK-IMPACT临床测序和TCGA泛癌症图谱研究,共21289例患者。并且我们只使用具有突变信息的样本,包括错义、截短、框内、剪接和结构变异/融合。该图显示了NOTCH的四种受体在不同癌症类型中的突变频率。 EC,子宫内膜癌; SCLC,小细胞肺癌; ESCC,食管鳞状细胞癌; HNSCC,头颈部鳞状细胞癌; SGC,唾液腺癌; SAC,胃腺癌; CRC,结直肠癌; EAC,食管胃腺癌; CSCC,宫颈鳞状细胞癌; NSCLC,非小细胞肺癌;布克,膀胱尿路上皮癌; HCC,肝细胞癌; BC,乳腺癌; RCC,肾细胞癌; CCA,胆管癌; OC,卵巢癌; PAC,前列腺腺癌

Table 2 表2

NOTCH Signaling in Cancers
癌症中的NOTCH信号

Cancer type 癌症类型Involved NOTCH components
涉及的NOTCH组件
Relevant evidence 相关证据Ref. 参考文献
NOTCH signaling pathway plays an oncogenic role
NOTCH信号通路发挥致癌作用
T-cell acute lymphoblastic leukemia
t细胞急性淋巴细胞白血病
NOTCH1, NOTCH3 NOTCH 1、NOTCH 3

More than 50% of T-ALL patients have NOTCH1 somatic activating mutations;
超过50%的T-ALL患者存在NOTCH 1体细胞激活突变;

Transplanted hematopoietic progenitor cells with activation of Notch1 signaling in murine models can develop T-ALL;
Notch 1信号通路激活的造血祖细胞移植小鼠可发生T-ALL;

Activating mutations of NOTCH3 without NOTCH1 has also been found in several T-ALLs.
在几种T-ALL中也发现了没有NOTCH 1NOTCH 3激活突变。

,,
Splenic marginal zone lymphoma
脾边缘区淋巴瘤
NOTCH1, NOTCH2 NOTCH 1、NOTCH 2Activating mutations of NOTCH signaling appeared in 58% of SMZLs, related to inferior survival.
NOTCH信号的激活突变出现在58%的SMZL中,与较差的生存率相关。
B-chronic lymphocytic leukemiaNOTCH1-2, JAG1-2

Constitutively expression of NOTCH1, NOTCH2 proteins and their ligands JAG1 and JAG2 were detected in B-CLL;

Dysfunction of NOTCH signaling reduces the morbidity of B-CLL, while activation of NOTCH signaling increases its survival.

,
Lung adenocarcinomaNOTCH1, NOTCH3

NOTCH1 and NOTCH3 were detected highly expressed, suggesting poor prognosis and intensive invasion;

Notch1-3 were confirmed contributing to the initiation and progression of LUAD in vivo and in vitro.

,,
Breast cancerNOTCH1, NOTCH4, JAG1

Upregulation of non-mutated NOTCH1 and JAG1 is associated with poor prognosis of BC;

The mutations of Notch1 and Notch4 mediated by the mouse mammary tumor virus can promote epithelial mammary tumorigenesis;

BC cell lines with functionally recurrent rearrangements of NOTCH genes are sensitive to NOTCH inhibitors.

,,
Colorectal cancerNOTCH1

Upregulation of NOTCH ligands (DLL1, DLL3, DLL4, JAG1 and JAG2) and aberrant activation of NOTCH1 were detected;

Active Notch1 signaling induces the proliferation and activation of colon cancer hepatocytes, promoting cell invasion and metastasis.

,
Ovarian cancerNOTCH1, NOTCH3

Ntch1 and Notch3 promote the occurrence and development of ovarian cancer;

Overexpression of Notch3 is related to cell hyperproliferation and anti-apoptosis.

Adenoid cystic carcinomaNOTCH1-2

Activated mutations of NOTCH1 and NOTCH2 were frequently detected in ACC;

NOTCH1 inhibitors have significant antitumor efficacy in both ACC patients and PDX models.

Clear cell renal cell carcinomaNOTCH1Overexpression of NOTCH ligands and receptors were observed in CCRCC tissues, and activated NOTCH1 led to dysplastic hyperproliferation of tubular epithelial cells.
Hepatocellular carcinoma*NOTCH1

Approximately 30% of human HCC samples have activated NOTCH signaling, promoting the formation of liver tumors in mice;

NOTCH activation facilitates EMT progression and metastasis in HCC;

Mutations in the NOTCH target gene HES5 in HCC samples can present both protumorigenic and antitumorigenic functions.

,,
Glioma*NOTCH1-2

Inhibiting NOTCH signaling with a γ-secretase inhibitor in glioma constrains tumor growth both in vivo and in vitro.

NOTCH1 has oncogenic potential in the brain associating other oncogenic hotspots, such as p53 loss.

Positive feedback of NOTCH1-SOX2 enhances glioma stem cell invasion along white matter tracts.

Inactivation of Rbpj, Notch1 or Notch2 accelerates tumor growth in a mouse model.

NOTCH signaling pathway palys a tumor suppressing role
Squamous cell cancersNOTCH1-3

Inactivated NOTCH1-3 were detected in SCC specimens;

The genomic aberrations in NOTCH1 induced by mutagenic agent could cause an increasing tumor burden in SCCs;

DNMAML1, an inhibitor to canonical NOTCH transcription, promotes de novo SCC formation.

,,
Neuroendocrine tumorsNOTCH1, DLL3

Nearly 25% of human SCLC cases present inactivation of NOTCH target genes;

DLL3, an inhibitory NOTCH signaling components, was detected highly expressed in SCLC and lung carcinoid tumors;

Gastroenteropancreatic and lung neuroendocrine tumors exhibit decreased NOTCH expression and mutated NOTCH components;

Activating NOTCH1 could inhibit the growth of thyroid neuroendocrine cancer cells in vitro.

,,,
Pancreatic ductal adenocarcinomaaNOTCH1

Notch1 could inhibit the formation of pancreatic intraepithelial neoplasia in a PDAC mouse model;

Notch1 loss is required for progression in a Kras-induced PDAC model.

T-ALL T-cell acute lymphoblastic leukemia, SMZL splenic marginal zone lymphoma, B-CLL B-cell chronic lymphocytic leukemia, LUAD lung adenocarcinoma, BC breast cancer, ACC adenoid cystic carcinoma, PDX patient-derived xenograft; CCRCC clear cell renal cell carcinoma, HCC hepatocellular carcinoma, EMT epithelial–mesenchymal transition, SCC, squamous cell cancer; SCLC small-cell lung cancer, DANMAML1 Dominant-Negative Mastermind Like1, PDAC pancreatic ductal adenocarcinoma
T-ALLT细胞急性淋巴细胞白血病、SMZL脾边缘区淋巴瘤、B-CLLB细胞慢性淋巴细胞白血病、LUAD肺腺癌、BC乳腺癌、ACC腺样囊性癌、PDX患者源性异种移植物;CCRCC透明细胞肾细胞癌、HCC肝细胞癌、EMT上皮-间质转化、SCC、鳞状细胞癌;SCLC小细胞肺癌、DANMAML 1显性阴性母细胞样1、PDAC胰腺导管腺癌

aNOTCH might act as a tumor suppressor in oncogenic-oriented HCC and GBM, while as an oncogene in tumorsuppressive-oriented PDAC
NOTCH可能在致癌导向的HCC和GBM中作为肿瘤抑制基因,而在肿瘤抑制导向的PDAC-中作为癌基因

Hematological malignancies
血液恶性肿瘤

The oncogenic effects of NOTCH were first identified with the chromosome t (7;9) translocation of the NOTCH1 gene in T-ALL,. More than 50% of T-ALL patients have NOTCH1 somatic activating mutations. Transplanted hematopoietic progenitor cells with constitutive activation of NOTCH1 signaling in murine models can lead to the development of T-ALL. Mechanistically, NOTCH1 activation in T-ALL might involve the extracellular heterodimerization domain (HD) and/or the C-terminal PEST domain. Mutations destabilizing the HD of NOTCH1 could facilitate ligand-independent pathway activation. Furthermore, mutations disrupting the intracellular PEST domain could increase the half-life of NICD1. Many studies suggest that NOTCH1 may induce the expression of MYC by regulating its enhancer N-Me and play a key role in the initiation and maintenance of T-ALL. The interaction of NOTCH1 and PTEN promotes anabolic pathways in T-ALL. In addition to these synergistic effects, NOTCH1 can directly regulate the expression of specific lncRNAs, such as LUNAR1, which is essential for the malignant proliferation of T-ALL cells. Additionally, NOTCH signaling regulates the progression of the T-ALL cell cycle via the expression of the G(1) phase proteins cyclin D3, CDK4, and CDK6. In recent years, activating mutations of NOTCH3 independent of NOTCH1 mutations have also been found in several cases, providing novel insights into NOTCH mutations in T-ALL.
NOTCH的致癌作用首先在T-ALL 342、343中通过NOTCH 1基因的染色体t(7;9)易位被鉴定。超过50%的T-ALL患者具有NOTCH 1体细胞激活突变。在鼠模型中移植的具有NOTCH 1信号传导组成性激活的造血祖细胞可导致T-ALL 345的发展。从机制上讲,T-ALL中的NOTCH 1活化可能涉及细胞外异源二聚化结构域(HD)和/或C-末端PEST结构域。使NOTCH 1的HD不稳定的突变可促进配体非依赖性途径活化。此外,破坏细胞内PEST结构域的突变可以增加NICD 1的半衰期。 许多研究表明,NOTCH 1可能通过调节MYC增强子N-Me来诱导MYC的表达,在T-ALL 346的发生和维持中发挥关键作用。NOTCH 1PTEN的相互作用促进T-ALL 347中的合成代谢途径。除了这些协同作用之外,NOTCH 1还可以直接调节特异性lncRNA如LUNAR 1的表达,这对于T-ALL细胞的恶性增殖是必需的。此外,NOTCH信号传导通过G(1)期蛋白细胞周期蛋白D3、CDK 4和CDK 6的表达调节T-ALL细胞周期的进展。 近年来,在几个病例中也发现了独立于NOTCH 1突变的NOTCH 3激活突变,为T-ALL中的NOTCH突变提供了新的见解

In addition, activating mutations in NOTCH have been identified in other hematological malignancies. Approximately 58% of splenic marginal zone lymphoma cases have activating NOTCH mutations, termed NNK-SMZLs, and such cases are related to inferior survival. In a B cell chronic lymphocytic leukemia (B-CLL) murine model, dysfunction of NOTCH signaling reduces morbidity, while activation of NOTCH signaling increases the survival and apoptosis resistance of B-CLL cells. In diffuse large B-cell lymphoma (DLBCL), NOTCH also participates in the tumor growth through the FBXW7-NOTCH-CCL2/CSF1 axis. Although NOTCH plays an oncogenic role in most hematological malignancies, it inhibits the growth and survival of acute myeloid leukemia (AML), and consistent activation of NOTCH1-4 leads to AML growth arrest and caspase-dependent apoptosis.
此外,在其他血液恶性肿瘤中也发现了NOTCH的激活突变。大约58%的脾边缘区淋巴瘤病例具有激活的NOTCH突变,称为NNK-SMZL,并且此类病例与较差的存活率相关。在B细胞慢性淋巴细胞白血病(B-CLL)鼠模型中,NOTCH信号传导的功能障碍降低发病率,而NOTCH信号传导的激活增加B-CLL细胞的存活和凋亡抗性。在弥漫性大B细胞淋巴瘤(DLBCL)中,NOTCH还通过FBXW 7-N 0 TCH-CCL 2/CSF 1轴353参与肿瘤生长。 尽管NOTCH在大多数血液恶性肿瘤中起致癌作用,但其抑制急性髓性白血病(AML)的生长和存活,并且NOTCH 1 -4的持续活化导致AML生长停滞和半胱天冬酶依赖性细胞凋亡

Lung adenocarcinoma 肺腺癌

In lung adenocarcinoma (LUAD) patients, high expression of NOTCH1 and NOTCH3 has been detected,. This alteration involves loss of NUMB expression, which increases NOTCH activity, and gain-of-function mutations of the NOTCH1 gene. In vivo and in vitro studies confirmed that NOTCH1-3 contributes to the initiation and progression of LUAD, indicating that NOTCH acts as an oncogene in LUAD. The tumorigenesis effect might involve activating mutations of downstream genes regulating the tumor-initiating cell phenotype. First, NOTCH3 is a key driver gene in KRAS-mediated LUAD that activates PKCι-ELF3-NOTCH3 signaling to regulate asymmetric cell division in tumor initiation and maintenance processes. Second, coactivation of NOTCH1 and MYC increases the frequency of NICD1-induced adenoma formation and enables tumor progression and metastases in a mouse model. In addition, NOTCH1 activation in KRAS-induced LUAD suppresses p53-mediated apoptosis. However, NOTCH mutations have opposite effects in LUAD and squamous cell carcinoma (SCC) according to recent studies. Since most studies of NOTCH are conducted in undistinguished non-small-cell lung cancer (NSCLC) patients, the specific effect of NOTCH in LUAD needs further research.
在肺腺癌(LUAD)患者中,已经检测到NOTCH 1和NOTCH 3的高表达。这种改变涉及增加NOTCH活性的NUMB表达的丧失,以及NOTCH 1基因的功能获得性突变。体内和体外研究证实,NOTCH 1 -3有助于LUAD 358 - 360的起始和进展,表明NOTCH在LUAD中充当癌基因。肿瘤发生效应可能涉及激活调节肿瘤起始细胞表型的下游基因的突变。首先,N 0 TCH 3是KRAS介导的LUAD中的关键驱动基因,其激活PKC 1-ELF 3-N 0 TCH 3信号传导以调节肿瘤起始和维持过程中的不对称细胞分裂。 第二,NOTCH 1和MYC的共活化增加了NICD 1诱导的腺瘤形成的频率,并使小鼠模型中的肿瘤进展和转移成为可能。此外,KRAS诱导的LUAD中的N0TCH 1活化抑制p53介导的细胞凋亡。然而,根据最近的研究,NOTCH突变在LUAD和鳞状细胞癌(SCC)中具有相反的作用。由于目前关于NOTCH的研究大多数是在非小细胞肺癌(NSCLC)患者中进行的,因此NOTCH在LUAD中的特异性作用有待进一步研究。

Colorectal cancer 结直肠癌

Physiologically, NOTCH signaling is essential for the development and homeostasis of normal intestinal epithelia; for example, NOTCH signaling regulates the differentiation of colonic goblet cells and stem cells,. In human colorectal cancer (CRC) tissues, significant upregulation of NOTCH ligands (DLL1, DLL3, DLL4, JAG1, and JAG2) and aberrant activation of the NOTCH receptor (NOTCH1) are found,. Such abnormal NOTCH activation is associated with poorer prognosis and metastasis of CRC. Inhibiting NOTCH by miR-34a and Numb suppresses the proliferation and differentiation of colon cancer stem cells, indicating that NOTCH activation is a trigger of colon cancer development. Abnormal NOTCH signaling promotes the invasion and metastasis of CRC cells, possibly through the NOTCH-DAB1-ABL-TRIO pathway, EMT and TGF-β-dependent neutrophil effects. On the one hand, NOTCH promotes CRC invasion by inducing ABL tyrosine kinase activation and phosphorylation of the RHOGEF protein TRIO. On the other hand, active NOTCH signaling promotes the occurrence of metastasis by reshaping the tumor microenvironment and regulating EMT-associated transcription factors such as SLUG and SNAIL,,. In conclusion, the NOTCH pathway induces EMT in colon cancer with TP53 deletion,,.
在生理学上,NOTCH信号传导对于正常肠上皮细胞的发育和稳态是必不可少的;例如,NOTCH信号传导调节结肠杯状细胞和干细胞的分化。在人结肠直肠癌(CRC)组织中,发现NOTCH配体(DLL 1、DLL 3、DLL 4、JAG 1和JAG 2)的显著上调和NOTCH受体(NOTCH 1)的异常活化。这种异常的NOTCH活化与CRC 367的较差预后和转移相关。通过miR-34 a和Numb抑制NOTCH抑制结肠癌干细胞368的增殖和分化,表明NOTCH活化是结肠癌发展的触发因素。 异常NOTCH信号传导促进CRC细胞的侵袭和转移,可能通过NOTCH-DAB 1-ABL-TRIO途径、EMT和TGF-β依赖性中性粒细胞作用。一方面,NOTCH通过诱导ABL酪氨酸激酶活化和RHOGEF蛋白TRIO 370的磷酸化促进CRC侵袭。另一方面,活性NOTCH信号传导通过重塑肿瘤微环境和调节EMT相关转录因子如SLUG和SNAIL促进转移的发生。总之,NOTCH途径诱导TP 53缺失的结肠癌中的EMT

Breast cancer 乳腺癌

Studies of NOTCH signaling in epithelial tumors were first performed in breast cancer. Upregulation of non-mutated NOTCH signaling-related proteins, such as NOTCH1 and JAG1, is associated with poor prognosis in breast cancer. In mouse models, mutations in Notch1 and Notch4 mediated by mouse mammary tumor viruses can promote epithelial mammary tumorigenesis,. Moreover, functionally recurrent rearrangements of NOTCH gene families are found in breast cancer, of which cell lines are sensitive to NOTCH inhibitors. In HER2-expressing breast cancer cells, NOTCH activation seems to be associated with cytotoxic chemotherapy resistance. Such an abnormal increase in NOTCH signaling expression is believed to be related to a lack of NUMB expression, and its promoting effect on breast cancer tumorigenesis might be exerted from multiple aspects. First, NOTCH signaling maintains the stemness of breast cancer cells and promotes initiation,. Second, NOTCH signaling shapes elements of the breast cancer microenvironment, especially tumor-associated macrophages (TAMs), which is related to the innate immune phenotype. In addition, NOTCH can be activated by the ASPH-Notch axis, providing materials for the synthesis/release of prometastatic exosomes in breast cancer.
上皮肿瘤中NOTCH信号传导的研究首先在乳腺癌中进行 - 。非突变的NOTCH信号相关蛋白如NOTCH 1和JAG 1的上调与乳腺癌的不良预后相关。在小鼠模型中,小鼠乳腺肿瘤病毒介导的Notch 1Notch 4突变可促进上皮乳腺肿瘤发生。此外,在乳腺癌中发现NOTCH基因家族的功能性复发性重排,其中细胞系对NOTCH抑制剂敏感。在表达HER 2的乳腺癌细胞中,NOTCH活化似乎与细胞毒性化疗耐药性相关。 NOTCH信号表达的这种异常增加被认为与NUMB表达的缺乏有关,并且其对乳腺癌肿瘤发生的促进作用可能从多个方面发挥。首先,NOTCH信号传导维持乳腺癌细胞的干性并促进起始。其次,NOTCH信号传导塑造乳腺癌微环境的要素,特别是肿瘤相关巨噬细胞(TAM),其与先天免疫表型相关。此外,NOTCH可以被ASPH-Notch轴激活,为乳腺癌中促转移性外泌体的合成/释放提供材料

Ovarian cancer 卵巢癌

In ovarian cancer, approximately 23% of patients have NOTCH signaling alterations. NOTCH1 and NOTCH3 have been discovered to directly promote the occurrence and development of ovarian cancer. Overexpression of NOTCH3 is related to cell hyperproliferation and apoptosis inhibition, as well as tumor metastasis and recurrence,. As NOTCH3 is positively correlated with JAG1 and JAG2 expression in ovarian cancer, the carcinogenic function of NOTCH3 is potentially mediated by JAG1-NOTCH3 activation, and dynamin-dependent endocytosis is required. Notch2/Notch3 and other NOTCH signaling molecules have achieved certain effects by inhibiting Jag1 in a mouse ovarian cancer model,. In addition, through methylation of the VEGFR2 promoter, NOTCH signaling facilitates angiogenesis in ovarian cancer mediated by VEGFR2 negative feedback.
在卵巢癌中,大约23%的患者有NOTCH信号改变已经发现N 0 TCH 1N 0 TCH 3直接促进卵巢癌的发生和发展 - 。NOTCH 3的过表达与细胞过度增殖和凋亡抑制以及肿瘤转移和复发相关。由于NOTCH 3与卵巢癌中的JAG 1和JAG 2表达正相关,因此NOTCH 3的致癌功能可能由JAG 1-NOTCH 3活化介导,并且需要动力蛋白依赖性内吞作用。 Notch 2/Notch 3和其他NOTCH信号分子通过抑制小鼠卵巢癌模型中的Jag 1而实现了某些效果。此外,通过VEGFR 2启动子的甲基化,NOTCH信号传导促进由VEGFR 2负反馈介导的卵巢癌中的血管生成

Hepatocellular carcinoma 肝细胞癌

NOTCH signaling is a pathogenic factor in NASH, yet its role in hepatocellular carcinoma (HCC) is less well defined. Approximately 30% of human HCC samples have activated NOTCH signaling, which in mice promotes the formation of liver tumors. Recently, NOTCH activation was found in some HCC subtypes with unique molecular and clinicopathologic features and was found to be associated with poor prognosis. NOTCH activation is also related to the activation of insulin-like growth factor 2, which contributes to hepatocarcinogenesis. Furthermore, NOTCH activation facilitates EMT progression and metastasis in HCC. On the other hand, NOTCH activation slows HCC growth and can predict HCC patient prognosis. Mutations in the NOTCH target gene HES5 in HCC samples can present both protumorigenic and antitumorigenic functions. A close relationship between the function of NOTCH1 and the P53 mutation state has been reported, in which NOTCH1 activation increases the invasiveness of P53 WT HCC cells while decreasing that of P53-mutated HCC cells. Although showing contradictory functions in HCC, NOTCH is still mainly considered an oncogenic factor.
NOTCH信号传导是NASH中的致病因子,但其在肝细胞癌(HCC)中的作用尚不明确。大约30%的人HCC样品具有激活的NOTCH信号传导,其在小鼠中促进肝肿瘤的形成。最近,在一些具有独特分子和临床病理特征的HCC亚型中发现了NOTCH激活,并发现其与不良预后相关NOTCH激活也与胰岛素样生长因子2的激活有关,其有助于肝癌发生。此外,NOTCH激活促进HCC 402中的EMT进展和转移。 另一方面,NOTCH激活减缓HCC生长并且可以预测HCC患者预后。HCC样品中NOTCH靶基因HES5中的突变可以呈现促肿瘤发生和抗肿瘤发生功能。已经报道了N0TCH 1的功能与P53突变状态之间的密切关系,其中N0TCH 1活化增加P53 WT HCC细胞的侵袭性,同时降低P53突变的HCC细胞的侵袭性。尽管在HCC中表现出相互矛盾的功能,但NOTCH仍然主要被认为是致癌因子。

Glioma 胶质瘤

NOTCH signaling used to be considered oncogenic in glioma, in which it maintains brain cancer stem cells. Knockdown of NOTCH ligands in human brain microvascular endothelial cells (hBMECs) or inhibition of NOTCH signaling with a γ-secretase inhibitor in glioma constrains tumor growth both in vitro and in vivo,. Notch1 has potentially oncogenic effects in the brain in association with other oncogenic hits, such as p53 loss in a medulloblastoma mouse model. Positive feedback of NOTCH1-SOX2 enhances glioma stem cell invasion along white matter tracts. NOTCH also induces the expression of lncRNA and TUG1 to maintain the stemness of glioma stem cells and suppress differentiation. Moreover, NOTCH1 signaling promotes the invasion and growth of glioma-initiating cells by modulating the CXCL12/CXCR4 chemokine system. However, NOTCH suppresses forebrain tumor subtypes. Inactivation of Rbpj, Notch1, or Notch2 receptors accelerates tumor growth in a mouse model. Such a subtype-specific effect of NOTCH in glioma might be related to cooperation with P53. Overall, NOTCH signaling acts either as an oncogenic factor or a tumor suppressor in different glioma subtypes, and the mechanisms need further exploration.
NOTCH信号传导过去被认为是神经胶质瘤中的致癌性,其中它维持脑癌干细胞。人脑微血管内皮细胞(hBMEC)中NOTCH配体的敲低或胶质瘤中用γ-分泌酶抑制剂抑制NOTCH信号传导在体外和体内均抑制肿瘤生长Notch 1在脑中具有与其他致癌命中相关的潜在致癌作用,例如髓母细胞瘤小鼠模型409中的p53缺失。NOTCH 1-SOX 2的正反馈增强神经胶质瘤干细胞沿沿着白色物质束的侵袭。NOTCH还诱导lncRNA和TUG 1的表达以维持神经胶质瘤干细胞的干性并抑制分化。 此外,NOTCH 1信号传导通过调节CXCL 12/CXCR 4趋化因子系统412促进神经胶质瘤起始细胞的侵袭和生长。然而,NOTCH抑制前脑肿瘤亚型。Rbpj、Notch 1或Notch 2受体的失活加速小鼠模型中的肿瘤生长。NOTCH在胶质瘤中的这种亚型特异性作用可能与P53的协同作用有关。总体而言,NOTCH信号传导在不同胶质瘤亚型中充当致癌因子或肿瘤抑制因子,并且机制需要进一步探索

Other cancers 其他癌症

Adenoid cystic carcinoma (ACC), commonly found in the salivary gland, frequently features activating NOTCH1 and NOTCH2 mutations. NOTCH1 inhibitors have significant antitumor efficacy in both ACC patients and patient-derived xenograft (PDX) models,. Upregulation of MYB signaling through NOTCH mutation and amplification might also be a potential driving mechanism of ACC. Activated NOTCH1 also produces CD133(+) ACC cells, regarded as cancer stem-like cells in ACC. In clear cell renal cell carcinoma (CCRCC), the overexpression of NOTCH ligands and receptors is observed in tumor tissues. Activated NOTCH1 leads to dysplastic hyperproliferation of tubular epithelial cells, and treatment involving a γ-secretase inhibitor leads to CCRCC cell inhibition both in vitro and in vivo.
腺样囊性癌(ACC),常见于唾液腺,经常以激活NOTCH 1NOTCH 2突变为特征 - 。N 0 TCH 1抑制剂在ACC患者和患者来源的异种移植物(PDX)模型中都具有显著的抗肿瘤功效。通过NOTCH突变和扩增上调MYB信号也可能是ACC 421的潜在驱动机制。活化的NOTCH 1还产生CD 133(+)ACC细胞,其被认为是ACC中的癌干细胞样细胞。在透明细胞肾细胞癌(CCRCC)中,在肿瘤组织中观察到NOTCH配体和受体的过度表达。 活化的N 0 TCH 1导致肾小管上皮细胞的发育异常过度增殖,并且涉及γ-分泌酶抑制剂的治疗导致体外和体内CCRCC细胞抑制

NOTCH as a tumor suppressor in cancers
NOTCH作为癌症的肿瘤抑制因子

NOTCH may be involved in many cancers as a protumor effector, but it can also act as a tumor suppressor in others, such as squamous cell carcinoma (SCC) and neuroendocrine tumors(图 .(Fig.4,4, Table Table2).2). Antitumor mechanisms include regulating transcription factors with malignant effects, activating downstream suppressive genes, inhibiting the cell cycle, etc. In light of studies regarding its antitumor effects, the traditional opinion of NOTCH as an oncogene has been challenged.

Neuroendocrine tumors

NOTCH is now believed to act as a suppressor in neuroendocrine tumors (NETs), including tumors derived from the thyroid, neuroendocrine cells of the gut, the pancreas, and the respiratory system. Small-cell lung cancer (SCLC) is the most common type of pulmonary NET, with nearly 25% of human SCLC cases presenting inactivation of NOTCH target genes in one comprehensive genomic profiling analysis. A recent study used a multiomics approach to analyze the dynamic changes during transdifferentiation from NSCLC to SCLC, which is a special feature of acquired resistance to EGFR-TKIs in LUAD. This study found that the downregulation of NOTCH signaling was essential for the initial cell state switch of LUAD cells, indicating that NOTCH plays a tumor-suppressive role in SCLC. Furthermore, high DLL3 expression is frequently detected in SCLC and lung carcinoid tumors,, which downregulates NOTCH signaling via cis-inhibition. In an SCLC mouse model, activation of Notch1 or Notch2 reduces the expression of synaptophysin and Ascl1, inhibiting the cell cycle process,. Likewise, in human medullary thyroid cancer (MTC) tumor samples, NOTCH1 protein is undetectable, while the expression of NICD1 inhibits MTC cell proliferation. In an analysis of gastroenteropancreatic NET tumor specimens, reduced NOTCH expression and mutated components were found,. Mechanistically, some studies consider that such an antitumorigenesis effect might be mediated by the NOTCH-ASCL1-RB-P53 tumor suppression pathway,, while others hold that activated NOTCH could inhibit cell growth via cell cycle arrest associated with upregulated P21,. NOTCH could also mark and initiate deprogramming in rare pulmonary NET cells that serve as stem cells in SCLC. Considering the suppressor effect of NOTCH in NETs, drugs targeting DLL3 have been tested in SCLC, with promising results witnessed in preclinical trials (discussed in detail in the following sections).
现在认为NOTCH在神经内分泌肿瘤(NET)中起抑制剂的作用,所述神经内分泌肿瘤包括源自甲状腺、肠道、胰腺和呼吸系统的神经内分泌细胞的肿瘤。小细胞肺癌(SCLC)是最常见的肺NET类型,在一项全面的基因组分析中,近25%的人SCLC病例呈现NOTCH靶基因失活。最近的一项研究使用多组学方法分析了从NSCLC转分化为SCLC 426过程中的动态变化,这是LUAD中对EGFR-TKI获得性耐药的一个特殊特征。本研究发现,NOTCH信号的下调对于LUAD细胞426的初始细胞状态转换是必需,表明NOTCH在SCLC中起肿瘤抑制作用。 此外,在SCLC和肺类癌肿瘤中经常检测到高DLL 3表达 - ,其通过顺式抑制下调NOTCH信号传导。在SCLC小鼠模型中,Notch 1Notch 2的激活降低突触素和Ascl 1的表达,抑制细胞周期过程。同样,在人甲状腺髓样癌(MTC)肿瘤样品中,N 0 TCH 1蛋白是不可检测的,而NICD 1的表达抑制MTC细胞增殖。在对胃肠胰腺NET肿瘤标本的分析中,发现NOTCH表达减少和突变成分。 从机制上讲,一些研究认为这种抗肿瘤发生作用可能由NOTCH-ASCL 1-RB-P53肿瘤抑制途径介导,而其他研究认为活化的NOTCH可以通过与上调的P21相关的细胞周期停滞来抑制细胞生长。NOTCH还可以标记并启动在SCLC 437中作为干细胞的罕见肺NET细胞中的去编程。考虑到NOTCH在NET中的抑制作用,已经在SCLC中测试了靶向DLL 3的药物,在临床前试验中看到了有希望的结果(在以下章节中详细讨论)。

Squamous cell cancers 鳞状细胞癌

In SCC specimens, inactivated NOTCH1-3 has been detected. 40% of head and neck squamous cell cancer (HNSCC) cases are found to have inactivated NOTCH1,. In cutaneous squamous cell cancer (cSCC) and its adjacent normal tissue, NOTCH receptors are also frequently found mutated, resulting in loss of function or downregulation. Similarly, malfunction of NOTCH1 and NOTCH2 was found in lung squamous cell carcinoma (LUSC) patients. This negative relation between NOTCH and carcinogenesis was also found in bladder, esophageal,, and cervical SCC. In an SCC mouse model, genomic aberrations in NOTCH1 induced by mutagenic agents result in an increased tumor burden,. Dominant-negative Mastermind-like 1 (DNMAML1), an inhibitor of canonical NOTCH transcription, promotes de novo SCC formation. Moreover, a study of γ-secretase inhibitors in Alzheimer’s disease (AD) patients showed that inhibiting S3 cleavage in NOTCH might increase the risk of nonmelanoma skin cancer. Most studies of the mutated form of NOTCH in SCCs show that NOTCH function relies deeply on context; for example, NOTCH function can be affected by factors such as the P53 pathway and the intrinsic transcription-repressive protein RBP-Jκ. The detailed regulatory mechanism is unclear, although some studies believe that NOTCH signaling maintains the CD133 phenotype in stem cells of SCCs. Furthermore, decreased NOTCH1 expression also dysregulates cell cycle-associated genes in SCCs such as LUSC.
在SCC标本中,已检测到灭活的NOTCH 1 -3 - 。发现40%的头颈部鳞状细胞癌(HNSCC)病例具有失活的N 0 TCH 1。在皮肤鳞状细胞癌(cSCC)及其邻近的正常组织中,也经常发现NOTCH受体突变,导致功能丧失或下调。类似地,在肺鳞状细胞癌(LUSC)患者中发现NOTCH 1和NOTCH 2的功能障碍。在膀胱癌445、食管癌446、447和宫颈鳞癌448中也发现了NOTCH与癌变之间的这种负相关。 在SCC小鼠模型中,诱变剂诱导的NOTCH 1基因组畸变导致肿瘤负荷增加。显性负性母细胞样蛋白1(DNMAML 1),一种典型的NOTCH转录抑制剂,促进SCC从头形成。此外,一项针对阿尔茨海默病(AD)患者的γ-分泌酶抑制剂研究表明,抑制NOTCH中的S3切割可能会增加非黑色素瘤皮肤癌的风险。大多数对SCC中NOTCH突变形式的研究表明,NOTCH功能严重依赖于环境;例如,NOTCH功能可能受到P53途径和内在转录抑制蛋白RBP-Jκ 440等因素的影响。 详细的调控机制尚不清楚,尽管一些研究认为NOTCH信号传导维持SCC 453干细胞中的CD133表型。此外,降低的NOTCH1表达也使SCC如LUSC 362中的细胞周期相关基因失调

Pancreatic ductal carcinoma
胰腺导管癌

NOTCH mutation is common in PDAC. NOTCH1 can inhibit the formation of pancreatic intraepithelial neoplasia (PanIN) in a PDAC mouse model. Additionally, Notch1 loss is required progression in a Kras-induced PDAC mouse model, suggesting its role as a tumor suppressor gene. However, previous studies suggest that NOTCH plays an oncogenic role in the occurrence and development of PDAC. NOTCH signaling has been found to be activated in PDAC, which causes the growth of premalignant PDAC cells.
NOTCH突变在PDAC 454中是常见NOTCH 1可以抑制PDAC小鼠模型中胰腺上皮内瘤形成(PanIN)。此外,Notch 1丢失是Kras诱导的PDAC小鼠模型中所需的进展,表明其作为肿瘤抑制基因的作用。然而,先前的研究表明,NOTCH在PDAC 457 - 459的发生和发展中起致癌作用。已经发现NOTCH信号传导在PDAC中被激活,这导致恶变前PDAC细胞的生长

NOTCH signaling in the tumor microenvironment
肿瘤微环境中的NOTCH信号传导

The tumor microenvironment (TME) refers to the factors surrounding tumor cells during their generation and development, including various immune cells, fibroblasts, extracellular matrix (ECM) components, and vasculature,. NOTCH signaling is deeply involved in regulating the diversified components of the TME(图 .(Fig.55).
肿瘤微环境(TME)是指在肿瘤细胞产生和发育期间围绕肿瘤细胞的因素,包括各种免疫细胞、成纤维细胞、细胞外基质(ECM)组分和脉管系统。NOTCH信号传导深深地参与调节TME 462的多样化组分图10)。图5 -5)。

An external file that holds a picture, illustration, etc.
Object name is 41392_2022_934_Fig5_HTML.jpg

NOTCH signaling pathway in antitumor immunity. NOTCH signaling plays important roles in both tumor-suppressive and tumor-promoting immune cells. NOTCH signaling promotes the differentiation of many immune cells. DLL and JAG mediate both similar and distinct effects. DC, dendritic cell; CD8T, CD8+ T cell; MDSC, myeloid-derived suppressor cell; CD4T, CD4+ T cell; Th1, type1 T helper cell; Th2, type2 T helper cell; Treg, regulatory T cell; TAM, tumor-associated macrophage; TAN, tumor-associated neutrophil; PD-1, programmed death-1; EOMES, eomesodermin; GZMB, granzyme B; DLL, delta-like ligand; CCL2, C-C motif chemokine ligand 2
抗肿瘤免疫中的NOTCH信号通路。NOTCH信号传导在肿瘤抑制性和肿瘤促进性免疫细胞中起重要作用。NOTCH信号传导促进许多免疫细胞的分化。DLL和JAG介导相似和不同的效果。DC,树突细胞; CD 8 T,CD 8 + T细胞; MDSC,髓源性抑制细胞; CD 4 T,CD 4 + T细胞; Th 1,1型T辅助细胞; Th 2,2型T辅助细胞; Treg,调节性T细胞; TAM,肿瘤相关巨噬细胞; TAN,肿瘤相关中性粒细胞; PD-1,程序性死亡-1; EOMES,原中胚层蛋白; GZMB,颗粒酶B; DLL,δ样配体; CCL 2,C-C基序趋化因子配体2

NOTCH signaling in immune cells

Generally, immune cells in the TME can be classified into two clusters, inflammatory (tumor-suppressive) immune cells and immune-suppressive (tumor-promoting) immune cells, and NOTCH signaling plays important roles in both cell types. NOTCH signaling not only determines the differentiation of immune cells but also regulates their functional states.

Dendritic cells

In a mouse model with CD11c lineage-specific deletion of Dll1, CD8+ T cells are decreased, while regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) are increased, leading to faster tumor growth. Administration of a DLL1 analog can reverse Dll1 deficiency-induced immunosuppression. However, mice with CD11c lineage-specific deletion of JAG2 do not show this phenotype, and administration of a JAG1-competitive antagonist reduces Tregs, improving antitumor immunity. In the colitis-associated colorectal cancer (CRC) model, Notch2 deficiency in the CD11c lineage impairs dendritic cell (DC) differentiation, reduces DC migration, and suppresses antigen-presenting capacity, mirroring those conditions found in a pioneering study in nontumoral conditions. In conclusion, both NOTCH ligands (DLL1) and receptors (NOTCH2) play positive roles in DC function, while JAG2 on DCs plays negative roles. As NOTCH signaling is crucial for DC differentiation and maturation, two research groups developed a method to increase the yield of cDC1s from mouse and human hematopoietic progenitor cells by employing DLL1-expressing stroma,, which might be applicable for autologous DC-based vaccination.


树突状细胞
在Dll 1的CD11c谱系特异性缺失的小鼠模型中,CD8+ T细胞减少,而调节性T细胞(TcB)和骨髓源性抑制细胞(MDSC)增加,导致肿瘤生长更快464。施用DLL1类似物可以逆转DLL1缺陷诱导的免疫抑制464。然而,具有JAG2的CD11c谱系特异性缺失的小鼠不显示这种表型,并且施用JAG1竞争性拮抗剂降低TcR,从而改善抗肿瘤免疫464。在结肠炎相关的结直肠癌(CRC)模型中,CD11c谱系中的Notch2缺陷损害树突状细胞(DC)分化,减少DC迁移,并抑制抗原呈递能力465,反映了在非肿瘤条件下的开创性研究中发现的那些条件240。总之,NOTCH配体(DLL1)和受体(NOTCH 2)在DC功能中起积极作用,而DC上的JAG 2起消极作用。 由于NOTCH信号传导对于DC分化和成熟至关重要,两个研究小组开发了一种方法,通过使用表达DLL1的基质466,467来增加来自小鼠和人类造血祖细胞的cDC1的产量,这可能适用于自体DC疫苗接种468。

CD8+ T cells

First, the DLL1-NOTCH1/2 axis is necessary for naïve CD8+ T cells to differentiate into effector T cells because it regulates the expression of the transcription factor eomesodermin (EOMES) and effector molecules (granzyme B and perforin). Selective activation of DLL1/4-NOTCH inhibits tumor growth. In addition, NOTCH signaling is involved in the TCR-mediated self-amplification of T cells (section “The noncanonical NOTCH signaling pathway”). The activated TCR/CD3 complex can directly promote the cleavage of NOTCH receptors on endosomes, initiating the response of CD8+ T cells independent of NOTCH ligands. As adenosine A2A receptor (A2AR) stimulation decreases TCR-mediated NOTCH activity, inhibiting A2AR might help boost the CD8+ T cell response. Second, NOTCH signaling is essential for the persistence and function of human lung tissue-resident memory T cells (TRM cells), thus assisting long tumor control. Third, NOTCH signaling is also reported to have a negative impact on CD8+ T cells. NOTCH signaling upregulates the PD-1 expression of CD8+ T cells, thus promoting their exhaustion. Inhibition of the NOTCH signaling pathway decreases the PD-1 level of CD8+ T cells and promotes the cytotoxicity of tumor-infiltrating CD8+ T cells in CRC patients. Collectively, NOTCH receptors on CD8+ T cells play positive roles in antitumor immunity, paving the way for displaying NOTCH receptors on T cells for autologous T cell transfer therapy. One challenge in current chimeric antigen receptor-T (CAR-T) cell therapy is the exhaustion of transferred CAR-T cells. In light of this challenge, researchers designed new CAR-T cells with a synthetic NOTCH (synNOTCH) receptor loaded on the cell membrane,. These synNOTCH CAR-T cells not only promote the immune response but also maintain a higher fraction of effector T cells in the memory state,, which suggests the utility of such a strategy for next-generation CAR-T cell engineering,.


首先,DLL 1-NOTCH 1/2轴对于幼稚的CD 8 + T细胞分化成效应T细胞是必需的,因为它调节转录因子始中胚层蛋白(EOMES)和效应分子(颗粒酶B和穿孔素)的表达469-472。DLL 1/4-NOTCH的选择性激活抑制肿瘤生长473.此外,NOTCH信号传导参与TCR介导的T细胞自我扩增(“非经典NOTCH信号传导途径”部分)。活化的TCR/CD 3复合物可以直接促进内体上的NOTCH受体的裂解,启动不依赖于NOTCH配体的CD 8 + T细胞的应答87。由于腺苷A2 A受体(A2 AR)刺激降低TCR介导的NOTCH活性474,抑制A2 AR可能有助于增强CD 8 + T细胞应答41。第二,NOTCH信号传导对于人肺组织驻留记忆T细胞(TRM细胞)的持久性和功能是必不可少的475,因此有助于长期肿瘤控制476 -478。 第三,据报道NOTCH信号传导也对CD 8 + T细胞产生负面影响。NOTCH信号传导上调CD 8 + T细胞的PD-1表达,从而促进其耗竭479。NOTCH信号通路的抑制降低了CRC患者中CD 8 + T细胞的PD-1水平,并促进了肿瘤浸润性CD 8 + T细胞的细胞毒性480。总之,CD 8 + T细胞上的NOTCH受体在抗肿瘤免疫中发挥积极作用,为自体T细胞转移治疗在T细胞上展示NOTCH受体铺平了道路。当前嵌合抗原受体-T(CAR-T)细胞疗法的一个挑战是转移的CAR-T细胞的耗尽。鉴于这一挑战,研究人员设计了新的CAR-T细胞,其细胞膜上装载了合成的NOTCH(synNOTCH)受体481,482。 这些synNOTCH CAR-T细胞不仅促进免疫应答,而且在记忆状态中维持更高比例的效应T细胞481,482,这表明这种策略可用于下一代CAR-T细胞工程483,484。

CD4+ T cells, B cells, and NK cells

Different ligand-mediated NOTCH signaling pathways also induce further differentiation and functions of CD4+ T cells. DLL-mediated NOTCH signaling promotes type1 T helper cell (Th1) differentiation, while JAG1/2-mediated NOTCH signaling induces the differentiation of Th2 and Tregs. Blocking NOTCH signaling with a GSI deeply impaired the generation and immunosuppressive function of Tregs. However, Charbonnier et al. found that deletion of NOTCH components enhanced the immune-suppressive functions of Tregs, while transgenic overexpression of the NOTCH1 intracellular domain impaired Treg fitness. As NOTCH signaling plays diversified roles in the generation and function of Tregs, distinguishing different signal-sending cells, ligands and receptors might be of much significance. DLL1-NOTCH2 signaling also mediates the development of splenic MZB cells. NK cells isolated from cancer patients show lower expression levels of NOTCH receptors than those of healthy donors.


CD 4 + T细胞、B细胞和NK细胞
不同的配体介导的NOTCH信号传导途径也诱导CD 4 + T细胞的进一步分化和功能485。DLL介导的NOTCH信号促进1型T辅助细胞(Th 1)分化,而JAG 1/2介导的NOTCH信号诱导Th 2和Tregs的分化485 -487。用GSI阻断NOTCH信号传导严重损害Tregs 488的产生和免疫抑制功能。然而,Charbonnier等人发现,NOTCH组分的缺失增强了TcG的免疫抑制功能,而NOTCH 1胞内结构域的转基因过表达损害了Treg适应性489。由于NOTCH信号通路在TGFAP的产生和功能中起着多种作用,因此区分不同的信号传递细胞、配体和受体可能具有重要意义。DLL 1-N 0 TCH 2信号传导还介导脾MZB细胞的发育。 从癌症患者中分离的NK细胞显示出比健康供体更低的NOTCH受体表达水平490。

Tumor-associated macrophages

First, NOTCH signaling is necessary for the terminal differentiation of tumor-associated marcrophages (TAMs). The deletion of CSL in monocyte lineages abrogates TAM differentiation and functions. A recent study found that inhibition of NOTCH signaling indeed impeded the differentiation of monocyte-derived TAMs while increasing the differentiation of Kupffer cell-like TAMs (kclTAMs) by upregulating Wnt/β-catenin signaling. Second, NOTCH signaling participates in the recruitment of TAMs in basal-like breast cancer (BLBC). JAG1-NOTCH1/2/3 signaling in BLBC cells promotes the secretion of IL-1β and CCL2, recruiting TAMs into the TME. Simultaneously, the TAMs secrete transforming growth factor-β (TGF-β) to induce JAG1 expression in BLBC cells via the TGFβR1-SMAD2/3 pathway. This paracrine loop contributes to the suppressive immune microenvironment of BLBC and also indicates therapeutic opportunities. Third, NOTCH signaling regulates the polarization of TAMs between M1-like (tumor-suppressive) and M2-like (tumor-promoting) phenotypes. JAG1-NOTCH signaling between endocrine-resistant breast cancer cells and TAMs results in the differentiation of TAMs toward an M2-like phenotype, contributing to resistance to endocrine therapy. NOTCH signaling mediates M2 polarization of TAMs in diffuse large B cell lymphoma (DLBCL) through the CREBBP/EP300-FBXW7-NOTCH-CCL2/CSF1 pathway. However, NOTCH signaling is also reported to promote the M1 polarization of macrophages in anti-infection immunity, and anticancer immunity,. In terms of transplanted tumors, macrophages with insufficient NOTCH signaling exhibit M2 phenotypes, while macrophages with forced activation of NOTCH signaling show M1 phenotypes and promote tumor shrinkage,.


首先,NOTCH信号传导对于肿瘤相关巨噬细胞(TAM)的终末分化是必需的491。在单核细胞谱系中CSL的缺失消除了TAM分化和功能491。最近的一项研究发现,抑制NOTCH信号传导确实阻碍了单核细胞衍生的TAM的分化,同时通过上调Wnt/β-连环蛋白信号传导增加了枯否细胞样TAM(kclTAM)的分化492。第二,NOTCH信号传导参与基底样乳腺癌(BLBC)中TAM的募集387。BLBC细胞中的JAG 1-NOTCH 1/2/3信号传导促进IL-1β和CCL 2的分泌,将TAM募集到TME中。同时,TAM分泌转化生长因子-β(TGF-β)以通过TGFβR1-SMAD 2/3途径诱导BLBC细胞中JAG 1的表达。这种旁分泌回路有助于BLBC的抑制性免疫微环境,也表明了治疗机会。 第三,NOTCH信号调节TAM在M1样(肿瘤抑制)和M2样(肿瘤促进)表型之间的极化。内分泌耐药乳腺癌细胞和TAM之间的JAG 1-NOTCH信号传导导致TAM向M2样表型分化,导致对内分泌治疗的耐药性493。在弥漫性大B细胞淋巴瘤(DLBCL)中,NOTCH信号传导通过CREBBP/EP 300-FBXW 7-NOTCH-CCL 2/CSF 1途径介导TAM的M2极化353。然而,NOTCH信号传导也被报道在抗感染免疫494,495和抗癌免疫496,497中促进巨噬细胞的M1极化。就移植肿瘤而言,NOTCH信号不足的巨噬细胞表现出M2表型,而NOTCH信号强制激活的巨噬细胞表现出M1表型并促进肿瘤缩小496,497。

Myeloid-derived suppressor cells

Similar to its role in TAMs, NOTCH signaling also participates in the differentiation, chemotaxis, and function of MDSCs. Regarding functional regulation, tumor-derived factors upregulate JAG1/2 on MDSCs through NFkB-p65 signaling, forming a suppressive immune microenvironment. Anti-JAG1/2 antibodies decrease the accumulation and tolerogenic activity of MDSCs and inhibit the expression of the immunosuppressive factors arginase I and iNOS, thus restoring defective antitumor immunity. In addition to its immune-regulatory functions, NOTCH signaling also participates in the MDSC-mediated regulation of tumor cell behaviors. Bone marrow-derived CD11b+JAG2+ cells infiltrate primary colorectal tumors and initiate the EMT program of tumor cells, thus promoting tumor metastasis. Polymorphonuclear-MDSCs (PMN-MDSCs) interact with circulating tumor cells (CTCs) through NOTCH signaling, enhancing CTC dissemination and metastatic potency. MDSCs activate NOTCH signaling in tumor cells to endow them with stem cell-like qualities in breast cancer,. In summary, NOTCH signaling mainly promotes the immune-suppressive and tumor-promoting functions of MDSCs; thus, targeting JAG1/2 might be a promising strategy.

Tumor-associated neutrophils

Jackstadt et al. reported that NOTCH1 signaling in CRC cells could promote the secretion of CXCL5 and TGF-β, recruiting tumor-associated neutrophils (TANs) to drive metastasis. Additionally, JAG2-expressing TANs impair the cytotoxicity of CD8+ T cells via NOTCH signaling.

NOTCH signaling in cancer-associated fibroblasts and the extracellular matrix

On the one hand, NOTCH signaling participates in the differentiation of cancer-associated fibroblasts (CAFs). In keratinocyte tumors, loss of NOTCH signaling promotes CAF differentiation and further tumor initiation. However, in colon and prostate cancer, CAF differentiation is initiated by elevated NOTCH signaling,. In addition, CAFs activate NOTCH signaling in cancer cells to promote various malignant behaviors, including the cancer stem cell phenotype, chemotherapy resistance, metastasis,, and disease recurrence. ECM components, such as fibulin-1, fibulin-3, microfibril-associated glycoprotein 2 (MAGP2), and laminin α5 (LAMA5), can also regulate the intensity of NOTCH signaling in cancer cells. Furthermore, activated NOTCH signaling in PDAC cells is reported to reshape the ECM through exosomes, thus promoting lung metastasis.

NOTCH signaling in the tumor vasculature

The balance of DLL4 and JAG1 endothelial expression is important for tumor vasculature generation. When DLL4 is inhibited, small blood vessel branches sprout, tumor vascular density increases, vascular function remains poor, overall tumor perfusion decreases, and tumor growth is inhibited. Such effects on the tumor vasculature thus could be employed for antitumor therapy,. After binding to NOTCH receptors, JAG1 promotes angiogenesis by competing with DLL4. In breast cancer, JAG1 has been confirmed to induce tumor angiogenesis and tumor growth,. Additionally, NOTCH activation in ECs promotes lung metastasis, while endothelial NOTCH1 activation in the liver reduces intercellular adhesion molecule-1 expression and endothelial tumor cell adhesion and retention, thereby reducing liver metastasis,. During radiotherapy, endothelial NOTCH1 activation protects tumor vessels from radiotherapy-induced damage and regulates endothelial-mesenchymal transition. Surprisingly, NOTCH3 acts as a receptor-dependent receptor in the endothelium to induce endothelial cell apoptosis and can be blocked by JAG1. Furthermore, NOTCH blockade in VSMC-DA suppresses the contractile phenotype and promotes the secretory phenotype of VSMC-DA cells, thereby enhancing tumor cell invasion and proliferation.

Notch-targeted therapies

As a classical and fundamental signaling pathway in humans, NOTCH is crucial for the development and homeostasis of most tissues. Deregulated NOTCH signaling leads to various diseases, as presented above. For decades, NOTCH-targeting therapeutic strategies have been searched, with many drugs being studied in the preclinical stage or tested in clinical trials. NOTCH signaling has been investigated as a therapeutic target for the treatment of cancer, most recently in the fields of immunity and inflammatory disorders. In the following chapter, research on ongoing or completed NOTCH-targeted therapeutics will be presented according to the employed mechanism (Table (Table33).

Table 3

Drugs targeting the NOTCH signaling pathway assessed in clinical trials

TypeDrugsNCT/Ref.YearPhaseStatusCancer type and patientsResults
GSIPF-03084014NCT008781892009ICompleted 完成Solid malignancies, N = 64
实体恶性肿瘤,N= 64

ORR: 13%;

1 CR observed in patients with advanced thyroid cancer, and 5 PRs in patients with desmoid tumors;
晚期甲状腺癌患者中观察到1例CR,硬纤维瘤患者中观察到5例PR;

All-grade AEs: 84.4%, grade ≥ 3 AEs: 35.9%.
所有级别AE:84.4%,≥ 3级AE:35.9%。

NCT008781892009ICompletedT-ALL and T-LBL, N = 81 CR in a T-ALL patient with NOTCH1 mutation.
NCT022996352015IITerminatedTNBC, N = 19

SAEs: 6/19;

study terminated prematurely based on project reprioritization by the sponsor.

NCT019815512013IIActiveDesmoid tumors (aggressive fibromatosis), N = 175 (29%) patients experienced a PR for more than 2 years with tolerable toxicity.
NCT041953992020IIRecruitingProgressive, surgically unresectable desmoid tumors, N = 35-
RO4929097NCT005320902007ICompletedPlatinum-resistant ovarian cancer, N = 110

1 PR in patients with colorectal adenocarcinoma with neuroendocrine features;

1 nearly complete FDG-PET response in a patient with melanoma.

NCT0111959920100/ICompletedGlioma, N = 21

No dose-limiting toxicities were observed in combination with temozolomide;

decreased expression of NICD in tumor cells and blood vessels.

NCT011753432010IICompletedPlatinum-resistant ovarian cancer, N = 45No objective responses were observed.
NCT011229012010IICompletedGBM, N = 47Inactive in recurrent GBM patients.
NCT011202752016IICompletedMetastatic melanoma, n = 32Tolerated but did not achieve NOTCH target inhibition.
NCT011166872010IICompletedMetastatic colorectal cancer, N = 37No radiographic responses were seen, and time to progression was short.
MK-0752NCT001001522005ITerminatedT-ALL, N = 50

1/6 patients showed 45% reduction in mediastinal mass;

study was halted for severe diarrhea.

NCT001061452005ICompletedSolid tumors, N = 103

1 objective response and 10 cases of SD were observed in patients with high-grade gliomas;

weekly dosing was generally well tolerated.

NCT005721822008ITerminatedBrain and central nervous system tumors, N = 33

No objective responses were reported in 23 pediatric patients;

study terminated by sponsor.

NCT006453332008I/IICompletedBreast cancer, N = 30Enhanced the efficacy of docetaxel with manageable toxicity.
NCT007567172008IVCompletedBreast cancer, N = 20

No serious adverse events;

No available efficacy data..

LY3039478NCT01695005,,2012ICompletedSolid cancers, N = 237

Prednisone might reduce gastrointestinal toxicities;

PR was observed in 1 patient with breast cancer, 1 patient with leiomyosarcoma and 1 patient with angiosarcoma.

NCT025181132015ICompletedT- ALL/T-LBL, N = 36

6 patients (16.7%) experienced DLTs;

1 patient (2.8%) had a confirmed response that lasted 10.51 months.

NCT027847952016IbCompletedSolid cancer, N = 94Combination with other anticancer agents produced disappointing results.
LY900009NCT011584042010ICompletedSolid cancer, N = 35

No objective response;

5/35 patients had a SD.

AL101NCT044616002020IIrecruitingNOTCH-activated TNBC, N = 67-
NCT049736832021IrecruitingNOTCH-activated ACC, N = 12-
DLL3Rovalpituzumab tesirine (Rova-T)NCT019016532013ICompletedSCLC, N = 74

11 (18%) patients had an objective response, ten of whom had high DLL3 expression;

28 (38%) suffered serious drug-related adverse events.

NCT028199992016ITerminatedSCLC, N = 26There was no clear efficacy benefit of combining Rova-T with platinum-based chemotherapy.
NCT030261662017I/IITerminatedSCLC, N = 42

ORR was 30% in patients treated with combination therapy with Rova-T and ICIs; however, the toxicity was high, suggesting that the combination was not well tolerated;

enrollment was stopped because of the DLT.

NCT026745682016IICompletedSCLC, N = 339

Median OS was 5.6 months;

grade 3-5 AEs were seen in 213 (63%) patients;

Demonstrated modest clinical activity in 3L+ SCLC, with associated toxicities.

NCT030335112017IIITerminatedSCLC, N = 748

Lack of survival benefit of maintenance therapy with rovalpituzumab tesirine after first-line platinum-based chemotherapy;

the study did not meet its primary end point and was terminated early.

NCT030618122017IIICompletedSCLC, N = 444Compared with topotecan, Rova-T exhibited an inferior OS and higher rates of serosal effusions, photosensitivity reactions, and peripheral edema.
SC-002NCT025009142015ITerminatedSCLC, N = 35

5 (14%) patients achieved a PR;

37% of patients had serious AEs considered to be related to SC-002;

no further development is planned because of the systemic toxicity and limited efficacy.

AM757NCT033199402017IRecruitingSCLC, N = 332-
HPN328NCT044717272020IRecruitingSCLC, N = 67-
DLL4Enoticumab (REGN421)NCT001871592015ICompletedSolid tumors, N = 53

2 PRs were observed in patients with NSCLC and ovarian cancer;

MTD was not reached.

Demcizumab (OMP-21M18)NCT007445632014ICompletedSolid tumors, N = 55Demonstrated antitumor activity with a low dose.
NCT011899682010ICompletedMetastatic nonsquamous NSCLC, N = 40

Modulated the expression of genes regulating NOTCH signaling and angiogenesis;

increased the risk of cardiovascular disease when combined with pemetrexed and carboplatin.

NCT019522492013Ib/IIPhase Ib, completed; phase II, terminatedPlatinum-resistant ovarian, primary peritoneal, and fallopian tube cancer, N = 19

Researchers are no longer pursuing ovarian cancer as an indication;

the phase II portion of the study was terminated.

NOTCH1Brontictuzumab (OMP-52M51)NCT017784392013ICompletedSelected refractory solid tumors, N = 48

2 patients achieved PR and 4 patients achieved ≥ 6 months of SD in ACC with NOTCH1 activation;

DLTs included diarrhea and fatigue.

NOTCH2/3Tarextumab (OMP-59R5)NCT012771462011ICompletedSolid tumors, N = 42

9 subjects had SD;

Lower doses were tolerated.

NCT016478282012IICompletedUntreated metastatic pancreatic cancer, N = 177There were no OS, PFS, or ORR benefits with the addition of tarextumab to nab-paclitaxel and gemcitabine in first-line metastatic PDAC.
NCT018597412019I/IITerminatedSCLC, N = 172Terminated for unimproved PFS in combination with etoposide and platinum therapy.
NOTCH3PF-06650808NCT021292052014ITerminatedBreast cancer and other advanced solid tumors, N = 40

5 PRs were observed with manageable safety;

all of responders had positive NOTCH3 expression;

the study was terminated due to a change in sponsor prioritization.

T-ALL T cell acute lymphoblastic leukemia, T-LBL T cell lymphoblastic lymphoma, TNBC triple-negative breast cancer, SCLC small-cell lung cancer, NSCLC non-small-cell lung cancer, PDAC pancreatic ductal adenocarcinoma, GBM glioblastoma, ORR objective response rate, CR complete response, PR partial response, SD stable disease, PFS progression-free survival, OS overall survival, AE adverse event, SAE serious adverse event, ACC adenoid cystic carcinoma, FDG-PET [18F]-2-fluoro-2-deoxy-D-glucose-positron emission tomography, DLT dose-limiting toxicity, NICD NOTCH intracellular domain, 3L+ more than 3 lines of therapy, MTD maximum tolerated dose
T-ALLT细胞急性淋巴细胞白血病、T-LBLT细胞淋巴细胞淋巴瘤、TNBC三阴性乳腺癌、SCLC小细胞肺癌、非小细胞肺癌、PDAC胰腺导管腺癌、GBM胶质母细胞瘤、ORR客观缓解率、CR完全缓解、PR部分缓解、SD疾病稳定、PFS无进展生存期、OS总生存期、AE不良事件、SAE严重不良事件、ACC腺样囊性癌、FDG-PET[18 F]-2-氟-2-脱氧-D-葡萄糖-正电子发射断层扫描、DLT剂量限制性毒性、NICDNOTCH细胞内结构域、3L+3线以上治疗、MTD最大耐受剂量

Cleavage inhibitors 切割抑制剂

S1 cleavage S1分裂

Precursors of NOTCH receptors require S1 cleavage in the Golgi before integration with their ligands. Sarcoendoplasmic reticulum Ca2+-ATPase (SERCA) is an important accessory factor in this process that modulates ATP-dependent calcium pumps. Malfunction of SERCAs impairs NOTCH signaling, especially that of mutant NOTCH1. Mutant NOTCH1 protein acts as an oncogene in T-ALL as well as other malignant tumors, making SERCAs potential therapeutic targets. Thapsigargin, a guaianolide compound of plant origin that inhibits SERCAs in mammalian cells, has been tested in breast cancer and leukemia at the preclinical stage. CPA, CAD204520 and other small molecular inhibitors of SERCA with lower off-target toxicity have been investigated in the laboratory, yet no surprising results have been reported to encourage further clinical trials.
NOTCH受体的前体在与其配体整合之前需要高尔基体中的S1裂解。肌内质网Ca 2 +-ATP酶(SERCA)是该过程中调节ATP依赖性钙泵的重要辅助因子。SERCA的功能障碍损害NOTCH信号传导,尤其是突变体NOTCH 1。突变体NOTCH 1蛋白在T-ALL以及其他恶性肿瘤中充当致癌基因,使得SERCA成为潜在的治疗靶标。毒胡萝卜素是一种抑制哺乳动物细胞中SERCA的植物来源的愈创木酚化合物,已在临床前阶段535 - 537在乳腺癌和白血病中进行了测试。 CPA、CAD 204520和其他具有较低脱靶毒性的SERCA小分子抑制剂已在实验室进行了研究,但尚未报告任何令人惊讶的结果来鼓励进一步的临床试验。

S2 cleavage

S2 cleavage occurs in the ligand–receptor binding domain, mediating ectodomain shedding and regulating the transmission speed of NOTCH signaling,. A disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) or ADAM17 (also called tumor necrosis factor-alpha convertase, TACE) can be exploited to prevent S2 cleavage and NOTCH signaling transmission, as they are key enzymes of S2 cleavage,. Similar to SERCA inhibitors, ADAM inhibitors target the entire NOTCH pathway. Small molecule drugs targeting ADAMs have been studied in non-small-cell lung cancer, hepatocellular carcinoma, renal carcinoma, breast cancer, and systemic sclerosis. Some of these inhibitors have shown anti-NOTCH activities in vitro and in animal experiments, yet no clinical trial has been initiated.
S2裂解发生在配体-受体结合结构域中,介导胞外域脱落并调节NOTCH信号传导的传输速度。可以利用含有去整合素和金属蛋白酶结构域的蛋白10(ADAM 10)或ADAM 17(也称为肿瘤坏死因子-α转化酶,TACE)来防止S2裂解和NOTCH信号传导,因为它们是S2裂解的关键酶 - 。与SERCA抑制剂类似,ADAM抑制剂针对整个NOTCH途径。 靶向亚当斯的小分子药物已经在非小细胞肺癌、肝细胞癌、肾癌、乳腺癌和系统性硬化症。这些抑制剂中的一些已经在体外和动物实验中显示出抗NOTCH活性,但尚未启动临床试验。

S3 cleavage S3裂解

The canonical signal transmission of NOTCH signaling from outisde the cell to inside the cell relies heavily on S3 cleavage mediated by the γ-secretase complex,, suggesting that it is promising to modulate the function of γ-secretase for treatment.
NOTCH信号传导从细胞外到细胞内的典型信号传递严重依赖于由γ-分泌酶复合物介导的S3切割,这表明有希望调节γ-分泌酶的功能用于治疗。

γ-Secretase inhibitors

γ-Secretase inhibitors (GSIs) were first tested as a treatment for Alzheimer’s disease (AD) in clinical trials because γ-secretase contributes to catalyzing the production of β-amyloid peptide. Unfortunately, the study was terminated shortly after it began because of serious NOTCH-associated adverse events such as gastrointestinal symptoms, infections, and nonmelanoma skin cancers. Since then, researchers have attempted to treat cancer with GSIs to disrupt NOTCH signaling. In preclinical studies, GSIs are widely studied as a treatment for cancer, showing antitumor activity in diverse tumor types, such as breast cancer,, hepatocellular carcinoma,, non-small-cell lung cancer, colorectal cancer, prostate cancer, and gliomas. Cancer patients were first documented to receive GSI treatment in 2006, with one of six patients with T-ALL or acute myeloid leukemia receiving MK-0752 in a phase I clinical trial; the trial showed a promising 45% reduction in mediastinal mass after 28 days, although the treatment was paused because of severe diarrhea (NCT00100152). Other drugs, including PF-03084014, RO4929097,, BMS-986115, LY900009, LY3039478, and MK-0752,, have emerged in phase I trials, all of which have shown antitumor efficacy. However, most have presented dose-limiting toxicities. To date, only RO4929097 and PF-03084014 have entered phase II trials. Unfortunately, although the adverse events (AEs) were well tolerated, only 1 patient among 32 patients with metastatic melanoma treated with RO4929097 achieved a partial response. Similar outcomes occurred in platinum-resistant epithelial ovarian cancer and colorectal cancer, with no objective response among valid participants,; thus, few agents have entered phase III/IV clinical trials. PF-03084014, also called nirogacestat, achieved more promising outcomes in patients with desmoid tumors (aggressive fibromatosis) than RO4929097, as 29% of the 15 patients experienced a confirmed partial response that was maintained for more than 2 years. A phase III clinical trial for nirogacestat has already been registered, although the trial has yet to begin (NCT03785964).


γ-分泌酶抑制剂
γ-分泌酶抑制剂(GSI)首先在临床试验中作为阿尔茨海默病(AD)的治疗方法进行测试,因为γ-分泌酶有助于催化β-淀粉样肽的产生。不幸的是,这项研究在开始后不久就被终止了,因为严重的NOTCH相关不良事件,如胃肠道症状,感染和非黑色素瘤皮肤癌551。从那时起,研究人员试图用GSI来破坏NOTCH信号来治疗癌症。在临床前研究中,GSI被广泛研究用于治疗癌症,在多种肿瘤类型中显示出抗肿瘤活性,如乳腺癌552,553,肝细胞癌554,555,非小细胞肺癌556,结直肠癌557,前列腺癌558和神经胶质瘤559。 癌症患者在2006年首次被记录接受GSI治疗,其中六名T-ALL或急性髓性白血病患者中的一名在I期临床试验中接受MK-0752;该试验显示28天后纵隔肿块减少了45%,尽管治疗因严重腹泻而暂停(NCT 00100152)。其他药物,包括PF-03084014560、RO 4929097561,562、BMS-986115563、LY 900009564、LY 3039478565和MK-0752566,567,已在I期试验中出现,所有这些药物均显示出抗肿瘤疗效。然而,大多数都表现出剂量限制性毒性。迄今为止,只有RO 4929097和PF-03084014进入了II期试验。不幸的是,尽管不良事件(AE)耐受良好,但在接受RO 4929097治疗的32例转移性黑色素瘤患者中,仅1例患者获得部分缓解568。 铂类耐药的上皮性卵巢癌和结直肠癌也出现了类似的结果,有效参与者中没有客观反应569,570;因此,很少有药物进入III/IV期临床试验。PF-03084014(也称为nirogacestat)在硬纤维瘤(侵袭性纤维瘤病)患者中取得了比RO 4929097更有希望的结局,因为15例患者中有29%的患者证实部分缓解,并维持超过2年571。尼罗加司他的III期临床试验已经注册,尽管该试验尚未开始(NCT 03785964)。

In addition to cancer, because NOTCH plays a critical role in the differentiation of Th cells, GSIs have also been studied in allergic diseases such as asthma. NOTCH signaling regulates Th1 and Th2 responses in allergic pulmonary inflammation, indicating its promising targetability in immune disease.
除了癌症之外,由于NOTCH在Th细胞的分化中起关键作用,GSI也在过敏性疾病如哮喘中进行了研究。NOTCH信号调节过敏性肺部炎症中的Th1和Th2应答,表明其在免疫性疾病中有希望的靶向性。

γ-Secretase modulators

γ-Secretase modulators (GSMs) were originally studied in AD. As a superior option to GSIs, GSMs aim to modify the catalytic activity of γ-secretase rather than to nonselectively inhibit it, enabling partial NOTCH signaling function to be maintained and thus theoretically ameliorating adverse events. The selective inhibitor MRK-560 targeting PSEN1, an important catalytic subclass of γ-secretase complexes, has been proven to effectively decrease mutant NOTCH1 processing and cause cell cycle arrest in T-ALL without associated gut toxicity. GSMs are only applied in AD as drugs that are designed to modulate amyloid-β (Aβ) peptide generation without impacting the function of NOTCH,.

Antibody-drug conjugates

Given the severe adverse events of inhibiting the overall NOTCH pathway, antibodies targeting different receptors and ligands have been explored to achieve precise targeting of NOTCH signaling,. There are five ligands and four receptors in the NOTCH signaling pathway. Although the roles of each component are not completely clear, functions related to specific diseases have been confirmed, making them potential targets.

Antibodies against ligands

JAG1

As reported previously, the upregulated expression of JAG1 enhances proliferation and angiogenesis in various malignant tumors, including adrenocortical carcinoma, breast cancer, and prostate cancer. These pathological mechanisms make JAG1 a promising target, and monoclonal antibodies against JAG1 have been studied in breast cancer, ovarian cancer, and other malignant tumors. 15D11, one of the most promising fully human monoclonal antibodies against JAG1, has been studied at the preclinical stage; 15D11 increases chemotherapy sensitivity, reduces neoplastic growth in bone metastases, and, most importantly, causes minor adverse effects.

DLL3

DLL3 is an inhibitory ligand of NOTCH signaling that is highly upregulated and aberrantly expressed on the cell surface of small-cell lung cancer (SCLC) and other high-grade neuroendocrine tumors as a key driving gene,,. DLL3-directed antibody-drug conjugates (ADCs) induce durable and safe responses in SCLC and large-cell neuroendocrine cancer (LCNEC) PDX tumor models. Positive results inspired further clinical trials. In 2017, Charles M Rudin et al. first reported their encouraging results of rovalpituzumab tesirine (Rova-T); 11 of 60 assessable patients with SCLC or LCNEC had confirmed objective responses, and the objective response rate (ORR) was relatively higher in patients with high DLL3 expression. Although 38% of 74 patients suffered severe drug-related AEs, the AEs could be controlled. Unfortunately, further phase II and III studies failed to achieve their efficacy end points. Relapsed/refractory SCLC patients receiving Rova-T after at least two lines of therapy achieved a median overall survival (mOS) time of only 5.6 months, and the ORR was 12.4%. A study of Rova-T as a maintenance therapy after first-line platinum-based chemotherapy was terminated shortly after it began due to a lack of survival benefit. Compared with concurrent standard second-line chemotherapy, Rova-T showed shorter OS and lower safety. Attempts to combine chemotherapy and immune checkpoint inhibitors also failed, with extra toxicities and moderate efficacy,. Although the abovementioned studies failed to meet their expected end points, complete responses appeared in nearly every study, indicating that this therapeutic strategy has good prospects. However, strategies to stratify patients and appropriate biomarkers should be explored. Researchers have also attempted to explore further indications and novel drugs related to DLL3-targeting antibodies. IDH-mutant gliomas show selective and homogeneous expression of DLL3, and researchers found that patient-derived IDH-mutant glioma tumorspheres were sensitive to Rova-T in vitro. Another DLL3 ADC, SC-002, presented an ORR of 14% and a severe AE rate of 37% in a phase I clinical trial in SCLC. Furthermore, some novel drugs targeting DLL3 are in trials actively recruiting patients, such as AM757 (a bispecific antibody targeting DLL3 and CD3, NCT04702737) and HPN328 (a trispecific antibody, NCT04471727).

DLL4

DLL4 is an important regulator of tumor angiogenesis and cancer stem cells and is activated in a wide range of human cancers. The combination of specific DLL4 blockade and ionizing radiation impairs tumor growth by promoting nonfunctional tumor angiogenesis and extensive tumor necrosis. When combined with VEGF blockade, REGN421, a monoclonal antibody targeting DLL4, presented antitumor effects in ovarian cancer. A phase I clinical trial of REGN421, also called enoticumab, was conducted in patients with advanced solid tumors. Of the 32 treated patients in whom toxicity was tolerable, 2 patients had partial response, and 16 patients had stable disease. Demcizumab, another anti-DLL4 antibody, showed antitumor activity at the minimum dose and with shorter exposure in a phase I clinical study of solid tumors but presented a significant risk of cardiac toxicity. After dose optimization, combining demcizumab with paclitaxel achieved an ORR of 21% in platinum-resistant ovarian cancer patients without dose-limiting toxicity. Strategies employing dual variable domain immunoglobulin (DVD-Ig) molecules targeting DLL4 and VEGF have been studied, such as ABT-165, which showed superior efficacy and safety in preclinical models, and navicixizumab (OMP-305B83), which presented modest antitumor potency and toxicity in a phase Ib clinical trial of solid tumors.

JAG2/DLL1

JAG2, believed to promote cell survival and proliferation, interacts with NOTCH2, the nucleus pulposus (NP), and hematopoietic stem and progenitor cells (HSPCs). Additionally, high expression of JAG2 facilitates the development of cancers, such as lung adenocarcinoma and bladder cancer. DLL1 is essential for the development and differentiation of B lymphocytes,. These two ligands might be promising targets, although drugs targeting these ligands have yet to be reported.

Antibodies against receptors

NOTCH1

Mutant NOTCH1 induces the occurrence of T-ALL and T-ALL cell proliferation,. It can also act as an oncogene in colorectal carcinoma, glioma and other malignant tumors, making it a possible antitumor target. In phase I clinical trials, a monoclonal antibody targeting NOTCH1 called brontictuzumab was tested in patients with solid tumors (NCT03031691 and NCT01778439) and lymphoid malignancies (NCT01703572). A clinical benefit was achieved in 6 of 12 ACC patients with tolerable toxicity. In addition to tumor activation, NOTCH1 also promotes the immune response depending on Tregs. In preclinical trials, drugs selectively inhibiting NOTCH1 have been shown to strengthen the function of Tregs to suppress the progression of inflammatory arthritis and modulate the immune response in transplantation.

NOTCH2/NOTCH3

Dysregulated NOTCH2 is vital for the development of cancers such as some B cell leukemias, pancreatic ductal adenocarcinoma (PDAC), and malignant melanoma. Similarly, NOTCH3 acts as a facilitating factor in various tumors, such as lung cancer, ERBB2-negative breast cancer, and ovarian cancer. OMP-59R5 (tarextumab), which blocks both NOTCH2 and NOTCH3, is effective in treating a variety of tumors and has been tested as a treatment for PDAC, SCLC (NCT01859741), and other solid tumors in clinical trials. However, OMP-59R5 in combination with chemotherapy did not produce a superior outcome in PDAC or SCLC patients, and neither drug achieved a better objective response in other solid tumors. PF-06650808, a novel anti-NOTCH3 ADC, achieved 5 partial responses among 40 patients with breast cancer or other solid tumors, with a manageable safety profile and positive NOTCH3 expression detected in all responders.

NOTCH4

The functions of NOTCH4 differ in different types of cancer. The overexpression of NOTCH4 is regarded as a poor prognosis marker in some scenarios, while in others, it is considered a favorable marker. There are no mature drugs targeting NOTCH4.

Transcription blockers 转录阻断剂

Activating the transcription of target genes is the last step of NOTCH signaling. Therapies targeting downstream mediators of NOTCH signaling remain unexplored. NOTCH transcription depends on the NOTCH ternary complex (NTC), which contains the DNA-binding protein CSL (also called CBF-1/RBPJ, Su (H), or Lag-1), NICD and MAML1,. RIN1, a small molecule inhibitor of RBPJ, causes proliferation of hematologic cancer cell lines in vitro. IMR-1, a small molecule inhibitor of MAML1, inhibits the growth of NOTCH-dependent cell lines in vitro. CB-103, an orally active small molecule altering NTC function, produces loss-of-function NOTCH phenotypes and inhibits the growth of human breast cancer and leukemia xenografts, notably without causing the dose-limiting intestinal toxicity of other NOTCH inhibitors. Such novel drugs may represent new agents for NOTCH-based diseases.
激活靶基因的转录是NOTCH信号传导的最后一步。靶向NOTCH信号传导的下游介质的疗法仍然未被探索。NOTCH转录依赖于NOTCH三元复合物(NTC),其含有DNA结合蛋白CSL(也称为CBF-1/RBPJ、Su(H)或Lag-1)、NICD和MAML 1。RIN 1,RBPJ的小分子抑制剂,在体外引起血液癌细胞系的增殖。IMR-I,MAMLl的小分子抑制剂,在体外抑制NOTCH依赖性细胞系的生长。 CB-103是一种改变NTC功能的口服活性小分子,产生功能丧失的NOTCH表型并抑制人乳腺癌和白血病异种移植物的生长,特别是不会引起其他NOTCH抑制剂的剂量限制性肠毒性。这些新药物可能代表基于NOTCH的疾病的新药剂。

NOTCH signaling agonists NOTCH信号激动剂

NOTCH signaling can both accelerate and suppress the development of diseases, which unsurprisingly applies in cancers,. That is, enhancing NOTCH signaling can be a targeted therapy strategy. Some chrysin and hesperetin compounds have been used to activate NOTCH signaling in anaplastic thyroid cancer with NOTCH1 deficiency,. Inhibitory effects on established tumor cell lines were found, although the underlying mechanism remains unclear. The negative regulatory region (NRR) can autoinhibit the metalloprotease cleavage of NOTCH to enhance its signaling. Some activating antibodies of NOTCH receptors induce conformational changes in the NRR, making it accessible to ADAM metalloproteinases, thus facilitating activation of NOTCH signaling.
NOTCH信号传导可以加速和抑制疾病的发展,这毫不奇怪地适用于癌症。也就是说,增强NOTCH信号传导可以是靶向治疗策略。一些白杨素和橙皮素化合物已被用于激活NOTCH 1缺乏的未分化甲状腺癌中的NOTCH信号。发现对已建立的肿瘤细胞系有抑制作用,但其潜在机制仍不清楚。负调控区(NRR)可以自身抑制金属蛋白酶切割NOTCH以增强其信号传导。NOTCH受体的一些活化抗体诱导NRR的构象变化,使其可接近ADAM金属蛋白酶,从而促进NOTCH信号转导的活化

Summary of clinical trials
临床试验小结

Several NOTCH-targeted therapies have been evaluated in clinical trials; specifically, these therapies have been tested in cancers. Among cleavage inhibitors, drugs targeting S1-S2 cleavage are still within preclinical stages. Drugs targeting S3 cleavage (GSIs and GSMs) have made their way into further clinical research; research of GSIs has been restrained due to severe toxicities, though GSMs are being continuously explored. Among the antibodies against ligands, drugs targeting JAG1, DLL3 and DLL4 have shown promising results in preclinical studies. Drugs targeting DLL3 and DLL4 have been studied in early clinical trials, with only those targeting DLL3 performing well. Unfortunately, further studies of agents targeting DLL3 failed to meet expectations. Drugs targeting JAG2/DLL1 have shown great potential, but no drug has reached mature development. Among the antibodies against receptors, the majority have achieved mediocre results. Of the transcription blockers and signal agonists, the blockers have only been studied in the preclinical stage, while agonists remain only theoretical. Of the abovementioned agents, those targeting DLL3 and GSIs are the most popular because they have shown potential.
一些NOTCH靶向疗法已在临床试验中进行了评估;具体而言,这些疗法已在癌症中进行了测试。在裂解抑制剂中,靶向S1-S2裂解的药物仍处于临床前阶段。靶向S3切割的药物(GSI和GSMs)已经进入了进一步的临床研究; GSI的研究由于严重的毒性而受到限制,尽管GSMs正在不断探索。在针对配体的抗体中,靶向JAG 1、DLL 3和DLL 4的药物在临床前研究中显示出有希望的结果。靶向DLL 3和DLL 4的药物已经在早期临床试验中进行了研究,只有靶向DLL 3的药物表现良好。不幸的是,针对DLL 3的药物的进一步研究未能达到预期。针对JAG 2/DLL 1的药物已经显示出巨大的潜力,但还没有药物达到成熟的开发。在针对受体的抗体中,大多数都取得了平庸的结果。 在转录阻断剂和信号激动剂中,阻断剂仅在临床前阶段进行了研究,而激动剂仅停留在理论上。在上述药物中,靶向DLL3和GSI的药物是最受欢迎的,因为它们显示出潜力。

However, neither of these agents can be applied clinically considering safety and efficacy. On the one hand, most pan-NOTCH inhibitors exhibit dose-limiting gastrointestinal toxicities mediated by hyperplasia of intestinal goblet cells, including diarrhea and vomiting, which often lead to suspension of further investigations,. Regarding GSIs, attempts have been made to improve tolerance, such as combining GSIs with glucocorticoids, using intermittent dosing regimens, and applying drugs that inhibit disease-specific subunits of the γ-secretase complex. On the other hand, the majority of ADCs have failed to reach the expected efficacy in cancer studies, although they have performed well in some individuals. Cell heterogeneity might be an explanation for such findings. Taking SCLC as an example, researchers found that a minority of nonneuroendocrine SCLC cells with NOTCH activation could sustain the growth of neuroendocrine SCLC cells without NOTCH activation and exhibit cancer stem cell-like properties, resulting in primary resistance to anti-DLL3 drugs. Insufficient affinity of ADCs might be another reasonable explanation. Additionally, the complexity of NOTCH signaling and bypass signaling might circumvent NOTCH-targeted therapies. In the future, exploring predictive biomarkers, reducing drug toxicities, and exploiting multitargeted drugs might overcome the challenges of NOTCH-targeted therapies.
然而,考虑到安全性和有效性,这两种药物都不能在临床上应用。一方面,大多数pan-NOTCH抑制剂表现出由肠杯状细胞增生介导的剂量限制性胃肠道毒性,包括腹泻和呕吐,这通常导致进一步研究的暂停。关于GSI,已经尝试改善耐受性,例如将GSI与糖皮质激素组合,使用间歇给药方案,以及应用抑制γ-分泌酶复合物的疾病特异性亚基的药物。另一方面,大多数ADC在癌症研究中未能达到预期的疗效,尽管它们在一些个体中表现良好。 细胞异质性可能是这种发现的一种解释。以SCLC为例,研究人员发现,少数具有NOTCH激活的非神经内分泌SCLC细胞可以在没有NOTCH激活的情况下维持神经内分泌SCLC细胞的生长,并表现出癌症干细胞样特性,导致对抗DLL3药物的原发性耐药性。ADC的亲和力不足可能是另一个合理的解释。此外,NOTCH信号传导和旁路信号传导的复杂性可能会规避NOTCH靶向治疗。在未来,探索预测性生物标志物,降低药物毒性和开发多靶向药物可能会克服NOTCH靶向治疗的挑战。

Concluding remarks and future perspectives
结束语和未来展望

It has been approximately 110 years since the NOTCH gene was first identified in D. melanogaster. We summarized both classical and cutting-edge findings of NOTCH signaling in this review, illustrating the history, architecture, regulatory mechanism, physiology, and pathology of NOTCH signaling as well as therapeutics targeting NOTCH signaling. We identified certain areas of basic research and clinical applications of NOTCH signaling as worthy of further exploration.
自NOTCH基因在D.黑腹菌我们总结了NOTCH信号的经典和前沿研究成果,阐述了NOTCH信号的历史,结构,调节机制,生理和病理以及针对NOTCH信号的治疗方法。我们确定了NOTCH信号的基础研究和临床应用的某些领域值得进一步探索。

One of the most interesting things regarding NOTCH signaling is the dual role it plays in different conditions, particularly in cancers. First, the functions of NOTCH signaling are different within the same tissues, and this is possibly caused by the utilization of different ligands; for example, DLL4/JAG1 regulates tumor vasculature, and DLL1/JAG2 regulate DC functions. Second, the functions of NOTCH signaling vary in different tissues. For instance, NOTCH acts as an oncogene in some tumors and as a tumor suppressor gene in others. Several mechanisms might explain this phenomenon: (a) Different tissues have different expression patterns of NOTCH signaling components, and thus, the outcomes of NOTCH signaling are tissue-specific; for example, DLL3 has tissue-specific effects in SCLC, and NOTCH1 has tissue-specific effects in T-ALL. (b) NOTCH signaling effects occur over a small range, while the cell morphology and intercellular distance are diverse in different tissues. (c) NOTCH signaling activates the transcription of a series of genes containing both positive and negative regulators of biological events. As these downstream genes are also regulated by other driver genes, such as Myc and P53, the mutational status of these driver genes also affects the outcome of NOTCH signaling. Third, tumors are massive complexes containing different clones of cancer cells and multiple types of noncancerous cells, making the overall effect of NOTCH signaling complicated and unpredictable.
关于NOTCH信号传导最有趣的事情之一是它在不同条件下发挥的双重作用,特别是在癌症中。首先,NOTCH信号传导的功能在相同组织内是不同的,这可能是由不同配体的利用引起的;例如,DLL 4/JAG 1调节肿瘤血管,DLL 1/JAG 2调节DC功能。其次,NOTCH信号传导的功能在不同组织中不同。例如,NOTCH在一些肿瘤中作为致癌基因,在另一些肿瘤中作为肿瘤抑制基因。几种机制可以解释这种现象:(a)不同组织具有不同的NOTCH信号传导组分的表达模式,因此,NOTCH信号传导的结果是组织特异性的;例如,DLL 3在SCLC中具有组织特异性作用,而NOTCH 1在T-ALL中具有组织特异性作用。(b)NOTCH信号的作用范围较小,不同组织的细胞形态和细胞间距不同。 (c)NOTCH信号传导激活一系列基因的转录,这些基因包含生物事件的正调控因子和负调控因子。由于这些下游基因也受到其他驱动基因(如MycP53)的调控,因此这些驱动基因的突变状态也会影响NOTCH信号转导的结果。第三,肿瘤是包含不同克隆的癌细胞和多种类型的非癌细胞的巨大复合物,使得NOTCH信号传导的整体效果复杂且不可预测。

Several strategies can be employed to clarify the mechanisms of NOTCH signaling. First, deciphering the subtle differences between different ligand–receptor interactions is essential. Second, spatially resolved transcriptomic analyses, which dissect the embedded tissues into very small pieces and acquire their expression profiles, can be used to explore the impact of spatial characteristics on the outcome of NOTCH signaling. Third, comprehensive analysis of NOTCH target genes is needed because there may be more target genes than are currently known, and epigenetic and transcriptomic analyses might help.
可以采用几种策略来阐明NOTCH信令的机制。首先,破译不同配体-受体相互作用之间的细微差异至关重要。第二,空间分辨转录组分析,其将包埋的组织解剖成非常小的块并获取其表达谱,可用于探索空间特征对NOTCH信号传导结果的影响。第三,需要对NOTCH靶基因进行全面分析,因为靶基因可能比目前已知的更多,表观遗传学和转录组学分析可能会有所帮助。

NOTCH-targeted therapy has been studied for decades but has failed to meet expectations. The reasons for these shortcomings might be the cytotoxicity induced by pan-NOTCH inhibitors, the low affinity of current ADCs, and the upregulation of bypass pathways. Novel drugs such as isoform-specific drugs and high-affinity ADCs may be a solution, as they might have increased efficacy and lower cytotoxicity. In addition, protein refolding is an attractive mode of action to employ to restore the functions of inactivated NOTCH signaling. Another strategy is to develop novel treatment strategies, such as DC-pulsed vaccine therapy and synNOTCH CAR-T cell therapy. Complementary combination therapies, such as combination of inhibitors of other pathways, chemotherapy, radiation therapy, and immunotherapy, are also promising. Among these potential combinations, combinations with immunotherapy are expected to be the most useful.
NOTCH靶向治疗已经研究了几十年,但未能达到预期。这些缺点的原因可能是pan-NOTCH抑制剂诱导的细胞毒性、当前ADC的低亲和力以及旁路途径的上调。新型药物如亚型特异性药物和高亲和力ADC可能是一种解决方案,因为它们可能具有更高的疗效和更低的细胞毒性。此外,蛋白质重折叠是用于恢复失活的NOTCH信号传导的功能的有吸引力的作用模式。另一种策略是开发新的治疗策略,如DC脉冲疫苗疗法和synNOTCH CAR-T细胞疗法。互补的组合疗法,例如其他途径的抑制剂、化学疗法、放射疗法和免疫疗法的组合,也是有希望的。在这些潜在的组合中,与免疫疗法的组合预计是最有用的。

Much work remains to be accomplished for combining NOTCH-targeted therapy with immunotherapy, and the following strategies might help. First, functional studies are needed to comprehensively delineate the consequences of different NOTCH mutations and their effects on the immune microenvironment. NOTCH plays a complex role in tumor immunity, and its overall impact on tumors remains unclear. Second, clinical applications targeting different stages and types of cancer should be considered separately. Canonical NOTCH signaling is widely activated among cells to mediate adjacent intercellular interactions, yet its effects are highly dependent on context and/or cancer type. Third, appropriate ligands and/or receptors should be well chosen because they may have contradictory biological effects. For example, DLL1-NOTCH mainly functions as an immune-activating signal in DCs and CD8+ T cells. However, JAG1/2-NOTCH mainly functions as an immunosuppressive signal, inhibiting DCs and CD8+ T cells while activating many immunosuppressive cells. It is evident that drugs selectively enhancing DLL1-NOTCH signaling while inhibiting JAG1/2-NOTCH signaling can outperform pan-NOTCH-targeting drugs in actual practice. Fourth, conditions triggering the anti-immune or proimmune effects of NOTCH signaling in tumor cells should be considered. It has been acknowledged that NOTCH signaling may be immunosuppressive or tumor suppressive, yet the conditions or triggering factors leading to certain effects remain unknown. Thus, the effect of NOTCH signaling under different microenvironments should be investigated to generate better and more predictable medical applications. Fifth, cytotoxicity should be considered, including the toxicity of the drug itself and the toxicities induced by combination therapies. Sixth, predictive biomarkers should be explored to bolster NOTCH-targeting monotherapy and/or ICI therapy should be combined with NOTCH-targeting monotherapy to achieve maximum efficacy.
将NOTCH靶向治疗与免疫治疗相结合还有很多工作要做,以下策略可能会有所帮助。首先,需要功能研究来全面描述不同NOTCH突变的后果及其对免疫微环境的影响。NOTCH在肿瘤免疫中起着复杂的作用,其对肿瘤的总体影响尚不清楚。其次,针对不同阶段和类型癌症的临床应用应分开考虑。典型的NOTCH信号在细胞中被广泛激活以介导相邻的细胞间相互作用,但其作用高度依赖于背景和/或癌症类型。第三,应选择适当的配体和/或受体,因为它们可能具有相互矛盾的生物学作用。例如,DLL 1-NOTCH主要在DC和CD 8 + T细胞中发挥免疫激活信号的作用。 然而,JAG 1/2-NOTCH主要用作免疫抑制信号,抑制DC和CD 8 + T细胞,同时激活许多免疫抑制细胞。显然,在实际应用中,选择性增强DLL 1-NOTCH信号传导同时抑制JAG 1/2-NOTCH信号传导的药物可以优于泛NOTCH靶向药物。第四,应考虑触发肿瘤细胞中NOTCH信号传导的抗免疫或促免疫作用的条件。人们已经认识到,NOTCH信号可能是免疫抑制或肿瘤抑制,但导致某些影响的条件或触发因素仍然未知。因此,应研究NOTCH信号在不同微环境下的作用,以产生更好和更可预测的医疗应用。第五,应考虑细胞毒性,包括药物本身的毒性和联合治疗引起的毒性。 第六,应探索预测性生物标志物以支持NOTCH靶向单药治疗和/或ICI治疗应与NOTCH靶向单药治疗相结合以实现最大疗效。

In summary, NOTCH factors present complicated and highly changeable functions, suggesting that elaboration of the general mechanism is required. Novel drugs with higher efficacy and lower cytotoxicity are worth investigating, as are new therapeutic strategies. Once a complete understanding of NOTCH signaling is achieved, it can be applied in actual medical practice, fulfilling the long-overdue mission of benefiting patients.
总之,NOTCH因子呈现复杂且高度可变的功能,这表明需要详细阐述一般机制。具有更高疗效和更低细胞毒性的新药值得研究,新的治疗策略也是如此。一旦对NOTCH信号有了完整的理解,就可以将其应用于实际的医疗实践,完成期待已久的造福患者的使命。

Acknowledgements 确认

This work was supported by the National Natural Science Foundation of China (No. 62131009, 82072597, 81874120, and 82073370).
这项工作得到了国家自然科学基金(编号:62131009、82072597、81874120、82073370)的资助。

Author contributions 作者贡献

Q.C. conceptualized this review. B.Z. and W.L. primarily searched for the papers and made the outline. B.Z., W.L., and Y.L. drafted the manuscript and drew the figures. Y.Y. edited the language. H.Z. helped with paper searching. Q.C. and K.W. provided helpful suggestions on the structure and content of this review. All authors revised the manuscript. All authors have read and approved the article.
Q.C.将这一审查概念化。B.Z.和W.L.之间。主要是搜索论文并做提纲。B. Z.,W.L.,和Y. L.起草手稿并绘制图形。Y.Y.编辑语言。H. Z.帮助搜索文件。Q.C.和K.W.就本次审查的结构和内容提出了有益的建议。所有作者都修改了手稿。所有作者均已阅读并批准该文章。

Competing interests 相互竞争的利益

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Figures were created with biorender.com.
作者声明,本研究是在不存在任何可能被视为潜在利益冲突的商业或财务关系的情况下进行的。图片由biorender.com创建。

Footnotes 脚注

These authors contributed equally: Binghan Zhou, Wanling Lin, Yaling Long
这些作者贡献均等:周秉涵,林万玲,龙亚玲

Supplementary information
补充资料

The online version contains supplementary material available at 10.1038/s41392-022-00934-y 假设:40.8 Q1 .
在线版本包含补充材料,可通过10.1038/s41392-022-00934-y假设:40.8Q1

References 引用

1. Metz CW, Bridges CB. Incompatibility of mutant races in Drosophila. Proc. Natl Acad. Sci. USA. 1917;3:673–678. [PMC free article] [PubMed] []
1. 梅斯CW,布里奇斯CB。果蝇突变小种的不相容性。美国国家科学院院报Sci. USA. 1917;3:673-678. [PMC免费文章][PubMed][]
2. Mohr OL. Character changes caused by mutation of an entire region of a chromosome in Drosophila. Genetics. 1919;4:275–282. [PMC free article] [PubMed] []
2. 莫尔山口果蝇染色体的整个区域突变引起的性状变化。遗传学1919;4:275-282. [PMC免费文章][PubMed][]
3. Bridges CB. Non-disjunction as proof of the chromosome theory of heredity (concluded) Genetics. 1916;1:107–163. [PMC free article] [PubMed] []
3. Bridges CB.不分离作为遗传的染色体理论的证据(结束)遗传学。1916;1:107-163. [PMC免费文章][PubMed][]
4. Yochem J, Weston K, Greenwald I. The Caenorhabditis elegans lin-12 gene encodes a transmembrane protein with overall similarity to Drosophila Notch. Nature. 1988;335:547–550. [PubMed] []
4. 作者:J. Yochem J,韦斯顿K,格林沃尔德I.秀丽隐杆线虫lin-12基因编码与果蝇Notch总体相似的跨膜蛋白。自然1988;335:547-550. [PubMed][]
5. Austin J, Kimble J. Transcript analysis of glp-1 and lin-12, homologous genes required for cell interactions during development of C. elegans. Cell. 1989;58:565–571. [PubMed] []
5. 奥斯汀J,金布尔J。转录分析glp-1和lin-12,同源基因所需的细胞相互作用在发展过程中的C。优雅的Cell. 1989;58:565-571. [PubMed][]
6. Coffman C, Harris W, Kintner C. Xotch, the Xenopus homolog of Drosophila notch. Science. 1990;249:1438–1441. [PubMed] []
6. Coffman C,Harris W,Kintner C. Xotch是果蝇notch的爪蟾同源物。科学1990;249:1438-1441. [PubMed][]
7. Stubbs JD, et al. cDNA cloning of a mouse mammary epithelial cell surface protein reveals the existence of epidermal growth factor-like domains linked to factor VIII-like sequences. Proc. Natl Acad. Sci. USA. 1990;87:8417–8421. [PMC free article] [PubMed] []
7. Stubbs JD等人,小鼠乳腺上皮细胞表面蛋白的cDNA克隆揭示了与因子VIII样序列相关的表皮生长因子样结构域的存在。美国国家科学院院报Sci. USA. 1990;87:8417-8421. [PMC免费文章][PubMed][]
8. Lodewijk GA, Fernandes DP, Vretzakis I, Savage JE, Jacobs FMJ. Evolution of human brain size-associated NOTCH2NL genes proceeds toward reduced protein levels. Mol. Biol. Evol. 2020;37:2531–2548. [PMC free article] [PubMed] []
8. Lodewijk GA,Fernandes DP,Vretzakis I,Savage JE,Jacobs FMJ.人脑大小相关的NOTCH 2NL基因的进化朝着蛋白质水平降低的方向进行。摩尔生物学评价2020;37:2531-2548. [PMC免费文章][PubMed][]
9. Artavanis-Tsakonas S, Muskavitch MA, Yedvobnick B. Molecular cloning of Notch, a locus affecting neurogenesis in Drosophila melanogaster. Proc. Natl Acad. Sci. USA. 1983;80:1977–1981. [PMC free article] [PubMed] []
9. Artavanis-Tsakonas S,Muskavitch MA,Yedvobnick B.黑腹果蝇神经发生相关基因Notch的分子克隆美国国家科学院院报Sci. USA. 1983;80:1977-1981。[PMC免费文章][PubMed][]
10. Wharton KA, Johansen KM, Xu T, Artavanis-Tsakonas S. Nucleotide sequence from the neurogenic locus notch implies a gene product that shares homology with proteins containing EGF-like repeats. Cell. 1985;43:567–581. [PubMed] []
10. Wharton KA,Johansen KM,Xu T,Artavanis-Tsakonas S.来自神经源性位点notch的核苷酸序列意味着与含有EGF样重复的蛋白质共享同源性的基因产物。Cell. 1985;43:567-581. [PubMed][]
11. Kidd S, Kelley MR, Young MW. Sequence of the notch locus of Drosophila melanogaster: relationship of the encoded protein to mammalian clotting and growth factors. Mol. Cell Biol. 1986;6:3094–3108. [PMC free article] [PubMed] []
11. Kidd S、Kelley MR、Young MW。果蝇notch基因座的序列:编码蛋白与哺乳动物凝血和生长因子的关系。摩尔Cell Biol.1986; 6:3094-3108. [PMC免费文章][PubMed][]
12. Johansen KM, Fehon RG, Artavanis-Tsakonas S. The notch gene product is a glycoprotein expressed on the cell surface of both epidermal and neuronal precursor cells during Drosophila development. J. Cell Biol. 1989;109:2427–2440. [PMC free article] [PubMed] []
12. Johansen KM,Fehon RG,Artavanis-Tsakonas S. Notch基因产物是果蝇发育过程中表皮和神经元前体细胞表面表达的一种糖蛋白。细胞生物学杂志。1989;109:2427-2440。[PMC免费文章][PubMed][]
13. Rykowski MC, Parmelee SJ, Agard DA, Sedat JW. Precise determination of the molecular limits of a polytene chromosome band: regulatory sequences for the Notch gene are in the interband. Cell. 1988;54:461–472. [PubMed] []
13. Rykowski MC,Parmelee SJ,Agard DA,Sedat JW.精确测定多线染色体带的分子限度:Notch基因的调控序列在带间。Cell. 1988;54:461-472. [PubMed][]
14. Cagan RL, Ready DF. Notch is required for successive cell decisions in the developing Drosophila retina. Genes Dev. 1989;3:1099–1112. [PubMed] []
14. Cagan RL,Ready DF. Notch是果蝇视网膜发育过程中连续细胞决定所必需的。Genes Dev. 1989;3:1099-1112. [PubMed][]
15. Xu T, Rebay I, Fleming RJ, Scottgale TN, Artavanis-Tsakonas S. The Notch locus and the genetic circuitry involved in early Drosophila neurogenesis. Genes Dev. 1990;4:464–475. [PubMed] []
15. 徐T,Rebay I,Fleming RJ,Scottgale TN,Artavanis-Tsakonas S. Notch基因座和遗传电路参与早期果蝇神经发生。Genes Dev. 1990;4:464-475. [PubMed][]
16. Hartley DA, Xu TA, Artavanis-Tsakonas S. The embryonic expression of the Notch locus of Drosophila melanogaster and the implications of point mutations in the extracellular EGF-like domain of the predicted protein. EMBO J. 1987;6:3407–3417. [PMC free article] [PubMed] []
16. 作者:Jiangxi,Xu TA,Jiangxi.黑腹果蝇Notch基因座的胚胎表达及预测蛋白胞外EGF样结构域点突变的意义EMBO J.1987;6:3407-3417. [PMC免费文章][PubMed][]
17. Breeden L, Nasmyth K. Similarity between cell-cycle genes of budding yeast and fission yeast and the Notch gene of Drosophila. Nature. 1987;329:651–654. [PubMed] []
17. 放大图片创作者:Breeden L.芽殖酵母和裂殖酵母细胞周期基因与果蝇Notch基因的相似性。自然1987;329:651-654. [PubMed][]
18. Kidd S, Young MW. Transposon-dependent mutant phenotypes at the Notch locus of Drosophila. Nature. 1986;323:89–91. [PubMed] []
18. Kidd S,Young MW.果蝇Notch基因座的转座子依赖突变表型。自然1986;323:89-91. [PubMed][]
19. Austin J, Kimble J. glp-1 is required in the germ line for regulation of the decision between mitosis and meiosis in C. elegans. Cell. 1987;51:589–599. [PubMed] []
19. glp-1基因在家蚕生殖细胞系中是必需的,它调控着家蚕有丝分裂和减数分裂之间的决定。优雅的Cell. 1987;51:589-599. [PubMed][]
20. Greenwald IS, Sternberg PW, Horvitz HR. The lin-12 locus specifies cell fates in Caenorhabditis elegans. Cell. 1983;34:435–444. [PubMed] []
20. Greenwald IS,斯滕贝格PW,Horvitz HR. lin-12基因座在秀丽隐杆线虫中指定细胞命运。Cell. 1983;34:435-444. [PubMed][]
21. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137:216–233. [PMC free article] [PubMed] []
21. Kopan R,伊拉甘MX.经典Notch信号通路:打开激活机制。Cell. 2009;137:216-233. [PMC免费文章][PubMed][]
22. Gazave E, et al. Origin and evolution of the notch signalling pathway: an overview from eukaryotic genomes. BMC Evol. Biol. 2009;9:249. [PMC free article] [PubMed] []
22. Gazave E,et al.,Origin and Evolution of the notch signaling pathway:an overview from eukaryotic genomes. BMC评估2009; 9:249。[PMC免费文章][PubMed][]
23. Käsbauer T, et al. The Notch signaling pathway in the cnidarian Hydra. Dev. Biol. 2007;303:376–390. [PubMed] []
23. Käsbauer T,et al. The Notch signaling pathway in the cnidarian Hydra. Dev. 2007; 303:376-390。[PubMed][]
24. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284:770–776. [PubMed] []
24. Artavanis-Tsakonas S,兰德医学博士,RJ湖。Notch信号:发育中的细胞命运控制和信号整合。科学1999;284:770-776. [PubMed][]
25. Fernández R, Gabaldón T. Gene gain and loss across the metazoan tree of life. Nat. Ecol. Evol. 2020;4:524–533. [PMC free article] [PubMed] []
25. Fernández R,Gabaldón T.后生动物生命之树中的基因获得和损失。自然生态学评价2020;4:524-533. [PMC免费文章][PubMed][]
26. Cary GA, et al. Systematic comparison of sea urchin and sea star developmental gene regulatory networks explains how novelty is incorporated in early development. Nat. Commun. 2020;11:6235. [PMC free article] [PubMed] []
26. 卡里GA等.海胆和海星星发育基因调控网络的系统比较解释了新奇如何被纳入早期发展。国家通信2020;11:6235. [PMC免费文章][PubMed][]
27. Li L, et al. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat. Genet. 1997;16:243–251. [PubMed] []
27. Li L等人,Alagille综合征是由人类Jagged 1突变引起的,Jagged 1编码Notch 1的配体。Nat. Genet. 1997;16:243-251. [PubMed][]
28. Oda T, et al. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat. Genet. 1997;16:235–242. [PubMed] []
28. Oda T等人,人类Jagged 1基因的突变是Alagille综合征的原因。Nat. Genet. 1997;16:235-242. [PubMed][]
29. Deangelo DJ, et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J. Clin. Oncol. 2006;24:6585–6585. []
29. Deangelo DJ,et al. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma(T-ALL)and other leukemias. 《临床肿瘤杂志》2006;24:6585-6585. []
30. Andersson ER, Lendahl U. Therapeutic modulation of Notch signalling-are we there yet? Nat. Rev. Drug Discov. 2014;13:357–378. [PubMed] []
30. Andersson ER,Lendahl U. Notch信号的治疗性调节--我们到了吗?药物发现国家修订版2014;13:357-378. [PubMed][]
31. Yang G, et al. Structural basis of Notch recognition by human γ-secretase. Nature. 2019;565:192–197. [PubMed] []
31. Yang G,et al. Structural basis of Notch recognition by human γ-secretase. 自然2019;565:192-197. [PubMed][]
32. Zhou, R. et al. Recognition of the amyloid precursor protein by human γ-secretase. Science363, eaaw0930 (2019). [PubMed]
周河,巴西-地等人,Recognition of the amyloid precursor protein by human γ-secretase. 科学363,eaaw 0930(2019)。[PubMed]
33. Yang G, et al. Structural basis of γ-secretase inhibition and modulation by small molecule drugs. Cell. 2021;184:521–533.e514. [PubMed] []
33. Yang G等。小分子药物抑制和调节γ-分泌酶的结构基础。Cell. 2021;184:521-533.e514. [PubMed][]
34. Sarin A, Marcel N. The NOTCH1-autophagy interaction: regulating self-eating for survival. Autophagy. 2017;13:446–447. [PMC free article] [PubMed] []
34. 作者声明:Robert A. NOTCH 1-自噬相互作用:调节自我进食以生存。自噬2017;13:446-447. [PMC免费文章][PubMed][]
35. Polacheck WJ, et al. A non-canonical Notch complex regulates adherens junctions and vascular barrier function. Nature. 2017;552:258–262. [PMC free article] [PubMed] []
35. Polacheck WJ等人,A non-canonical Notch complex regulates adherens junctions and vascular barrier function. 自然2017;552:258-262. [PMC免费文章][PubMed][]
36. Li L, et al. Aberrant activation of notch1 signaling in glomerular endothelium induces albuminuria. Circ. Res. 2021;128:602–618. [PubMed] []
36. Li L,et al.肾小球内皮细胞notch 1信号传导的异常激活诱导白蛋白尿。Circ. Res. 2021; 128:602-618。[PubMed][]
37. Horita N, et al. Delta-like 1-expressing cells at the gland base promote proliferation of gastric antral stem cells in mouse. Cell Mol. Gastroenterol. Hepatol. 2021;13:275–287. [PMC free article] [PubMed] []
37. Horita N,et al.在腺基部的Delta样1表达细胞促进小鼠胃窦干细胞的增殖。细胞分子胃肠激素。Hepatol. 2021;13:275-287. [PMC免费文章][PubMed][]
38. Chang D, Shain AH. The landscape of driver mutations in cutaneous squamous cell carcinoma. NPJ Genom. Med. 2021;6:61. [PMC free article] [PubMed] []
38. Chang D,Shain AH.皮肤鳞状细胞癌中驱动基因突变的概况。NPJ Genom. 2021; 6:61。[PMC免费文章][PubMed][]
39. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat. Rev. Cancer. 2007;7:79–94. [PubMed] []
39. 多萨姆RT,古特金德JS. G蛋白偶联受体与癌症。国家癌症牧师。2007年;7:79-94。[PubMed][]
40. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–1134. [PMC free article] [PubMed] []
40. Lemmon MA,Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117-1134. [PMC免费文章][PubMed][]
41. Majumder S, et al. Targeting Notch in oncology: the path forward. Nat. Rev. Drug Discov. 2021;20:125–144. [PubMed] []
41. Majumder S等人,肿瘤学中的靶向缺口:前进的道路。药物发现国家修订版2021;20:125-144. [PubMed][]
42. Siebel C, Lendahl U. Notch signaling in development, tissue homeostasis, and disease. Physiol. Rev. 2017;97:1235–1294. [PubMed] []
42. Lendahl U. Notch信号在发育、组织稳态和疾病中的作用。生理学修订版2017;97:1235-1294。[PubMed][]
43. Kovall RA, Gebelein B, Sprinzak D, Kopan R. The canonical notch signaling pathway: structural and biochemical insights into shape, sugar, and force. Dev. Cell. 2017;41:228–241. [PMC free article] [PubMed] []
43. Kovall RA,Gebelein B,Sprinzak D,Kopan R.典型的Notch信号通路:对形状、糖和力的结构和生化见解。Dev. Cell. 2017;41:228-241. [PMC免费文章][PubMed][]
44. Lee TV, et al. Negative regulation of notch signaling by xylose. PLoS Genet. 2013;9:e1003547. [PMC free article] [PubMed] []
44. Lee TV等人,Negative regulation of notch signaling by xylose。PLoS基因组2013;9:e1003547。[PMC免费文章][PubMed][]
45. Sethi MK, et al. Identification of glycosyltransferase 8 family members as xylosyltransferases acting on O-glucosylated notch epidermal growth factor repeats. J. Biol. Chem. 2010;285:1582–1586. [PMC free article] [PubMed] []
45. Sethi MK等人,鉴定糖基转移酶8家族成员为木糖基转移酶,作用于O-葡萄糖基化缺口表皮生长因子重复序列。J. Biol. Chem.2010;285:1582-1586。[PMC免费文章][PubMed][]
46. Sethi MK, et al. Molecular cloning of a xylosyltransferase that transfers the second xylose to O-glucosylated epidermal growth factor repeats of notch. J. Biol. Chem. 2012;287:2739–2748. [PMC free article] [PubMed] []
46. Sethi MK等人,将第二个木糖转移到缺口的O-葡糖基化表皮生长因子重复序列的木糖基转移酶的分子克隆。J. Biol. Chem.2012;287:2739-2748。[PMC免费文章][PubMed][]
47. Shi S, Stanley P. Protein O-fucosyltransferase 1 is an essential component of Notch signaling pathways. Proc. Natl Acad. Sci. USA. 2003;100:5234–5239. [PMC free article] [PubMed] []
48. Sasamura T, et al. neurotic, a novel maternal neurogenic gene, encodes an O-fucosyltransferase that is essential for Notch-Delta interactions. Development. 2003;130:4785–4795. [PubMed] []
49. Moloney DJ, et al. Fringe is a glycosyltransferase that modifies Notch. Nature. 2000;406:369–375. [PubMed] []
50. Wang Y, et al. Fucosylation deficiency in mice leads to colitis and adenocarcinoma. Gastroenterology. 2017;152:193–205.e10. [PMC free article] [PubMed] []
51. Servián-Morilla E, et al. POGLUT1 biallelic mutations cause myopathy with reduced satellite cells, α-dystroglycan hypoglycosylation and a distinctive radiological pattern. Acta Neuropathol. 2020;139:565–582. [PMC free article] [PubMed] []
52. Zeronian, M. R. et al. Notch-Jagged signaling complex defined by an interaction mosaic. Proc Natl Acad Sci USA118, e2102502118 (2021). [PMC free article] [PubMed]
53. Yuan X, et al. Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett. 2015;369:20–27. [PubMed] []
54. Capaccione KM, Pine SR. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis. 2013;34:1420–1430. [PMC free article] [PubMed] []
55. Owen DH, et al. DLL3: an emerging target in small cell lung cancer. J. Hematol. Oncol. 2019;12:61. [PMC free article] [PubMed] []
56. Pitulescu ME, et al. Dll4 and Notch signalling couples sprouting angiogenesis and artery formation. Nat. Cell Biol. 2017;19:915–927. [PubMed] []
57. Langridge PD, Struhl G. Epsin-dependent ligand endocytosis activates notch by force. Cell. 2017;171:1383–1396.E12. [PMC free article] [PubMed] []
58. Gordon WR, et al. Structural basis for autoinhibition of Notch. Nat. Struct. Mol. Biol. 2007;14:295–300. [PubMed] []
59. Stephenson NL, Avis JM. Direct observation of proteolytic cleavage at the S2 site upon forced unfolding of the Notch negative regulatory region. Proc. Natl Acad. Sci. USA. 2012;109:E2757–2765. [PMC free article] [PubMed] []
60. Gordon WR, et al. Mechanical allostery: evidence for a force requirement in the proteolytic activation of notch. Dev. Cell. 2015;33:729–736. [PMC free article] [PubMed] []
61. Xu X, et al. Insights into autoregulation of Notch3 from structural and functional studies of its negative regulatory region. Structure. 2015;23:1227–1235. [PMC free article] [PubMed] []
62. Seegar TCM, et al. Structural basis for regulated proteolysis by the α-secretase ADAM10. Cell. 2017;171:1638–1648.e1637. [PMC free article] [PubMed] []
63. Lambrecht BN, Vanderkerken M, Hammad H. The emerging role of ADAM metalloproteinases in immunity. Nat. Rev. Immunol. 2018;18:745–758. [PubMed] []
64. Du H, et al. Macrophage-released ADAMTS1 promotes muscle stem cell activation. Nat. Commun. 2017;8:669. [PMC free article] [PubMed] []
65. Groot AJ, Vooijs MA. The role of Adams in Notch signaling. Adv. Exp. Med. Biol. 2012;727:15–36. [PMC free article] [PubMed] []
66. Li YM, et al. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature. 2000;405:689–694. [PubMed] []
67. Li YM, et al. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc. Natl Acad. Sci. USA. 2000;97:6138–6143. [PMC free article] [PubMed] []
68. Kimberly WT, et al. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc. Natl Acad. Sci. USA. 2003;100:6382–6387. [PMC free article] [PubMed] []
69. Golde TE, Estus S, Younkin LH, Selkoe DJ, Younkin SG. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science. 1992;255:728–730. [PubMed] []
70. Takami M, et al. gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment. J. Neurosci. 2009;29:13042–13052. [PMC free article] [PubMed] []
71. Suzuki N, et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science. 1994;264:1336–1340. [PubMed] []
72. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256:184–185. [PubMed] []
73. Deatherage CL, et al. Structural and biochemical differences between the Notch and the amyloid precursor protein transmembrane domains. Sci. Adv. 2017;3:e1602794. [PMC free article] [PubMed] []
74. Conner SD. Regulation of notch signaling through intracellular transport. Int Rev. Cell Mol. Biol. 2016;323:107–127. [PubMed] []
75. Huenniger K, et al. Notch1 signaling is mediated by importins alpha 3, 4, and 7. Cell Mol. Life Sci. 2010;67:3187–3196. [PMC free article] [PubMed] []
76. Bottoni G, et al. CSL controls telomere maintenance and genome stability in human dermal fibroblasts. Nat. Commun. 2019;10:3884. [PMC free article] [PubMed] []
77. Dreval K, Lake RJ, Fan H-Y. HDAC1 negatively regulates selective mitotic chromatin binding of the Notch effector RBPJ in a KDM5A-dependent manner. Nucleic Acids Res. 2019;47:4521–4538. [PMC free article] [PubMed] []
78. Aster JC, Pear WS, Blacklow SC. The varied roles of notch in cancer. Annu Rev. Pathol. 2017;12:245–275. [PMC free article] [PubMed] []
79. Bray SJ. Notch signalling in context. Nat. Rev. Mol. Cell Biol. 2016;17:722–735. [PubMed] []
80. Lee, C., Sorensen, E. B., Lynch, T. R. & Kimble, J. C. elegans GLP-1/Notch activates transcription in a probability gradient across the germline stem cell pool. Elife5, e18370 (2016). [PMC free article] [PubMed]
81. Gomez-Lamarca MJ, et al. Activation of the notch signaling pathway in vivo elicits changes in CSL nuclear dynamics. Dev. Cell. 2018;44:611–623.e617. [PMC free article] [PubMed] []
82. Pillidge, Z. & Bray, S. J. SWI/SNF chromatin remodeling controls Notch-responsive enhancer accessibility. EMBO Rep.20, e46944 (2019). [PMC free article] [PubMed]
83. Lee C, Shin H, Kimble J. Dynamics of notch-dependent transcriptional bursting in its native context. Dev. Cell. 2019;50:426–435.e4. [PMC free article] [PubMed] []
84. Petrovic J, et al. Oncogenic notch promotes long-range regulatory interactions within hyperconnected 3D cliques. Mol. Cell. 2019;73:1174–1190. [PMC free article] [PubMed] []
85. Pamarthy S, Kulshrestha A, Katara GK, Beaman KD. The curious case of vacuolar ATPase: regulation of signaling pathways. Mol. Cancer. 2018;17:41. [PMC free article] [PubMed] []
86. Jin, K. et al. NOTCH-induced rerouting of endosomal trafficking disables regulatory T cells in vasculitis. J. Clin. Invest.131, e136042 (2021). [PMC free article] [PubMed]
87. Steinbuck MP, Arakcheeva K, Winandy S. Novel TCR-mediated mechanisms of notch activation and signaling. J. Immunol. 2018;200:997–1007. [PMC free article] [PubMed] []
88. Radtke F, MacDonald HR, Tacchini-Cottier F. Regulation of innate and adaptive immunity by Notch. Nat. Rev. Immunol. 2013;13:427–437. [PubMed] []
89. Song LL, et al. Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells. Oncogene. 2008;27:5833–5844. [PubMed] []
90. Yue F, et al. Pten is necessary for the quiescence and maintenance of adult muscle stem cells. Nat. Commun. 2017;8:14328. [PMC free article] [PubMed] []
91. Chen, L.-J. et al. Gm364 coordinates MIB2/DLL3/Notch2 to regulate female fertility through AKT activation. Cell Death Differ (2021). [PMC free article] [PubMed]
92. Li H, et al. NCSTN promotes hepatocellular carcinoma cell growth and metastasis via β-catenin activation in a Notch1/AKT dependent manner. J. Exp. Clin. Cancer Res. 2020;39:128. [PMC free article] [PubMed] []
93. Mangolini M, et al. Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia. Nat. Commun. 2018;9:3839. [PMC free article] [PubMed] []
94. Rajakulendran N, et al. Wnt and Notch signaling govern self-renewal and differentiation in a subset of human glioblastoma stem cells. Genes Dev. 2019;33:498–510. [PMC free article] [PubMed] []
95. Hammad H, Lambrecht BN. Wnt and Hippo pathways in regulatory T cells: a NOTCH above in asthma. Nat. Immunol. 2020;21:1313–1314. [PMC free article] [PubMed] []
96. Luo, K. Signaling cross talk between TGF-β/Smad and other signaling pathways. Cold Spring Harb. Perspect. Biol.9, a022137 (2017). [PMC free article] [PubMed]
97. Fernández-Majada V, et al. Nuclear IKK activity leads to dysregulated notch-dependent gene expression in colorectal cancer. Proc. Natl Acad. Sci. USA. 2007;104:276–281. [PMC free article] [PubMed] []
98. Hossain F, et al. Notch signaling regulates mitochondrial metabolism and NF-κB Activity in triple-negative breast cancer cells via IKKα-dependent non-canonical pathways. Front. Oncol. 2018;8:575. [PMC free article] [PubMed] []
99. Kuramoto T, et al. Dll4-Fc, an inhibitor of Dll4-notch signaling, suppresses liver metastasis of small cell lung cancer cells through the downregulation of the NF-κB activity. Mol. Cancer Ther. 2012;11:2578–2587. [PubMed] []
100. Gentle ME, Rose A, Bugeon L, Dallman MJ. Noncanonical Notch signaling modulates cytokine responses of dendritic cells to inflammatory stimuli. J. Immunol. 2012;189:1274–1284. [PMC free article] [PubMed] []
101. Lin S, et al. Non-canonical NOTCH3 signalling limits tumour angiogenesis. Nat. Commun. 2017;8:16074. [PMC free article] [PubMed] []
102. Pelullo M, et al. Kras/ADAM17-dependent Jag1-ICD reverse signaling sustains colorectal cancer progression and chemoresistance. Cancer Res. 2019;79:5575–5586. [PubMed] []
103. Stahl M, et al. Roles of Pofut1 and O-fucose in mammalian Notch signaling. J. Biol. Chem. 2008;283:13638–13651. [PMC free article] [PubMed] []
104. Yao D, et al. Protein O-fucosyltransferase 1 (Pofut1) regulates lymphoid and myeloid homeostasis through modulation of Notch receptor ligand interactions. Blood. 2011;117:5652–5662. [PMC free article] [PubMed] []
105. Wang Y, et al. Uncontrolled angiogenic precursor expansion causes coronary artery anomalies in mice lacking Pofut1. Nat. Commun. 2017;8:578. [PMC free article] [PubMed] []
106. Jafar-Nejad H, Leonardi J, Fernandez-Valdivia R. Role of glycans and glycosyltransferases in the regulation of Notch signaling. Glycobiology. 2010;20:931–949. [PMC free article] [PubMed] []
107. Takeuchi H, Haltiwanger RS. Role of glycosylation of Notch in development. Semin. Cell Dev. Biol. 2010;21:638–645. [PMC free article] [PubMed] []
108. Luther KB, Haltiwanger RS. Role of unusual O-glycans in intercellular signaling. Int. J. Biochem. Cell Biol. 2009;41:1011–1024. [PMC free article] [PubMed] []
109. Stanley P, Okajima T. Roles of glycosylation in Notch signaling. Curr. Top. Dev. Biol. 2010;92:131–164. [PubMed] []
110. Acar M, et al. Rumi is a CAP10 domain glycosyltransferase that modifies Notch and is required for Notch signaling. Cell. 2008;132:247–258. [PMC free article] [PubMed] []
111. Fernandez-Valdivia R, et al. Regulation of mammalian Notch signaling and embryonic development by the protein O-glucosyltransferase Rumi. Development. 2011;138:1925–1934. [PMC free article] [PubMed] []
112. Ge C, Stanley P. The O-fucose glycan in the ligand-binding domain of Notch1 regulates embryogenesis and T cell development. Proc. Natl Acad. Sci. USA. 2008;105:1539–1544. [PMC free article] [PubMed] []
113. Rana NA, et al. O-glucose trisaccharide is present at high but variable stoichiometry at multiple sites on mouse Notch1. J. Biol. Chem. 2011;286:31623–31637. [PMC free article] [PubMed] []
114. Bousseau S, et al. Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis. Pharm. Ther. 2018;191:92–122. [PubMed] []
115. Yeh C-H, Bellon M, Nicot C. FBXW7: a critical tumor suppressor of human cancers. Mol. Cancer. 2018;17:115. [PMC free article] [PubMed] []
116. Ye L, et al. NUMB maintains bone mass by promoting degradation of PTEN and GLI1 via ubiquitination in osteoblasts. Bone Res. 2018;6:32. [PMC free article] [PubMed] []
117. Guo Y, et al. Numb enriches a castration-resistant prostate cancer cell subpopulation associated with enhanced notch and hedgehog signaling. Clin. Cancer Res. 2017;23:6744–6756. [PubMed] []
118. Liu P, Verhaar AP, Peppelenbosch MP. Signaling size: ankyrin and SOCS box-containing ASB E3 ligases in action. Trends Biochem. Sci. 2019;44:64–74. [PubMed] []
119. Giebel B, Wodarz A. Tumor suppressors: control of signaling by endocytosis. Curr. Biol. 2006;16:R91–92. [PubMed] []
120. Thompson BJ, et al. Tumor suppressor properties of the ESCRT-II complex component Vps25 in Drosophila. Dev. Cell. 2005;9:711–720. [PubMed] []
121. Troost T, Jaeckel S, Ohlenhard N, Klein T. The tumour suppressor Lethal (2) giant discs is required for the function of the ESCRT-III component Shrub/CHMP4. J. Cell Sci. 2012;125:763–776. [PubMed] []
122. Vaccari T, Bilder D. The Drosophila tumor suppressor vps25 prevents nonautonomous overproliferation by regulating notch trafficking. Dev. Cell. 2005;9:687–698. [PubMed] []
123. Chastagner P, Israël A, Brou C. Itch/AIP4 mediates Deltex degradation through the formation of K29-linked polyubiquitin chains. EMBO Rep. 2006;7:1147–1153. [PMC free article] [PubMed] []
124. Hori K, Sen A, Kirchhausen T, Artavanis-Tsakonas S. Synergy between the ESCRT-III complex and Deltex defines a ligand-independent Notch signal. J. Cell Biol. 2011;195:1005–1015. [PMC free article] [PubMed] []
125. Shimizu H, et al. Compensatory flux changes within an endocytic trafficking network maintain thermal robustness of Notch signaling. Cell. 2014;157:1160–1174. [PMC free article] [PubMed] []
126. Wang W, Struhl G. Distinct roles for Mind bomb, Neuralized and Epsin in mediating DSL endocytosis and signaling in Drosophila. Development. 2005;132:2883–2894. [PubMed] []
127. Overstreet E, Fitch E, Fischer JA. Fat facets and Liquid facets promote Delta endocytosis and Delta signaling in the signaling cells. Development. 2004;131:5355–5366. [PubMed] []
128. Daskalaki A, et al. Distinct intracellular motifs of Delta mediate its ubiquitylation and activation by Mindbomb1 and Neuralized. J. Cell Biol. 2011;195:1017–1031. [PMC free article] [PubMed] []
129. Le Borgne R, Remaud S, Hamel S, Schweisguth F. Two distinct E3 ubiquitin ligases have complementary functions in the regulation of delta and serrate signaling in Drosophila. PLoS Biol. 2005;3:e96. [PMC free article] [PubMed] []
130. Fontana JR, Posakony JW. Both inhibition and activation of Notch signaling rely on a conserved Neuralized-binding motif in Bearded proteins and the Notch ligand Delta. Dev. Biol. 2009;333:373–385. [PMC free article] [PubMed] []
131. Nandagopal, N., Santat, L. A. & Elowitz, M. B. activation in the Notch signaling pathway. eLife8, e37880 (2019). [PMC free article] [PubMed]
132. Chapman G, Sparrow DB, Kremmer E, Dunwoodie SL. Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. Hum. Mol. Genet. 2011;20:905–916. [PubMed] []
133. Hoyne GF, Chapman G, Sontani Y, Pursglove SE, Dunwoodie SL. A cell autonomous role for the Notch ligand Delta-like 3 in αβ T-cell development. Immunol. Cell Biol. 2011;89:696–705. [PubMed] []
134. Kohlhaas V, et al. Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. Blood. 2021;137:646–660. [PubMed] []
135. Li Y, et al. Human NOTCH4 is a key target of RUNX1 in megakaryocytic differentiation. Blood. 2018;131:191–201. [PMC free article] [PubMed] []
136. Liu M, et al. Sirt6 deficiency exacerbates podocyte injury and proteinuria through targeting Notch signaling. Nat. Commun. 2017;8:413. [PMC free article] [PubMed] []
137. Malik N, et al. The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription. Nat. Commun. 2019;10:2071. [PMC free article] [PubMed] []
138. Gallo C, et al. The bHLH transcription factor DEC1 promotes thyroid cancer aggressiveness by the interplay with NOTCH1. Cell Death Dis. 2018;9:871. [PMC free article] [PubMed] []
139. Chen X, et al. MicroRNA-26a and −26b inhibit lens fibrosis and cataract by negatively regulating Jagged-1/Notch signaling pathway. Cell Death Differ. 2017;24:1990. [PMC free article] [PubMed] []
140. Qiao J, et al. MicroRNA-153 improves the neurogenesis of neural stem cells and enhances the cognitive ability of aged mice through the notch signaling pathway. Cell Death Differ. 2020;27:808–825. [PMC free article] [PubMed] []
141. Spitschak A, Meier C, Kowtharapu B, Engelmann D, Pützer BM. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit. Mol. Cancer. 2017;16:24. [PMC free article] [PubMed] []
142. Wasson CW, et al. Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH. Ann. Rheum. Dis. 2020;79:507–517. [PMC free article] [PubMed] []
143. Wang R, et al. iNOS promotes CD24CD133 liver cancer stem cell phenotype through a TACE/ADAM17-dependent Notch signaling pathway. Proc. Natl Acad. Sci. USA. 2018;115:E10127–E10136. [PMC free article] [PubMed] []
144. Majumdar, U. et al. Nitric oxide prevents aortic valve calcification by S-nitrosylation of USP9X to activate NOTCH signaling. Sci. Adv.7, eabe3706 (2021). [PMC free article] [PubMed]
145. Morrugares R, et al. Phosphorylation-dependent regulation of the NOTCH1 intracellular domain by dual-specificity tyrosine-regulated kinase 2. Cell Mol. Life Sci. 2020;77:2621–2639. [PMC free article] [PubMed] []
146. Suckling RJ, et al. Structural and functional dissection of the interplay between lipid and Notch binding by human Notch ligands. EMBO J. 2017;36:2204–2215. [PMC free article] [PubMed] []
147. Baonza A, Garcia-Bellido A. Notch signaling directly controls cell proliferation in the Drosophila wing disc. Proc. Natl Acad. Sci. USA. 2000;97:2609–2614. [PMC free article] [PubMed] []
148. Knust E, Campos-Ortega JA. The molecular genetics of early neurogenesis in Drosophila melanogaster. Bioessays. 1989;11:95–100. [PubMed] []
149. Dray N, et al. Dynamic spatiotemporal coordination of neural stem cell fate decisions occurs through local feedback in the adult vertebrate brain. Cell Stem Cell. 2021;28:1457–1472.e1412. [PMC free article] [PubMed] []
150. Hilton MJ, et al. Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat. Med. 2008;14:306–314. [PMC free article] [PubMed] []
151. Dong Y, et al. RBPjkappa-dependent Notch signaling regulates mesenchymal progenitor cell proliferation and differentiation during skeletal development. Development. 2010;137:1461–1471. [PMC free article] [PubMed] []
152. Zong Y, et al. Notch signaling controls liver development by regulating biliary differentiation. Development. 2009;136:1727–1739. [PMC free article] [PubMed] []
153. Sparks EE, Huppert KA, Brown MA, Washington MK, Huppert SS. Notch signaling regulates formation of the three-dimensional architecture of intrahepatic bile ducts in mice. Hepatology. 2010;51:1391–1400. [PMC free article] [PubMed] []
154. Alabi RO, Farber G, Blobel CP. Intriguing roles for endothelial ADAM10/Notch signaling in the development of organ-specific vascular beds. Physiol. Rev. 2018;98:2025–2061. [PMC free article] [PubMed] []
155. Herbert SP, Stainier DY. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat. Rev. Mol. Cell Biol. 2011;12:551–564. [PMC free article] [PubMed] []
156. Hellström M, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 2007;445:776–780. [PubMed] []
157. Jakobsson L, et al. Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat. Cell Biol. 2010;12:943–953. [PubMed] []
158. Minnis-Lyons, S. E. et al. Notch-IGF1 signaling during liver regeneration drives biliary epithelial cell expansion and inhibits hepatocyte differentiation. Sci. Signal14, eabe3706 (2021). [PubMed]
159. Peel AD, Chipman AD, Akam M. Arthropod segmentation: beyond the Drosophila paradigm. Nat. Rev. Genet. 2005;6:905–916. [PubMed] []
160. Dequéant ML, et al. A complex oscillating network of signaling genes underlies the mouse segmentation clock. Science. 2006;314:1595–1598. [PubMed] []
161. Diaz-Cuadros M, et al. In vitro characterization of the human segmentation clock. Nature. 2020;580:113–118. [PMC free article] [PubMed] []
162. Sonnen, K. F. et al. Modulation of phase shift between Wnt and Notch signaling oscillations controls mesoderm segmentation. Cell172, (2018). [PMC free article] [PubMed]
163. Lewis J. Autoinhibition with transcriptional delay: a simple mechanism for the zebrafish somitogenesis oscillator. Curr. Biol. 2003;13:1398–1408. [PubMed] []
164. Hubaud A, Regev I, Mahadevan L, Pourquié O. Excitable dynamics and yap-dependent mechanical cues drive the segmentation clock. Cell. 2017;171:668–682.e611. [PMC free article] [PubMed] []
165. Pourquié O. Vertebrate somitogenesis. Annu. Rev. Cell Dev. Biol. 2001;17:311–350. [PubMed] []
166. Bessho Y, Hirata H, Masamizu Y, Kageyama R. Periodic repression by the bHLH factor Hes7 is an essential mechanism for the somite segmentation clock. Genes Dev. 2003;17:1451–1456. [PMC free article] [PubMed] []
167. Dale JK, et al. Periodic notch inhibition by lunatic fringe underlies the chick segmentation clock. Nature. 2003;421:275–278. [PubMed] []
168. Cole SE, Levorse JM, Tilghman SM, Vogt TF. Clock regulatory elements control cyclic expression of Lunatic fringe during somitogenesis. Dev. Cell. 2002;3:75–84. [PubMed] []
169. Hubaud A, Pourquié O. Signalling dynamics in vertebrate segmentation. Nat. Rev. Mol. Cell Biol. 2014;15:709–721. [PubMed] []
170. Yoshioka-Kobayashi K, et al. Coupling delay controls synchronized oscillation in the segmentation clock. Nature. 2020;580:119–123. [PubMed] []
171. Jiang YJ, et al. Notch signalling and the synchronization of the somite segmentation clock. Nature. 2000;408:475–479. [PubMed] []
172. Zhang N, Gridley T. Defects in somite formation in lunatic fringe-deficient mice. Nature. 1998;394:374–377. [PubMed] []
173. Okubo Y, et al. Lfng regulates the synchronized oscillation of the mouse segmentation clock via trans-repression of Notch signalling. Nat. Commun. 2012;3:1141. [PubMed] []
174. Mead TJ, Yutzey KE. Notch pathway regulation of chondrocyte differentiation and proliferation during appendicular and axial skeleton development. Proc. Natl Acad. Sci. USA. 2009;106:14420–14425. [PMC free article] [PubMed] []
175. Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crombrugghe B. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev. 2002;16:2813–2828. [PMC free article] [PubMed] []
176. Tsingas M, et al. Sox9 deletion causes severe intervertebral disc degeneration characterized by apoptosis, matrix remodeling, and compartment-specific transcriptomic changes. Matrix Biol. 2020;94:110–133. [PMC free article] [PubMed] []
177. Long F, Ornitz DM. Development of the endochondral skeleton. Cold Spring Harb. Perspect. Biol. 2013;5:a008334. [PMC free article] [PubMed] []
178. Liu CF, Samsa WE, Zhou G, Lefebvre V. Transcriptional control of chondrocyte specification and differentiation. Semin. Cell Dev. Biol. 2017;62:34–49. [PMC free article] [PubMed] []
179. Luo Z, et al. Notch signaling in osteogenesis, osteoclastogenesis, and angiogenesis. Am. J. Pathol. 2019;189:1495–1500. [PMC free article] [PubMed] []
180. Yu J, Canalis E. Notch and the regulation of osteoclast differentiation and function. Bone. 2020;138:115474. [PMC free article] [PubMed] []
181. Hankenson KD, Gagne K, Shaughnessy M. Extracellular signaling molecules to promote fracture healing and bone regeneration. Adv. Drug Deliv. Rev. 2015;94:3–12. [PubMed] []
182. Wang C, et al. Transient gamma-secretase inhibition accelerates and enhances fracture repair likely via Notch signaling modulation. Bone. 2015;73:77–89. [PMC free article] [PubMed] []
183. High FA, Epstein JA. The multifaceted role of Notch in cardiac development and disease. Nat. Rev. Genet. 2008;9:49–61. [PubMed] []
184. Niessen K, Karsan A. Notch signaling in cardiac development. Circ. Res. 2008;102:1169–1181. [PubMed] []
185. Luxán G, D’Amato G, MacGrogan D, de la Pompa JL. Endocardial Notch signaling in cardiac development and disease. Circ. Res. 2016;118:e1–e18. [PubMed] []
186. de la Pompa JL, Epstein JA. Coordinating tissue interactions: Notch signaling in cardiac development and disease. Dev. Cell. 2012;22:244–254. [PMC free article] [PubMed] []
187. Rutenberg JB, et al. Developmental patterning of the cardiac atrioventricular canal by Notch and Hairy-related transcription factors. Development. 2006;133:4381–4390. [PMC free article] [PubMed] []
188. Papoutsi, T., Luna-Zurita, L., Prados, B., Zaffran, S. & de la Pompa, J. L. Bmp2 and Notch cooperate to pattern the embryonic endocardium. Development145 (2018). [PubMed]
189. Luna-Zurita L, et al. Integration of a Notch-dependent mesenchymal gene program and Bmp2-driven cell invasiveness regulates murine cardiac valve formation. J. Clin. Invest. 2010;120:3493–3507. [PMC free article] [PubMed] []
190. Timmerman LA, et al. Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev. 2004;18:99–115. [PMC free article] [PubMed] []
191. Chen H, et al. BMP10 is essential for maintaining cardiac growth during murine cardiogenesis. Development. 2004;131:2219–2231. [PMC free article] [PubMed] []
192. Grego-Bessa J, et al. Notch signaling is essential for ventricular chamber development. Dev. Cell. 2007;12:415–429. [PMC free article] [PubMed] []
193. Holderfield MT, Hughes CC. Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis. Circ. Res. 2008;102:637–652. [PubMed] []
194. Krebs LT, et al. Notch signaling is essential for vascular morphogenesis in mice. Genes Dev. 2000;14:1343–1352. [PMC free article] [PubMed] []
195. Lobov IB, et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc. Natl Acad. Sci. USA. 2007;104:3219–3224. [PMC free article] [PubMed] []
196. Suchting S, et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc. Natl Acad. Sci. USA. 2007;104:3225–3230. [PMC free article] [PubMed] []
197. Moldovan GE, Miele L, Fazleabas AT. Notch signaling in reproduction. Trends Endocrinol. Metab. 2021;32:1044–1057. [PMC free article] [PubMed] []
198. Zarkada G, Heinolainen K, Makinen T, Kubota Y, Alitalo K. VEGFR3 does not sustain retinal angiogenesis without VEGFR2. Proc. Natl Acad. Sci. USA. 2015;112:761–766. [PMC free article] [PubMed] []
199. Hultgren NW, et al. Slug regulates the Dll4-Notch-VEGFR2 axis to control endothelial cell activation and angiogenesis. Nat. Commun. 2020;11:5400. [PMC free article] [PubMed] []
200. Phng LK, et al. Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis. Dev. Cell. 2009;16:70–82. [PMC free article] [PubMed] []
201. Yang JM, et al. Dll4 suppresses transcytosis for arterial blood-retinal barrier homeostasis. Circ. Res. 2020;126:767–783. [PubMed] []
202. High FA, et al. An essential role for Notch in neural crest during cardiovascular development and smooth muscle differentiation. J. Clin. Invest. 2007;117:353–363. [PMC free article] [PubMed] []
203. High FA, et al. Endothelial expression of the Notch ligand Jagged1 is required for vascular smooth muscle development. Proc. Natl Acad. Sci. USA. 2008;105:1955–1959. [PMC free article] [PubMed] []
204. Boucher JM, Harrington A, Rostama B, Lindner V, Liaw L. A receptor-specific function for Notch2 in mediating vascular smooth muscle cell growth arrest through cyclin-dependent kinase inhibitor 1B. Circ. Res. 2013;113:975–985. [PMC free article] [PubMed] []
205. Campos AH, Wang W, Pollman MJ, Gibbons GH. Determinants of Notch-3 receptor expression and signaling in vascular smooth muscle cells: implications in cell-cycle regulation. Circ. Res. 2002;91:999–1006. [PubMed] []
206. Baeten JT, Lilly B. Differential Regulation of NOTCH2 and NOTCH3 Contribute to Their Unique Functions in Vascular Smooth Muscle Cells. J. Biol. Chem. 2015;290:16226–16237. [PMC free article] [PubMed] []
207. Briot A, et al. Repression of Sox9 by Jag1 is continuously required to suppress the default chondrogenic fate of vascular smooth muscle cells. Dev. Cell. 2014;31:707–721. [PMC free article] [PubMed] []
208. Hasan SS, et al. Endothelial Notch signalling limits angiogenesis via control of artery formation. Nat. Cell Biol. 2017;19:928–940. [PMC free article] [PubMed] []
209. Luo W, et al. Arterialization requires the timely suppression of cell growth. Nature. 2021;589:437–441. [PMC free article] [PubMed] []
210. You LR, et al. Suppression of Notch signalling by the COUP-TFII transcription factor regulates vein identity. Nature. 2005;435:98–104. [PubMed] []
211. Hainaud P, et al. The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res. 2006;66:8501–8510. [PubMed] []
212. Fischer A, Schumacher N, Maier M, Sendtner M, Gessler M. The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. Genes Dev. 2004;18:901–911. [PMC free article] [PubMed] []
213. Pereira FA, Qiu Y, Zhou G, Tsai MJ, Tsai SY. The orphan nuclear receptor COUP-TFII is required for angiogenesis and heart development. Genes Dev. 1999;13:1037–1049. [PMC free article] [PubMed] []
214. Corada M, Morini MF, Dejana E. Signaling pathways in the specification of arteries and veins. Arterioscler Thromb. Vasc. Biol. 2014;34:2372–2377. [PubMed] []
215. Trindade A, et al. Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. Blood. 2008;112:1720–1729. [PMC free article] [PubMed] []
216. Kume T, Jiang H, Topczewska JM, Hogan BL. The murine winged helix transcription factors, Foxc1 and Foxc2, are both required for cardiovascular development and somitogenesis. Genes Dev. 2001;15:2470–2482. [PMC free article] [PubMed] []
217. Mack JJ, et al. NOTCH1 is a mechanosensor in adult arteries. Nat. Commun. 2017;8:1620. [PMC free article] [PubMed] []
218. Weijts B, et al. Blood flow-induced Notch activation and endothelial migration enable vascular remodeling in zebrafish embryos. Nat. Commun. 2018;9:5314. [PMC free article] [PubMed] []
219. Ditadi A, et al. Human definitive haemogenic endothelium and arterial vascular endothelium represent distinct lineages. Nat. Cell Biol. 2015;17:580–591. [PMC free article] [PubMed] []
220. Butler JM, et al. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell. 2010;6:251–264. [PMC free article] [PubMed] []
221. Wendorff AA, et al. Hes1 is a critical but context-dependent mediator of canonical Notch signaling in lymphocyte development and transformation. Immunity. 2010;33:671–684. [PubMed] []
222. Chen ELY, Thompson PK, Zúñiga-Pflücker JC. RBPJ-dependent Notch signaling initiates the T cell program in a subset of thymus-seeding progenitors. Nat. Immunol. 2019;20:1456–1468. [PMC free article] [PubMed] []
223. Jenkinson EJ, Jenkinson WE, Rossi SW, Anderson G. The thymus and T-cell commitment: the right niche for Notch? Nat. Rev. Immunol. 2006;6:551–555. [PubMed] []
224. Yu VWC, et al. Specific bone cells produce DLL4 to generate thymus-seeding progenitors from bone marrow. J. Exp. Med. 2015;212:759–774. [PMC free article] [PubMed] []
225. Shah NJ, et al. An injectable bone marrow-like scaffold enhances T cell immunity after hematopoietic stem cell transplantation. Nat. Biotechnol. 2019;37:293–302. [PMC free article] [PubMed] []
226. Shukla S, et al. Progenitor T-cell differentiation from hematopoietic stem cells using Delta-like-4 and VCAM-1. Nat. Methods. 2017;14:531–538. [PubMed] []
227. Hozumi K, et al. Delta-like 1 is necessary for the generation of marginal zone B cells but not T cells in vivo. Nat. Immunol. 2004;5:638–644. [PubMed] []
228. Descatoire, M. et al. Identification of a human splenic marginal zone B cell precursor with NOTCH2-dependent differentiation properties. J. Exp. Med.211, (2014). [PMC free article] [PubMed]
229. Lechner M, et al. Notch2-mediated plasticity between marginal zone and follicular B cells. Nat. Commun. 2021;12:1111. [PMC free article] [PubMed] []
230. Graf R, et al. BCR-dependent lineage plasticity in mature B cells. Science. 2019;363:748–753. [PubMed] []
231. Hernández DC, et al. An in vitro platform supports generation of human innate lymphoid cells from CD34(+) hematopoietic progenitors that recapitulate ex vivo identity. Immunity. 2021;54:2417–2432.e2415. [PubMed] []
232. De Obaldia ME, Bhandoola A. Transcriptional regulation of innate and adaptive lymphocyte lineages. Annu. Rev. Immunol. 2015;33:607–642. [PubMed] []
233. Yang Q, et al. T cell factor 1 is required for group 2 innate lymphoid cell generation. Immunity. 2013;38:694–704. [PMC free article] [PubMed] []
234. Chea S, et al. Single-cell gene expression analyses reveal heterogeneous responsiveness of fetal innate lymphoid progenitors to notch signaling. Cell Rep. 2016;14:1500–1516. [PubMed] []
235. Perchet T, et al. The notch signaling pathway is balancing type 1 innate lymphoid cell immune functions. Front. Immunol. 2018;9:1252. [PMC free article] [PubMed] []
236. Magri G, et al. Innate lymphoid cells integrate stromal and immunological signals to enhance antibody production by splenic marginal zone B cells. Nat. Immunol. 2014;15:354–364. [PMC free article] [PubMed] []
237. Foldi J, Shang Y, Zhao B, Ivashkiv LB, Hu X. RBP-J is required for M2 macrophage polarization in response to chitin and mediates expression of a subset of M2 genes. Protein Cell. 2016;7:201–209. [PMC free article] [PubMed] []
238. López-López S, et al. NOTCH4 exhibits anti-inflammatory activity in activated macrophages by interfering with interferon-γ and TLR4 signaling. Front Immunol. 2021;12:734966. [PMC free article] [PubMed] []
239. Zhou J, Cheng P, Youn JI, Cotter MJ, Gabrilovich DI. Notch and wingless signaling cooperate in regulation of dendritic cell differentiation. Immunity. 2009;30:845–859. [PMC free article] [PubMed] []
240. Lewis KL, et al. Notch2 receptor signaling controls functional differentiation of dendritic cells in the spleen and intestine. Immunity. 2011;35:780–791. [PMC free article] [PubMed] []
241. Radke AL, et al. Mature human eosinophils express functional Notch ligands mediating eosinophil autocrine regulation. Blood. 2009;113:3092–3101. [PMC free article] [PubMed] []
242. Hofmann JJ, et al. Jagged1 in the portal vein mesenchyme regulates intrahepatic bile duct development: insights into Alagille syndrome. Development. 2010;137:4061–4072. [PMC free article] [PubMed] []
243. Antoniou A, et al. Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9. Gastroenterology. 2009;136:2325–2333. [PMC free article] [PubMed] []
244. Kageyama S, Nakamura K, Ke B, Busuttil RW, Kupiec-Weglinski JW. Serelaxin induces Notch1 signaling and alleviates hepatocellular damage in orthotopic liver transplantation. Am. J. Transpl. 2018;18:1755–1763. [PMC free article] [PubMed] []
245. Fiorotto R, et al. Notch signaling regulates tubular morphogenesis during repair from biliary damage in mice. J. Hepatol. 2013;59:124–130. [PMC free article] [PubMed] []
246. Cordero-Espinoza L, et al. Dynamic cell contacts between periportal mesenchyme and ductal epithelium act as a rheostat for liver cell proliferation. Cell Stem Cell. 2021;28:1907–1921. [PMC free article] [PubMed] []
247. Sayols, S. et al. Signalling codes for the maintenance and lineage commitment of embryonic gastric epithelial progenitors. Development147, dev188839 (2020). [PubMed]
248. Jensen J, et al. Control of endodermal endocrine development by Hes-1. Nat. Genet. 2000;24:36–44. [PubMed] []
249. Sallé J, et al. Intrinsic regulation of enteroendocrine fate by Numb. EMBO J. 2017;36:1928–1945. [PMC free article] [PubMed] []
250. Yin X, et al. Niche-independent high-purity cultures of Lgr5+ intestinal stem cells and their progeny. Nat. Methods. 2014;11:106–112. [PMC free article] [PubMed] []
251. Serra D, et al. Self-organization and symmetry breaking in intestinal organoid development. Nature. 2019;569:66–72. [PMC free article] [PubMed] []
252. Demitrack ES, et al. Notch signaling regulates gastric antral LGR5 stem cell function. EMBO J. 2015;34:2522–2536. [PMC free article] [PubMed] []
253. Gifford GB, et al. Notch1 and Notch2 receptors regulate mouse and human gastric antral epithelial cell homoeostasis. Gut. 2017;66:1001–1011. [PMC free article] [PubMed] []
254. Kim T-H, Shivdasani RA. Notch signaling in stomach epithelial stem cell homeostasis. J. Exp. Med. 2011;208:677–688. [PMC free article] [PubMed] []
255. Apelqvist A, et al. Notch signalling controls pancreatic cell differentiation. Nature. 1999;400:877–881. [PubMed] []
256. Fujikura J, et al. Notch/Rbp-j signaling prevents premature endocrine and ductal cell differentiation in the pancreas. Cell Metab. 2006;3:59–65. [PubMed] []
257. Rubey M, et al. DLL1- and DLL4-mediated notch signaling is essential for adult pancreatic islet homeostasis. Diabetes. 2020;69:915–926. [PubMed] []
258. Seymour PA, et al. Jag1 modulates an oscillatory Dll1-Notch-Hes1 signaling module to coordinate growth and fate of pancreatic progenitors. Dev. Cell. 2020;52:731–747. [PubMed] []
259. Louvi A, Artavanis-Tsakonas S. Notch signalling in vertebrate neural development. Nat. Rev. Neurosci. 2006;7:93–102. [PubMed] []
260. Portin P, Rantanen M. Interaction of master mind, big brain, neuralized and Notch genes of Drosophila melanogaster as expressed in adult morphology. Hereditas. 1991;114:197–200. [PubMed] []
261. Kelley MR, Kidd S, Deutsch WA, Young MW. Mutations altering the structure of epidermal growth factor-like coding sequences at the Drosophila Notch locus. Cell. 1987;51:539–548. [PubMed] []
262. Ye Y, Lukinova N, Fortini ME. Neurogenic phenotypes and altered Notch processing in Drosophila Presenilin mutants. Nature. 1999;398:525–529. [PubMed] []
263. Zamboni M, Llorens-Bobadilla E, Magnusson JP, Frisén J. A widespread neurogenic potential of neocortical astrocytes is induced by injury. Cell Stem Cell. 2020;27:605–617.e605. [PMC free article] [PubMed] []
264. Gao F, et al. Transcription factor RBP-J-mediated signaling represses the differentiation of neural stem cells into intermediate neural progenitors. Mol. Cell Neurosci. 2009;40:442–450. [PubMed] []
265. Chi Z, et al. Botch promotes neurogenesis by antagonizing Notch. Dev. Cell. 2012;22:707–720. [PMC free article] [PubMed] []
266. Mall M, et al. Myt1l safeguards neuronal identity by actively repressing many non-neuronal fates. Nature. 2017;544:245–249. [PMC free article] [PubMed] []
267. Cárdenas A, et al. Evolution of cortical neurogenesis in amniotes controlled by Robo signaling levels. Cell. 2018;174:590–606.e521. [PMC free article] [PubMed] []
268. Lui JH, Hansen DV, Kriegstein AR. Development and evolution of the human neocortex. Cell. 2011;146:18–36. [PMC free article] [PubMed] []
269. Nichane M, Ren X, Souopgui J, Bellefroid EJ. Hairy2 functions through both DNA-binding and non DNA-binding mechanisms at the neural plate border in Xenopus. Dev. Biol. 2008;322:368–380. [PubMed] []
270. Ngan ES, et al. Hedgehog/Notch-induced premature gliogenesis represents a new disease mechanism for Hirschsprung disease in mice and humans. J. Clin. Invest. 2011;121:3467–3478. [PMC free article] [PubMed] []
271. Tang W, et al. Exome-wide association study identified new risk loci for Hirschsprung’s disease. Mol. Neurobiol. 2017;54:1777–1785. [PubMed] []
272. Harima Y, Takashima Y, Ueda Y, Ohtsuka T, Kageyama R. Accelerating the tempo of the segmentation clock by reducing the number of introns in the Hes7 gene. Cell Rep. 2013;3:1–7. [PubMed] []
273. Hussain M, et al. Notch signaling: linking embryonic lung development and asthmatic airway remodeling. Mol. Pharm. 2017;92:676–693. [PubMed] []
274. Tsao P-N, et al. Epithelial Notch signaling regulates lung alveolar morphogenesis and airway epithelial integrity. Proc. Natl Acad. Sci. USA. 2016;113:8242–8247. [PMC free article] [PubMed] []
275. Rock JR, et al. Notch-dependent differentiation of adult airway basal stem cells. Cell Stem Cell. 2011;8:639–648. [PMC free article] [PubMed] []
276. Pardo-Saganta A, et al. Injury induces direct lineage segregation of functionally distinct airway basal stem/progenitor cell subpopulations. Cell Stem Cell. 2015;16:184–197. [PMC free article] [PubMed] []
277. Singh K, et al. JunB defines functional and structural integrity of the epidermo-pilosebaceous unit in the skin. Nat. Commun. 2018;9:3425. [PMC free article] [PubMed] []
278. Nguyen B-C, et al. Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev. 2006;20:1028–1042. [PMC free article] [PubMed] []
279. Ezratty EJ, et al. A role for the primary cilium in Notch signaling and epidermal differentiation during skin development. Cell. 2011;145:1129–1141. [PMC free article] [PubMed] []
280. Williams SE, Beronja S, Pasolli HA, Fuchs E. Asymmetric cell divisions promote Notch-dependent epidermal differentiation. Nature. 2011;470:353–358. [PMC free article] [PubMed] []
281. Veniaminova NA, et al. Niche-Specific Factors Dynamically Regulate Sebaceous Gland Stem Cells in the Skin. Dev. Cell. 2019;51:326–340.e4. [PMC free article] [PubMed] []
282. Gratton, R. et al. Pleiotropic role of notch signaling in human skin diseases. Int. J. Mol. Sci.21, 4214 (2020). [PMC free article] [PubMed]
283. Wang B, et al. Gamma-secretase gene mutations in familial acne inversa. Science. 2010;330:1065. [PubMed] []
284. Baudrimont M, Dubas F, Joutel A, Tournier-Lasserve E, Bousser MG. Autosomal dominant leukoencephalopathy and subcortical ischemic stroke. A clinicopathological study. Stroke. 1993;24:122–125. [PubMed] []
285. Joutel A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature. 1996;383:707–710. [PubMed] []
286. Joutel A, et al. Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet. 1997;350:1511–1515. [PubMed] []
287. Monet-Leprêtre M, et al. Abnormal recruitment of extracellular matrix proteins by excess Notch3 ECD: a new pathomechanism in CADASIL. Brain. 2013;136:1830–1845. [PMC free article] [PubMed] []
288. Okeda R, Arima K, Kawai M. Arterial changes in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in relation to pathogenesis of diffuse myelin loss of cerebral white matter: examination of cerebral medullary arteries by reconstruction of serial sections of an autopsy case. Stroke. 2002;33:2565–2569. [PubMed] []
289. Baron-Menguy C, Domenga-Denier V, Ghezali L, Faraci FM, Joutel A. Increased Notch3 activity mediates pathological changes in structure of cerebral arteries. Hypertension. 2017;69:60–70. [PMC free article] [PubMed] []
290. Dubroca C, et al. Impaired vascular mechanotransduction in a transgenic mouse model of CADASIL arteriopathy. Stroke. 2005;36:113–117. [PMC free article] [PubMed] []
291. Ling C, et al. Modeling CADASIL vascular pathologies with patient-derived induced pluripotent stem cells. Protein Cell. 2019;10:249–271. [PMC free article] [PubMed] []
292. Joutel A, et al. Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. J. Clin. Invest. 2010;120:433–445. [PMC free article] [PubMed] []
293. McDaniell R, et al. NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am. J. Hum. Genet. 2006;79:169–173. [PMC free article] [PubMed] []
294. Lykavieris P, Hadchouel M, Chardot C, Bernard O. Outcome of liver disease in children with Alagille syndrome: a study of 163 patients. Gut. 2001;49:431–435. [PMC free article] [PubMed] []
295. Fabris L, et al. Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. Nat. Rev. Gastroenterol. Hepatol. 2019;16:497–511. [PMC free article] [PubMed] []
296. Colliton RP, et al. Mutation analysis of Jagged1 (JAG1) in Alagille syndrome patients. Hum. Mutat. 2001;17:151–152. [PubMed] []
297. Warthen DM, et al. Jagged1 (JAG1) mutations in Alagille syndrome: increasing the mutation detection rate. Hum. Mutat. 2006;27:436–443. [PubMed] []
298. Suskind DL, Murray KF. Increasing the mutation rate for Jagged1 mutations in patients with Alagille syndrome. Hepatology. 2007;46:598–599. [PubMed] []
299. Kamath BM, Spinner NB, Rosenblum ND. Renal involvement and the role of Notch signalling in Alagille syndrome. Nat. Rev. Nephrol. 2013;9:409–418. [PubMed] []
300. Huch M, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell. 2015;160:299–312. [PMC free article] [PubMed] []
301. Andersson ER, et al. Mouse model of alagille syndrome and mechanisms of Jagged1 Missense mutations. Gastroenterology. 2018;154:1080–1095. [PMC free article] [PubMed] []
302. Adams JM, Jafar-Nejad H. A new model of alagille syndrome with broad phenotypic representation. Gastroenterology. 2018;154:803–806. [PubMed] []
303. Adams JM, et al. Sox9 is a modifier of the liver disease severity in a mouse model of alagille syndrome. Hepatology. 2020;71:1331–1349. [PMC free article] [PubMed] []
304. Pourquié O. Vertebrate segmentation: from cyclic gene networks to scoliosis. Cell. 2011;145:650–663. [PMC free article] [PubMed] []
305. Lefebvre M, et al. Diagnostic strategy in segmentation defect of the vertebrae: a retrospective study of 73 patients. J. Med. Genet. 2018;55:422–429. [PubMed] []
306. Dunwoodie SL. The role of Notch in patterning the human vertebral column. Curr. Opin. Genet. Dev. 2009;19:329–337. [PubMed] []
307. Kusumi K, et al. The mouse pudgy mutation disrupts Delta homologue Dll3 and initiation of early somite boundaries. Nat. Genet. 1998;19:274–278. [PubMed] []
308. Bulman MP, et al. Mutations in the human delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis. Nat. Genet. 2000;24:438–441. [PubMed] []
309. Whittock NV, et al. Mutated MESP2 causes spondylocostal dysostosis in humans. Am. J. Hum. Genet. 2004;74:1249–1254. [PMC free article] [PubMed] []
310. Makino Y, et al. Spatiotemporal disorder in the axial skeleton development of the Mesp2-null mouse: a model of spondylocostal dysostosis and spondylothoracic dysostosis. Bone. 2013;53:248–258. [PubMed] []
311. Sparrow DB, Sillence D, Wouters MA, Turnpenny PD, Dunwoodie SL. Two novel missense mutations in HAIRY-AND-ENHANCER-OF-SPLIT-7 in a family with spondylocostal dysostosis. Eur. J. Hum. Genet. 2010;18:674–679. [PMC free article] [PubMed] []
312. Sparrow DB, et al. Mutation of the LUNATIC FRINGE gene in humans causes spondylocostal dysostosis with a severe vertebral phenotype. Am. J. Hum. Genet. 2006;78:28–37. [PMC free article] [PubMed] []
313. Sparrow DB, et al. A mechanism for gene-environment interaction in the etiology of congenital scoliosis. Cell. 2012;149:295–306. [PubMed] []
314. Valenti L, et al. Hepatic notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease. Diabetes. 2013;62:4052–4062. [PMC free article] [PubMed] []
315. Zhu C, Tabas I, Schwabe RF, Pajvani UB. Maladaptive regeneration—the reawakening of developmental pathways in NASH and fibrosis. Nat. Rev. Gastroenterol. Hepatol. 2021;18:131–142. [PMC free article] [PubMed] []
316. Romeo SNotch. and Nonalcoholic Fatty Liver and Fibrosis. N. Engl. J. Med. 2019;380:681–683. [PubMed] []
317. Yu, J. et al. Hepatocyte TLR4 triggers inter-hepatocyte Jagged1/Notch signaling to determine NASH-induced fibrosis. Sci. Transl. Med.13, eabe1692 (2021). [PMC free article] [PubMed]
318. Zhu, C. et al. Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis. Sci. Transl. Med.10, eaat0344 (2018). [PMC free article] [PubMed]
319. Sassi N, et al. The role of the Notch pathway in healthy and osteoarthritic articular cartilage: from experimental models to ex vivo studies. Arthritis Res. Ther. 2011;13:208. [PMC free article] [PubMed] []
320. Monteagudo S, Lories RJ. A Notch in the joint that exacerbates osteoarthritis. Nat. Rev. Rheumatol. 2018;14:563–564. [PubMed] []
321. Liu Z, et al. A dual role for NOTCH signaling in joint cartilage maintenance and osteoarthritis. Sci. Signal. 2015;8:ra71. [PMC free article] [PubMed] []
322. Sun J, et al. Notch ligand Jagged1 promotes mesenchymal stromal cell-based cartilage repair. Exp. Mol. Med. 2018;50:1–10. [PMC free article] [PubMed] []
323. Hosaka Y, et al. Notch signaling in chondrocytes modulates endochondral ossification and osteoarthritis development. Proc. Natl Acad. Sci. USA. 2013;110:1875–1880. [PMC free article] [PubMed] []
324. Tindemans I, et al. Increased surface expression of NOTCH on memory T cells in peripheral blood from patients with asthma. J. Allergy Clin. Immunol. 2019;143:769–771.e3. [PubMed] []
325. Tindemans I, et al. Notch signaling in T cells is essential for allergic airway inflammation, but expression of the Notch ligands Jagged 1 and Jagged 2 on dendritic cells is dispensable. J. Allergy Clin. Immunol. 2017;140:1079–1089. [PubMed] []
326. Huang, M.-T., Chiu, C.-J. & Chiang, B.-L. Multi-faceted notch in allergic airway inflammation. Int. J. Mol. Sci.20, 3508 (2019). [PMC free article] [PubMed]
327. KleinJan A, et al. The Notch pathway inhibitor stapled α-helical peptide derived from mastermind-like 1 (SAHM1) abrogates the hallmarks of allergic asthma. J. Allergy Clin. Immunol. 2018;142:76–85.e8. [PMC free article] [PubMed] []
328. Tindemans I, et al. Notch signaling licenses allergic airway inflammation by promoting Th2 cell lymph node egress. J. Clin. Investig. 2020;130:3576–3591. [PMC free article] [PubMed] []
329. Harb H, et al. A regulatory T cell Notch4-GDF15 axis licenses tissue inflammation in asthma. Nat. Immunol. 2020;21:1359–1370. [PMC free article] [PubMed] []
330. Cao Z, et al. Targeting of the pulmonary capillary vascular niche promotes lung alveolar repair and ameliorates fibrosis. Nat. Med. 2016;22:154–162. [PMC free article] [PubMed] []
331. Steffes LC, et al. A Notch3-marked subpopulation of vascular smooth muscle cells is the cell of origin for occlusive pulmonary vascular lesions. Circulation. 2020;142:1545–1561. [PMC free article] [PubMed] []
332. Dabral S, et al. Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension. Eur. Respir. J. 2016;48:1137–1149. [PubMed] []
333. Gu X-Y, Chu X, Zeng X-L, Bao H-R, Liu X-J. Effects of PM2.5 exposure on the Notch signaling pathway and immune imbalance in chronic obstructive pulmonary disease. Environ. Pollut. 2017;226:163–173. [PubMed] []
334. Bodas M, et al. Cigarette smoke activates NOTCH3 to promote goblet cell differentiation in human airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 2021;64:426–440. [PMC free article] [PubMed] []
335. Ballester-López C, et al. The Notch ligand DNER regulates macrophage IFNγ release in chronic obstructive pulmonary disease. EBioMedicine. 2019;43:562–575. [PMC free article] [PubMed] []
336. Di Ianni M, et al. NOTCH and graft-versus-host disease. Front. Immunol. 2018;9:1825. [PMC free article] [PubMed] []
337. Radojcic V, et al. Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice. Blood. 2018;132:2188–2200. [PMC free article] [PubMed] []
338. Yvon ES, et al. Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells. Blood. 2003;102:3815–3821. [PubMed] []
339. Amsen D. T cells take directions from supporting cast in graft-versus-host disease. J. Clin. Investig. 2017;127:1215–1217. [PMC free article] [PubMed] []
340. Poe JC, et al. An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. Blood. 2017;130:2131–2145. [PMC free article] [PubMed] []
341. Bartolome A, Zhu C, Sussel L, Pajvani UB. Notch signaling dynamically regulates adult β cell proliferation and maturity. J. Clin. Invest. 2019;129:268–280. [PMC free article] [PubMed] []
342. Reynolds TC, Smith SD, Sklar J. Analysis of DNA surrounding the breakpoints of chromosomal translocations involving the beta T cell receptor gene in human lymphoblastic neoplasms. Cell. 1987;50:107–117. [PubMed] []
343. Ellisen LW, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66:649–661. [PubMed] []
344. Weng AP, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269–271. [PubMed] []
345. Pear WS, et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J. Exp. Med. 1996;183:2283–2291. [PMC free article] [PubMed] []
346. Herranz D, et al. A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nat. Med. 2014;20:1130–1137. [PMC free article] [PubMed] []
347. Herranz D, et al. Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. Nat. Med. 2015;21:1182–1189. [PMC free article] [PubMed] []
348. Trimarchi T, et al. Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia. Cell. 2014;158:593–606. [PMC free article] [PubMed] []
349. Joshi I, et al. Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood. 2009;113:1689–1698. [PMC free article] [PubMed] []
350. Bernasconi-Elias P, et al. Characterization of activating mutations of NOTCH3 in T-cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies. Oncogene. 2016;35:6077–6086. [PMC free article] [PubMed] []
351. Bonfiglio F, et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2021;139:732–747. [PubMed] []
352. Tardivon D, et al. Notch signaling promotes disease initiation and progression in murine chronic lymphocytic leukemia. Blood. 2021;137:3079–3092. [PubMed] []
353. Huang Y-H, et al. CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis. Signal Transduct. Target Ther. 2021;6:10. [PMC free article] [PubMed] []
354. Kannan S, et al. Notch activation inhibits AML growth and survival: a potential therapeutic approach. J. Exp. Med. 2013;210:321–337. [PMC free article] [PubMed] []
355. Yuan X, et al. Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis. Sci. Rep. 2015;5:10338. [PMC free article] [PubMed] []
356. Liu L, et al. An RFC4/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness. Nat. Commun. 2021;12:2693. [PMC free article] [PubMed] []
357. Westhoff B, et al. Alterations of the Notch pathway in lung cancer. Proc. Natl Acad. Sci. USA. 2009;106:22293–22298. [PMC free article] [PubMed] []
358. Licciulli S, et al. Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53. Cancer Res. 2013;73:5974–5984. [PMC free article] [PubMed] []
359. Xu X, et al. The cell of origin and subtype of K-Ras-induced lung tumors are modified by Notch and Sox2. Genes Dev. 2014;28:1929–1939. [PMC free article] [PubMed] []
360. Allen TD, Rodriguez EM, Jones KD, Bishop JM. Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma. Cancer Res. 2011;71:6010–6018. [PMC free article] [PubMed] []
361. Ali SA, Justilien V, Jamieson L, Murray NR, Fields AP. Protein kinase Cι drives a NOTCH3-dependent Stem-like phenotype in mutant KRAS lung adenocarcinoma. Cancer Cell. 2016;29:367–378. [PMC free article] [PubMed] []
362. Sinicropi-Yao SL, et al. Co-expression analysis reveals mechanisms underlying the varied roles of NOTCH1 in NSCLC. J. Thorac. Oncol. 2019;14:223–236. [PMC free article] [PubMed] []
363. Qiao L, Wong BC. Role of Notch signaling in colorectal cancer. Carcinogenesis. 2009;30:1979–1986. [PubMed] []
364. Tyagi, A., Sharma, A. K. & Damodaran, C. A review on Notch signaling and colorectal cancer. Cells9, 1549 (2020). [PMC free article] [PubMed]
365. Fre S, et al. Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. Proc. Natl Acad. Sci. USA. 2009;106:6309–6314. [PMC free article] [PubMed] []
366. Hayakawa Y, et al. BHLHA15-positive secretory precursor cells can give rise to tumors in intestine and colon in mice. Gastroenterology. 2019;156:1066–1081.e1016. [PMC free article] [PubMed] []
367. Jackstadt R, et al. Epithelial NOTCH signaling rewires the tumor microenvironment of colorectal cancer to drive poor-prognosis subtypes and metastasis. Cancer Cell. 2019;36:319–336.e317. [PMC free article] [PubMed] []
368. Bu P, et al. A miR-34a-numb feedforward loop triggered by inflammation regulates asymmetric stem cell division in intestine and colon cancer. Cell Stem Cell. 2016;18:189–202. [PMC free article] [PubMed] []
369. Ruland J. Colon cancer: epithelial notch signaling recruits neutrophils to drive metastasis. Cancer Cell. 2019;36:213–214. [PubMed] []
370. Sonoshita M, et al. Promotion of colorectal cancer invasion and metastasis through activation of NOTCH-DAB1-ABL-RHOGEF protein TRIO. Cancer Discov. 2015;5:198–211. [PubMed] []
371. Jackstadt R, Sansom OJ. Mouse models of intestinal cancer. J. Pathol. 2016;238:141–151. [PMC free article] [PubMed] []
372. Kranenburg OPrometastatic. NOTCH signaling in colon cancer. Cancer Discov. 2015;5:115–117. [PubMed] []
373. Chanrion M, et al. Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut. Nat. Commun. 2014;5:5005. [PMC free article] [PubMed] []
374. Sonoshita M, et al. Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell. 2011;19:125–137. [PubMed] []
375. Parida S, et al. A procarcinogenic colon microbe promotes breast tumorigenesis and metastatic progression and concomitantly activates Notch and β-Catenin Axes. Cancer Discov. 2021;11:1138–1157. [PubMed] []
376. Nabet BY, et al. Exosome RNA unshielding couples stromal activation to pattern recognition receptor signaling in cancer. Cell. 2017;170:352–366.e313. [PMC free article] [PubMed] []
377. Krishna BM, et al. Notch signaling in breast cancer: from pathway analysis to therapy. Cancer Lett. 2019;461:123–131. [PMC free article] [PubMed] []
378. Gallahan D, Kozak C, Callahan R. A new common integration region (int-3) for mouse mammary tumor virus on mouse chromosome 17. J. Virol. 1987;61:218–220. [PMC free article] [PubMed] []
379. Reedijk M, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005;65:8530–8537. [PubMed] []
380. Callahan R, Smith GH. MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways. Oncogene. 2000;19:992–1001. [PubMed] []
381. Theodorou V, et al. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat. Genet. 2007;39:759–769. [PubMed] []
382. Robinson DR, et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat. Med. 2011;17:1646–1651. [PMC free article] [PubMed] []
383. Jordan NV, et al. HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature. 2016;537:102–106. [PMC free article] [PubMed] []
384. Colaluca IN, et al. NUMB controls p53 tumour suppressor activity. Nature. 2008;451:76–80. [PubMed] []
385. Dittmer J. Breast cancer stem cells: features, key drivers and treatment options. Semin. Cancer Biol. 2018;53:59–74. [PubMed] []
386. Ibrahim SA, et al. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways. Mol. Cancer. 2017;16:57. [PMC free article] [PubMed] []
387. Shen Q, et al. Notch shapes the innate immunophenotype in breast cancer. Cancer Discov. 2017;7:1320–1335. [PubMed] []
388. Lin Q, et al. ASPH-notch axis guided exosomal delivery of prometastatic secretome renders breast cancer multi-organ metastasis. Mol. Cancer. 2019;18:156. [PMC free article] [PubMed] []
389. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature474, 609–615 (2011). [PMC free article] [PubMed]
390. Lu KH, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 2004;10:3291–3300. [PubMed] []
391. Park JT, et al. Notch3 gene amplification in ovarian cancer. Cancer Res. 2006;66:6312–6318. [PubMed] []
392. Hopfer O, Zwahlen D, Fey MF, Aebi S. The Notch pathway in ovarian carcinomas and adenomas. Br. J. Cancer. 2005;93:709–718. [PMC free article] [PubMed] []
393. Groeneweg JW, Foster R, Growdon WB, Verheijen RH, Rueda BR. Notch signaling in serous ovarian cancer. J. Ovarian Res. 2014;7:95. [PMC free article] [PubMed] []
394. Park JT, et al. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am. J. Pathol. 2010;177:1087–1094. [PMC free article] [PubMed] []
395. Choi JH, et al. Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res. 2008;68:5716–5723. [PMC free article] [PubMed] []
396. Steg AD, et al. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer. Clin. Cancer Res. 2011;17:5674–5685. [PMC free article] [PubMed] []
397. Yen WC, et al. Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin. Cancer Res. 2015;21:2084–2095. [PubMed] []
398. Hu W, et al. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res. 2011;71:6030–6039. [PMC free article] [PubMed] []
399. Zhu C, et al. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features. J. Hepatol. 2021;74:613–626. [PMC free article] [PubMed] []
400. Razumilava N, Gores GJ. Notch-driven carcinogenesis: the merging of hepatocellular cancer and cholangiocarcinoma into a common molecular liver cancer subtype. J. Hepatol. 2013;58:1244–1245. [PMC free article] [PubMed] []
401. Villanueva A, et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology. 2012;143:1660–1669.e1667. [PMC free article] [PubMed] []
402. Zhang L, et al. An essential role of RNF187 in Notch1 mediated metastasis of hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 2019;38:384. [PMC free article] [PubMed] []
403. Viatour P, et al. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J. Exp. Med. 2011;208:1963–1976. [PMC free article] [PubMed] []
404. Luiken S, et al. NOTCH target gene HES5 mediates oncogenic and tumor suppressive functions in hepatocarcinogenesis. Oncogene. 2020;39:3128–3144. [PMC free article] [PubMed] []
405. Lim SO, et al. Notch1 differentially regulates oncogenesis by wildtype p53 overexpression and p53 mutation in grade III hepatocellular carcinoma. Hepatology. 2011;53:1352–1362. [PubMed] []
406. Hu YY, et al. Notch signaling contributes to the maintenance of both normal neural stem cells and patient-derived glioma stem cells. BMC Cancer. 2011;11:82. [PMC free article] [PubMed] []
407. Zhu TS, et al. Endothelial cells create a stem cell niche in glioblastoma by providing NOTCH ligands that nurture self-renewal of cancer stem-like cells. Cancer Res. 2011;71:6061–6072. [PMC free article] [PubMed] []
408. Chu Q, Orr BA, Semenkow S, Bar EE, Eberhart CG. Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade. Clin. Cancer Res. 2013;19:3224–3233. [PMC free article] [PubMed] []
409. Natarajan S, et al. Notch1-induced brain tumor models the sonic hedgehog subgroup of human medulloblastoma. Cancer Res. 2013;73:5381–5390. [PMC free article] [PubMed] []
410. Wang J, et al. Invasion of white matter tracts by glioma stem cells is regulated by a NOTCH1-SOX2 positive-feedback loop. Nat. Neurosci. 2019;22:91–105. [PubMed] []
411. Katsushima K, et al. Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nat. Commun. 2016;7:13616. [PMC free article] [PubMed] []
412. Yi L, et al. Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4. J. Exp. Clin. Cancer Res. 2019;38:339. [PMC free article] [PubMed] []
413. Giachino C, et al. A tumor suppressor function for notch signaling in forebrain tumor subtypes. Cancer Cell. 2015;28:730–742. [PubMed] []
414. Parmigiani, E., Taylor, V. & Giachino, C. Oncogenic and tumor-suppressive functions of NOTCH signaling in glioma. Cells9 (2020). [PMC free article] [PubMed]
415. Stephens PJ, et al. Whole exome sequencing of adenoid cystic carcinoma. J. Clin. Invest. 2013;123:2965–2968. [PMC free article] [PubMed] []
416. Ho AS, et al. The mutational landscape of adenoid cystic carcinoma. Nat. Genet. 2013;45:791–798. [PMC free article] [PubMed] []
417. Drier Y, et al. An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma. Nat. Genet. 2016;48:265–272. [PMC free article] [PubMed] []
418. Karpinets TV, et al. Whole-genome sequencing of common salivary gland carcinomas: subtype-restricted and shared genetic alterations. Clin. Cancer Res. 2021;27:3960–3969. [PMC free article] [PubMed] []
419. Xie M, et al. Alterations of Notch pathway in patients with adenoid cystic carcinoma of the trachea and its impact on survival. Lung Cancer. 2018;121:41–47. [PubMed] []
420. Ferrarotto R, et al. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann. Oncol. 2018;29:1561–1568. [PubMed] []
421. Ferrarotto R, et al. Proteogenomic analysis of salivary adenoid cystic carcinomas defines molecular subtypes and identifies therapeutic targets. Clin. Cancer Res. 2021;27:852–864. [PMC free article] [PubMed] []
422. Bhagat TD, et al. Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer. J. Biol. Chem. 2017;292:837–846. [PMC free article] [PubMed] []
423. Nowell CS, Radtke F. Notch as a tumour suppressor. Nat. Rev. Cancer. 2017;17:145–159. [PubMed] []
424. Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing But NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19:991–1002. [PMC free article] [PubMed] []
425. Hu J, et al. Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential. Cancer Med. 2019;8:4338–4347. [PMC free article] [PubMed] []
426. Quintanal-Villalonga A, et al. Multi-omic analysis of lung tumors defines pathways activated in neuroendocrine transformation. Cancer Discov. 2021;11:3028–3047. [PMC free article] [PubMed] []
427. Saunders LR, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci. Transl. Med. 2015;7:302ra136. [PMC free article] [PubMed] []
428. Xie H, et al. Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors. Lung Cancer. 2019;135:73–79. [PubMed] []
429. Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat. Rev. Cancer. 2017;17:725–737. [PubMed] []
430. George J, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524:47–53. [PMC free article] [PubMed] []
431. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H. Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J. Biol. Chem. 2006;281:39819–39830. [PubMed] []
432. Wang H, Chen Y, Fernandez-Del Castillo C, Yilmaz O, Deshpande V. Heterogeneity in signaling pathways of gastroenteropancreatic neuroendocrine tumors: a critical look at notch signaling pathway. Mod. Pathol. 2013;26:139–147. [PubMed] []
433. Rekhtman N, et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin. Cancer Res. 2016;22:3618–3629. [PMC free article] [PubMed] []
434. Borromeo MD, et al. ASCL1 and NEUROD1 reveal heterogeneity in pulmonary neuroendocrine tumors and regulate distinct genetic programs. Cell Rep. 2016;16:1259–1272. [PMC free article] [PubMed] []
435. Meder L, et al. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Int. J. Cancer. 2016;138:927–938. [PMC free article] [PubMed] []
436. Wyche TP, et al. Thiocoraline activates the Notch pathway in carcinoids and reduces tumor progression in vivo. Cancer Gene Ther. 2014;21:518–525. [PMC free article] [PubMed] []
437. Ouadah Y, et al. Rare pulmonary neuroendocrine cells are stem cells regulated by Rb, p53, and Notch. Cell. 2019;179:403–416.e23. [PMC free article] [PubMed] []
438. Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333:1157–1160. [PMC free article] [PubMed] []
439. Natsuizaka M, et al. Interplay between Notch1 and Notch3 promotes EMT and tumor initiation in squamous cell carcinoma. Nat. Commun. 2017;8:1758. [PMC free article] [PubMed] []
440. Al Labban D, et al. Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B. J. Clin. Investig. 2018;128:2581–2599. [PMC free article] [PubMed] []
441. Agrawal N, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333:1154–1157. [PMC free article] [PubMed] []
442. Fukusumi T, Califano JA. The NOTCH pathway in head and neck squamous cell carcinoma. J. Dent. Res. 2018;97:645–653. [PMC free article] [PubMed] []
443. South AP, et al. NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis. J. Invest. Dermatol. 2014;134:2630–2638. [PMC free article] [PubMed] []
444. Wang NJ, et al. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc. Natl Acad. Sci. USA. 2011;108:17761–17766. [PMC free article] [PubMed] []
445. Rampias T, et al. A new tumor suppressor role for the Notch pathway in bladder cancer. Nat. Med. 2014;20:1199–1205. [PubMed] []
446. Gao YB, et al. Genetic landscape of esophageal squamous cell carcinoma. Nat. Genet. 2014;46:1097–1102. [PubMed] []
447. Agrawal N, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2012;2:899–905. [PMC free article] [PubMed] []
448. Khelil M, et al. Delta-like ligand-Notch1 signaling is selectively modulated by HPV16 E6 to promote squamous cell proliferation and correlates with cervical cancer prognosis. Cancer Res. 2021;81:1909–1921. [PubMed] []
449. Nassar D, Latil M, Boeckx B, Lambrechts D, Blanpain C. Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma. Nat. Med. 2015;21:946–954. [PubMed] []
450. Nicolas M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet. 2003;33:416–421. [PubMed] []
451. Proweller A, et al. Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res. 2006;66:7438–7444. [PubMed] []
452. Extance A. Alzheimer’s failure raises questions about disease-modifying strategies. Nat. Rev. Drug Discov. 2010;9:749–751. [PubMed] []
453. Quan XX, et al. Targeting Notch1 and IKKα enhanced NF-κB activation in CD133(+) skin cancer stem cells. Mol. Cancer Ther. 2018;17:2034–2048. [PMC free article] [PubMed] []
454. Bailey P, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531:47–52. [PubMed] []
455. Avila JL, Kissil JL. Notch signaling in pancreatic cancer: oncogene or tumor suppressor? Trends Mol. Med. 2013;19:320–327. [PMC free article] [PubMed] []
456. Hanlon L, et al. Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res. 2010;70:4280–4286. [PMC free article] [PubMed] []
457. Plentz R, et al. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology. 2009;136:1741–1749.e1746. [PMC free article] [PubMed] []
458. Maniati E, et al. Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in mice. J. Clin. Invest. 2011;121:4685–4699. [PMC free article] [PubMed] []
459. Cook N, et al. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J. Exp. Med. 2012;209:437–444. [PMC free article] [PubMed] []
460. Anderson NM, Simon MC. The tumor microenvironment. Curr. Biol. 2020;30:R921–r925. [PMC free article] [PubMed] []
461. Bejarano L, Jordāo MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Disco. 2021;11:933–959. [PubMed] []
462. Meurette O, Mehlen P. Notch signaling in the tumor microenvironment. Cancer Cell. 2018;34:536–548. [PubMed] []
463. Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79:4557–4566. [PMC free article] [PubMed] []
464. Tchekneva EE, et al. Determinant roles of dendritic cell-expressed Notch Delta-like and Jagged ligands on anti-tumor T cell immunity. J. Immunother. Cancer. 2019;7:95. [PMC free article] [PubMed] []
465. Wang L, et al. Notch-regulated dendritic cells restrain inflammation-associated colorectal carcinogenesis. Cancer Immunol. Res. 2021;9:348–361. [PMC free article] [PubMed] []
466. Kirkling ME, et al. Notch signaling facilitates in vitro generation of cross-presenting classical dendritic cells. Cell Rep. 2018;23:3658–3672.e3656. [PMC free article] [PubMed] []
467. Balan S, et al. Large-scale human dendritic cell differentiation revealing notch-dependent lineage bifurcation and heterogeneity. Cell Rep. 2018;24:1902–1915.e1906. [PMC free article] [PubMed] []
468. Guilliams M, Scott CL. ‘NOTCHing up’ the in vitro production of dendritic cells. Trends Immunol. 2018;39:765–767. [PubMed] []
469. Cho OH, et al. Notch regulates cytolytic effector function in CD8+ T cells. J. Immunol. 2009;182:3380–3389. [PMC free article] [PubMed] []
470. Maekawa Y, et al. Notch2 integrates signaling by the transcription factors RBP-J and CREB1 to promote T cell cytotoxicity. Nat. Immunol. 2008;9:1140–1147. [PubMed] []
471. Backer RA, et al. A central role for Notch in effector CD8(+) T cell differentiation. Nat. Immunol. 2014;15:1143–1151. [PMC free article] [PubMed] []
472. Kuijk LM, et al. Notch controls generation and function of human effector CD8+ T cells. Blood. 2013;121:2638–2646. [PubMed] []
473. Huang Y, et al. Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth. Cancer Res. 2011;71:6122–6131. [PMC free article] [PubMed] []
474. Sorrentino C, et al. Adenosine A2A receptor stimulation inhibits tcr-induced Notch1 activation in CD8+T-cells. Front. Immunol. 2019;10:162. [PMC free article] [PubMed] []
475. Hombrink P, et al. Programs for the persistence, vigilance and control of human CD8(+) lung-resident memory T cells. Nat. Immunol. 2016;17:1467–1478. [PubMed] []
476. Savas P, et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat. Med. 2018;24:986–993. [PubMed] []
477. Cho JW, et al. Dysregulation of T(FH)-B-T(RM) lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer. Nat. Commun. 2021;12:6068. [PMC free article] [PubMed] []
478. Mami-Chouaib F, et al. Resident memory T cells, critical components in tumor immunology. J. Immunother. Cancer. 2018;6:87. [PMC free article] [PubMed] []
479. Mathieu M, Cotta-Grand N, Daudelin JF, Thébault P, Labrecque N. Notch signaling regulates PD-1 expression during CD8(+) T-cell activation. Immunol. Cell Biol. 2013;91:82–88. [PubMed] []
480. Yu W, Wang Y, Guo P. Notch signaling pathway dampens tumor-infiltrating CD8(+) T cells activity in patients with colorectal carcinoma. Biomed. Pharmacother. 2018;97:535–542. [PubMed] []
481. Choe, J. H. et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci. Transl. Med.13, eabe7378 (2021). [PMC free article] [PubMed]
482. Roybal KT, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016;164:770–779. [PMC free article] [PubMed] []
483. Yu S, Yi M, Qin S, Wu K. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol. Cancer. 2019;18:125. [PMC free article] [PubMed] []
484. Hyrenius-Wittsten, A. et al. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci. Transl. Med.13, eabd8836 (2021). [PMC free article] [PubMed]
485. Amsen D, Antov A, Flavell RA. The different faces of Notch in T-helper-cell differentiation. Nat. Rev. Immunol. 2009;9:116–124. [PubMed] []
486. Kared H, et al. Jagged2-expressing hematopoietic progenitors promote regulatory T cell expansion in the periphery through notch signaling. Immunity. 2006;25:823–834. [PubMed] []
487. Cahill EF, Tobin LM, Carty F, Mahon BP, English K. Jagged-1 is required for the expansion of CD4+ CD25+ FoxP3+ regulatory T cells and tolerogenic dendritic cells by murine mesenchymal stromal cells. Stem Cell Res. Ther. 2015;6:19. [PMC free article] [PubMed] []
488. Samon JB, et al. Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells. Blood. 2008;112:1813–1821. [PMC free article] [PubMed] []
489. Charbonnier LM, Wang S, Georgiev P, Sefik E, Chatila TA. Control of peripheral tolerance by regulatory T cell-intrinsic Notch signaling. Nat. Immunol. 2015;16:1162–1173. [PMC free article] [PubMed] []
490. Zakiryanova GK, et al. Notch signaling defects in NK cells in patients with cancer. Cancer Immunol. Immunother. 2021;70:981–988. [PMC free article] [PubMed] []
491. Franklin RA, et al. The cellular and molecular origin of tumor-associated macrophages. Science. 2014;344:921–925. [PMC free article] [PubMed] []
492. Ye YC, et al. NOTCH Signaling via WNT regulates the proliferation of alternative, CCR2-independent tumor-associated macrophages in hepatocellular carcinoma. Cancer Res. 2019;79:4160–4172. [PubMed] []
493. Liu H, et al. Jagged1 promotes aromatase inhibitor resistance by modulating tumor-associated macrophage differentiation in breast cancer patients. Breast Cancer Res. Treat. 2017;166:95–107. [PubMed] []
494. Palaga T, et al. Notch signaling is activated by TLR stimulation and regulates macrophage functions. Eur. J. Immunol. 2008;38:174–183. [PubMed] []
495. Boonyatecha N, Sangphech N, Wongchana W, Kueanjinda P, Palaga T. Involvement of Notch signaling pathway in regulating IL-12 expression via c-Rel in activated macrophages. Mol. Immunol. 2012;51:255–262. [PMC free article] [PubMed] []
496. Wang YC, et al. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res. 2010;70:4840–4849. [PubMed] []
497. Zhao JL, et al. Forced activation of notch in macrophages represses tumor growth by upregulating miR-125a and disabling tumor-associated macrophages. Cancer Res. 2016;76:1403–1415. [PubMed] []
498. Saleem SJ, Conrad DH. Hematopoietic cytokine-induced transcriptional regulation and Notch signaling as modulators of MDSC expansion. Int Immunopharmacol. 2011;11:808–815. [PMC free article] [PubMed] []
499. Wang SH, et al. The blockage of Notch signalling promoted the generation of polymorphonuclear myeloid-derived suppressor cells with lower immunosuppression. Eur. J. Cancer. 2016;68:90–105. [PubMed] []
500. Jiang H, et al. Reduction of myeloid derived suppressor cells by inhibiting Notch pathway prevents the progression of endometriosis in mice model. Int. Immunopharmacol. 2020;82:106352. [PubMed] []
501. Yang Z, et al. Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-β1. J. Exp. Clin. Cancer Res. 2018;37:1. [PMC free article] [PubMed] []
502. Sierra RA, et al. Anti-jagged immunotherapy inhibits MDSCs and overcomes tumor-induced tolerance. Cancer Res. 2017;77:5628–5638. [PMC free article] [PubMed] []
503. Caiado F, et al. Bone marrow-derived CD11b+Jagged2+ cells promote epithelial-to-mesenchymal transition and metastasization in colorectal cancer. Cancer Res. 2013;73:4233–4246. [PubMed] []
504. Sprouse, M. L. et al. PMN-MDSCs enhance CTC metastatic properties through reciprocal interactions via ROS/notch/nodal signaling. Int. J. Mol. Sci.20, (2019). [PMC free article] [PubMed]
505. Peng D, et al. Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6/STAT3 and NO/NOTCH cross-talk signaling. Cancer Res. 2016;76:3156–3165. [PMC free article] [PubMed] []
506. Welte T, et al. Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nat. Cell Biol. 2016;18:632–644. [PMC free article] [PubMed] []
507. Yang M, et al. Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer. Br. J. Cancer. 2020;123:1404–1416. [PMC free article] [PubMed] []
508. Hu B, et al. Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell. 2012;149:1207–1220. [PMC free article] [PubMed] []
509. Procopio MG, et al. Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation. Nat. Cell Biol. 2015;17:1193–1204. [PMC free article] [PubMed] []
510. Demehri S, Turkoz A, Kopan R. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell. 2009;16:55–66. [PMC free article] [PubMed] []
511. Peng Y, et al. Direct contacts with colon cancer cells regulate the differentiation of bone marrow mesenchymal stem cells into tumor associated fibroblasts. Biochem. Biophys. Res. Commun. 2014;451:68–73. [PubMed] []
512. Su Q, et al. Jagged1 upregulation in prostate epithelial cells promotes formation of reactive stroma in the Pten null mouse model for prostate cancer. Oncogene. 2017;36:618–627. [PMC free article] [PubMed] []
513. Tsuyada A, et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 2012;72:2768–2779. [PMC free article] [PubMed] []
514. Liu C, et al. LSD1 stimulates cancer-associated fibroblasts to drive Notch3-dependent self-renewal of liver cancer stem-like cells. Cancer Res. 2018;78:938–949. [PubMed] []
515. Du Y, et al. Intracellular Notch1 signaling in cancer-associated fibroblasts dictates the plasticity and stemness of melanoma stem/initiating cells. Stem Cells. 2019;37:865–875. [PMC free article] [PubMed] []
516. Boelens MC, et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell. 2014;159:499–513. [PMC free article] [PubMed] []
517. Pelon F, et al. Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms. Nat. Commun. 2020;11:404. [PMC free article] [PubMed] []
518. Liubomirski Y, et al. Notch-mediated tumor-stroma-inflammation networks promote invasive properties and CXCL8 expression in triple-negative breast cancer. Front Immunol. 2019;10:804. [PMC free article] [PubMed] []
519. Strell C, et al. Impact of epithelial-stromal interactions on peritumoral fibroblasts in ductal carcinoma in situ. J. Natl Cancer Inst. 2019;111:983–995. [PMC free article] [PubMed] []
520. Gong J, et al. Increased expression of Fibulin-1 is associated with hepatocellular carcinoma progression by regulating the notch signaling pathway. Front Cell Dev. Biol. 2020;8:478. [PMC free article] [PubMed] []
521. Nandhu MS, et al. Development of a function-blocking antibody against Fibulin-3 as a targeted reagent for glioblastoma. Clin. Cancer Res. 2018;24:821–833. [PMC free article] [PubMed] []
522. Donovan LJ, Cha SE, Yale AR, Dreikorn S, Miyamoto A. Identification of a functional proprotein convertase cleavage site in microfibril-associated glycoprotein 2. Matrix Biol. 2013;32:117–122. [PubMed] []
523. Gordon-Weeks, A. et al. Tumour-derived laminin α5 (LAMA5) promotes colorectal liver metastasis growth, branching angiogenesis and notch pathway inhibition. Cancers (Basel)11, 630 (2019). [PMC free article] [PubMed]
524. Ogawa K, et al. Prometastatic secretome trafficking via exosomes initiates pancreatic cancer pulmonary metastasis. Cancer Lett. 2020;481:63–75. [PMC free article] [PubMed] []
525. Kuhnert F, et al. Dll4 blockade in stromal cells mediates antitumor effects in preclinical models of ovarian cancer. Cancer Res. 2015;75:4086–4096. [PubMed] []
526. Xu Z, et al. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth. Cancer Lett. 2016;372:118–127. [PubMed] []
527. Funahashi Y, et al. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res. 2008;68:4727–4735. [PMC free article] [PubMed] []
528. Boareto M, Jolly MK, Ben-Jacob E, Onuchic JN. Jagged mediates differences in normal and tumor angiogenesis by affecting tip-stalk fate decision. Proc. Natl Acad. Sci. USA. 2015;112:E3836–3844. [PMC free article] [PubMed] []
529. Banerjee D, et al. Notch suppresses angiogenesis and progression of hepatic metastases. Cancer Res. 2015;75:1592–1602. [PMC free article] [PubMed] []
530. Banerjee D, et al. High-dose radiation increases Notch1 in tumor vasculature. Int J. Radiat. Oncol. Biol. Phys. 2020;106:857–866. [PMC free article] [PubMed] []
531. Periz G, Fortini ME. Ca(2+)-ATPase function is required for intracellular trafficking of the Notch receptor in Drosophila. EMBO J. 1999;18:5983–5993. [PMC free article] [PubMed] []
532. Pagliaro L, Marchesini M, Roti G. Targeting oncogenic Notch signaling with SERCA inhibitors. J. Hematol. Oncol. 2021;14:8. [PMC free article] [PubMed] []
533. Malecki MJ, et al. Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. Mol. Cell Biol. 2006;26:4642–4651. [PMC free article] [PubMed] []
534. Roti G, et al. Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. Cancer Cell. 2013;23:390–405. [PMC free article] [PubMed] []
535. Roti G, et al. Leukemia-specific delivery of mutant NOTCH1 targeted therapy. J. Exp. Med. 2018;215:197–216. [PMC free article] [PubMed] []
536. Treiman M, Caspersen C, Christensen SB. A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca(2+)-ATPases. Trends Pharm. Sci. 1998;19:131–135. [PubMed] []
537. Jackisch C, et al. Delayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells. Clin. Cancer Res. 2000;6:2844–2850. [PubMed] []
538. Marchesini M, et al. Blockade of oncogenic NOTCH1 with the SERCA inhibitor CAD204520 in T cell acute lymphoblastic leukemia. Cell Chem. Biol. 2020;27:678–697.e613. [PMC free article] [PubMed] []
539. Mumm JS, et al. A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol. Cell. 2000;5:197–206. [PubMed] []
540. Cousin H, Abbruzzese G, Kerdavid E, Gaultier A, Alfandari D. Translocation of the cytoplasmic domain of ADAM13 to the nucleus is essential for Calpain8-a expression and cranial neural crest cell migration. Dev. Cell. 2011;20:256–263. [PMC free article] [PubMed] []
541. Saha N, Robev D, Himanen JP, Nikolov DB. ADAM proteases: emerging role and targeting of the non-catalytic domains. Cancer Lett. 2019;467:50–57. [PMC free article] [PubMed] []
542. Murthy A, et al. Notch activation by the metalloproteinase ADAM17 regulates myeloproliferation and atopic barrier immunity by suppressing epithelial cytokine synthesis. Immunity. 2012;36:105–119. [PubMed] []
543. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol. Asp. Med. 2008;29:258–289. [PMC free article] [PubMed] []
544. Lu HY, et al. Novel ADAM-17 inhibitor ZLDI-8 inhibits the proliferation and metastasis of chemo-resistant non-small-cell lung cancer by reversing Notch and epithelial mesenchymal transition in vitro and in vivo. Pharm. Res. 2019;148:104406. [PubMed] []
545. Yang B, et al. MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents. Cell Death Dis. 2019;10:784. [PMC free article] [PubMed] []
546. Guo Z, Jin X, Jia H. Inhibition of ADAM-17 more effectively down-regulates the Notch pathway than that of γ-secretase in renal carcinoma. J. Exp. Clin. Cancer Res. 2013;32:26. [PMC free article] [PubMed] []
547. Mullooly M, et al. ADAM10: a new player in breast cancer progression? Br. J. Cancer. 2015;113:945–951. [PMC free article] [PubMed] []
548. Kavian N, et al. Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum. 2010;62:3477–3487. [PubMed] []
549. Fortini ME. Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. Nat. Rev. Mol. Cell Biol. 2002;3:673–684. [PubMed] []
550. Mumm JS, Kopan R. Notch signaling: from the outside. Dev. Biol. 2000;228:151–165. [PubMed] []
551. Doody RS, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N. Engl. J. Med. 2013;369:341–350. [PubMed] []
552. Das A, et al. A novel triazole, NMK-T-057, induces autophagic cell death in breast cancer cells by inhibiting γ-secretase-mediated activation of Notch signaling. J. Biol. Chem. 2019;294:6733–6750. [PMC free article] [PubMed] []
553. Sardesai S, et al. A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer. Invest N. Drugs. 2020;38:1400–1410. [PMC free article] [PubMed] []
554. Han B, et al. Notch1 downregulation combined with interleukin-24 inhibits invasion and migration of hepatocellular carcinoma cells. World J. Gastroenterol. 2015;21:9727–9735. [PMC free article] [PubMed] []
555. Yong YL, et al. Gamma-secretase complex-dependent intramembrane proteolysis of CD147 regulates the Notch1 signaling pathway in hepatocellular carcinoma. J. Pathol. 2019;249:255–267. [PubMed] []
556. Pine SR. Rethinking gamma-secretase inhibitors for treatment of non-small-cell lung cancer: is notch the target? Clin. Cancer Res. 2018;24:6136–6141. [PMC free article] [PubMed] []
557. Akiyoshi T, et al. Gamma-secretase inhibitors enhance taxane-induced mitotic arrest and apoptosis in colon cancer cells. Gastroenterology. 2008;134:131–144. [PubMed] []
558. Cui D, et al. Notch pathway inhibition using PF-03084014, a γ-secretase inhibitor (GSI), enhances the antitumor effect of docetaxel in prostate cancer. Clin. Cancer Res. 2015;21:4619–4629. [PMC free article] [PubMed] []
559. Gilbert CA, Daou MC, Moser RP, Ross AH. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res. 2010;70:6870–6879. [PMC free article] [PubMed] []
560. Messersmith WA, et al. A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014. Clin. Cancer Res. 2015;21:60–67. [PubMed] []
561. Tolcher AW, et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J. Clin. Oncol. 2012;30:2348–2353. [PMC free article] [PubMed] []
562. Xu R, et al. Molecular and clinical effects of notch inhibition in glioma patients: a phase 0/i trial. Clin. Cancer Res. 2016;22:4786–4796. [PMC free article] [PubMed] []
563. Aung KL, et al. A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours. Invest N. Drugs. 2018;36:1026–1036. [PMC free article] [PubMed] []
564. Pant S, et al. A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer. Eur. J. Cancer. 2016;56:1–9. [PubMed] []
565. Massard C, et al. First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer. Ann. Oncol. 2018;29:1911–1917. [PubMed] []
566. Fouladi M, et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J. Clin. Oncol. 2011;29:3529–3534. [PMC free article] [PubMed] []
567. Cook N, et al. A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Br. J. Cancer. 2018;118:793–801. [PMC free article] [PubMed] []
568. Lee SM, et al. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer. 2015;121:432–440. [PMC free article] [PubMed] []
569. Diaz-Padilla I, et al. A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret, Chicago and California phase II consortia. Gynecol. Oncol. 2015;137:216–222. [PubMed] []
570. Strosberg, J. R. et al. A phase II study of RO4929097 in metastatic colorectal cancer. Eur. J. Cancer48, 997–1003 (2012). [PMC free article] [PubMed]
571. Kummar S, et al. Clinical activity of the γ-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis) J. Clin. Oncol. 2017;35:1561–1569. [PMC free article] [PubMed] []
572. Kang JH, et al. Gamma-secretase inhibitor reduces allergic pulmonary inflammation by modulating Th1 and Th2 responses. Am. J. Respir. Crit. Care Med. 2009;179:875–882. [PubMed] []
573. Kukar TL, et al. Substrate-targeting gamma-secretase modulators. Nature. 2008;453:925–929. [PMC free article] [PubMed] []
574. Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L. γ-Secretase inhibitors and modulators. Biochim. Biophys. Acta. 2013;1828:2898–2907. [PMC free article] [PubMed] []
575. Habets, R. A. et al. Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition. Sci. Transl. Med.11, eaau6246 (2019). [PubMed]
576. Zhang S, et al. A presenilin-1 mutation causes Alzheimer disease without affecting Notch signaling. Mol. Psychiatry. 2020;25:603–613. [PubMed] []
577. Soares HD, et al. The γ-secretase modulator, BMS-932481, modulates Aβ peptides in the plasma and cerebrospinal fluid of healthy volunteers. J. Pharm. Exp. Ther. 2016;358:138–150. [PMC free article] [PubMed] []
578. Murciano-Goroff YR, Taylor BS, Hyman DM, Schram AM. Toward a more precise future for oncology. Cancer Cell. 2020;37:431–442. [PMC free article] [PubMed] []
579. Hann CL, et al. A phase 1 study evaluating rovalpituzumab tesirine in frontline treatment of patients with extensive-stage SCLC. J. Thorac. Oncol. 2021;16:1582–1588. [PubMed] []
580. Simon DP, Giordano TJ, Hammer GD. Upregulated JAG1 enhances cell proliferation in adrenocortical carcinoma. Clin. Cancer Res. 2012;18:2452–2464. [PMC free article] [PubMed] []
581. Santagata S, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res. 2004;64:6854–6857. [PubMed] []
582. Masiero M, et al. Development of therapeutic anti-JAGGED1 antibodies for cancer therapy. Mol. Cancer Ther. 2019;18:2030–2042. [PMC free article] [PubMed] []
583. Zheng H, et al. Therapeutic antibody targeting tumor- and osteoblastic niche-derived Jagged1 sensitizes bone metastasis to chemotherapy. Cancer Cell. 2017;32:731–747.e736. [PMC free article] [PubMed] []
584. Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat. Rev. Clin. Oncol. 2017;14:549–561. [PMC free article] [PubMed] []
585. Puca, L. et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci. Transl. Med.11, eaav0891 (2019). [PMC free article] [PubMed]
586. Morgensztern D, et al. Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II TRINITY study. Clin. Cancer Res. 2019;25:6958–6966. [PMC free article] [PubMed] []
587. Johnson ML, et al. Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage-SCLC: results from the phase 3 MERU study. J. Thorac. Oncol. 2021;16:1570–1581. [PubMed] []
588. Blackhall F, et al. Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-High SCLC: results from the phase 3 TAHOE study. J. Thorac. Oncol. 2021;16:1547–1558. [PubMed] []
589. Malhotra J, et al. A phase 1-2 study of rovalpituzumab tesirine in combination with nivolumab plus or minus ipilimumab in patients with previously treated extensive-stage SCLC. J. Thorac. Oncol. 2021;16:1559–1569. [PubMed] []
590. Spino M, et al. Cell surface Notch ligand DLL3 is a therapeutic target in isocitrate dehydrogenase-mutant glioma. Clin. Cancer Res. 2019;25:1261–1271. [PMC free article] [PubMed] []
591. Morgensztern D, et al. SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study. Lung Cancer. 2020;145:126–131. [PMC free article] [PubMed] []
592. Ridgway J, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 2006;444:1083–1087. [PubMed] []
593. Liu SK, et al. Delta-like ligand 4-notch blockade and tumor radiation response. J. Natl Cancer Inst. 2011;103:1778–1798. [PubMed] []
594. Chiorean EG, et al. A phase i first-in-human study of enoticumab (REGN421), a fully human delta-like ligand 4 (Dll4) monoclonal antibody in patients with advanced solid tumors. Clin. Cancer Res. 2015;21:2695–2703. [PubMed] []
595. Smith DC, et al. A phase I dose escalation and expansion study of the anticancer stem cell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. Clin. Cancer Res. 2014;20:6295–6303. [PubMed] []
596. Coleman RL, et al. Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. Gynecol. Oncol. 2020;157:386–391. [PubMed] []
597. Li Y, et al. ABT-165, a dual variable domain immunoglobulin (DVD-Ig) targeting DLL4 and VEGF, demonstrates superior efficacy and favorable safety profiles in preclinical models. Mol. Cancer Ther. 2018;17:1039–1050. [PubMed] []
598. Jimeno A, et al. A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Invest N. Drugs. 2019;37:461–472. [PubMed] []
599. Long J, et al. JAG2/Notch2 inhibits intervertebral disc degeneration by modulating cell proliferation, apoptosis, and extracellular matrix. Arthritis Res. Ther. 2019;21:213. [PMC free article] [PubMed] []
600. Guo P, et al. Endothelial jagged-2 sustains hematopoietic stem and progenitor reconstitution after myelosuppression. J. Clin. Invest. 2017;127:4242–4256. [PMC free article] [PubMed] []
601. Yang Y, et al. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J. Clin. Invest. 2011;121:1373–1385. [PMC free article] [PubMed] []
602. Chen YT, et al. Jagged2 progressively increased expression from Stage I to III of Bladder Cancer and Melatonin-mediated downregulation of Notch/Jagged2 suppresses the Bladder Tumorigenesis via inhibiting PI3K/AKT/mTOR/MMPs signaling. Int J. Biol. Sci. 2020;16:2648–2662. [PMC free article] [PubMed] []
603. Santos MA, et al. Notch1 engagement by Delta-like-1 promotes differentiation of B lymphocytes to antibody-secreting cells. Proc. Natl Acad. Sci. USA. 2007;104:15454–15459. [PMC free article] [PubMed] []
604. Grabher C, von Boehmer H, Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat. Rev. Cancer. 2006;6:347–359. [PubMed] []
605. Liao W, et al. Antitumor activity of Notch‑1 inhibition in human colorectal carcinoma cells. Oncol. Rep. 2018;39:1063–1071. [PMC free article] [PubMed] []
606. Purow BW, et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 2005;65:2353–2363. [PubMed] []
607. Ferrarotto R, et al. Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors. J. Clin. Oncol. 2017;35:352–360. [PMC free article] [PubMed] []
608. Choi BY, et al. Inhibition of Notch1 induces population and suppressive activity of regulatory T cell in inflammatory arthritis. Theranostics. 2018;8:4795–4804. [PMC free article] [PubMed] []
609. Magee CN, et al. Notch-1 inhibition promotes immune regulation in transplantation via regulatory T cell-dependent mechanisms. Circulation. 2019;140:846–863. [PMC free article] [PubMed] []
610. Lee SY, et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci. 2009;100:920–926. [PMC free article] [PubMed] []
611. Mazur PK, et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc. Natl Acad. Sci. USA. 2010;107:13438–13443. [PMC free article] [PubMed] []
612. Massi D, et al. Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Mod. Pathol. 2006;19:246–254. [PubMed] []
613. Lin L, et al. Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer. Cancer Res. 2010;70:632–638. [PMC free article] [PubMed] []
614. Yamaguchi N, et al. NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Res. 2008;68:1881–1888. [PubMed] []
615. Hu ZI, et al. A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. Cancer Med. 2019;8:5148–5157. [PMC free article] [PubMed] []
616. Smith DC, et al. A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors. Invest N. Drugs. 2019;37:722–730. [PMC free article] [PubMed] []
617. Rosen LS, et al. A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody-drug conjugate, in patients with breast cancer and other advanced solid tumors. Invest N. Drugs. 2020;38:120–130. [PubMed] []
618. Harrison H, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010;70:709–718. [PMC free article] [PubMed] []
619. Xiu M, et al. Targeting Notch4 in cancer: molecular mechanisms and therapeutic perspectives. Cancer Manag. Res. 2021;13:7033–7045. [PMC free article] [PubMed] []
620. Nam Y, Sliz P, Song L, Aster JC, Blacklow SC. Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell. 2006;124:973–983. [PubMed] []
621. Tamura K, et al. Physical interaction between a novel domain of the receptor Notch and the transcription factor RBP-J kappa/Su(H) Curr. Biol. 1995;5:1416–1423. [PubMed] []
622. Hurtado C, et al. Disruption of NOTCH signaling by a small molecule inhibitor of the transcription factor RBPJ. Sci. Rep. 2019;9:10811. [PMC free article] [PubMed] []
623. Astudillo L, et al. The small molecule IMR-1 inhibits the notch transcriptional activation complex to suppress tumorigenesis. Cancer Res. 2016;76:3593–3603. [PMC free article] [PubMed] []
624. Lehal R, et al. Pharmacological disruption of the Notch transcription factor complex. Proc. Natl Acad. Sci. USA. 2020;117:16292–16301. [PMC free article] [PubMed] []
625. Koch U, Radtke F. Notch and cancer: a double-edged sword. Cell Mol. Life Sci. 2007;64:2746–2762. [PMC free article] [PubMed] []
626. Zage PE, et al. Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatr. Blood Cancer. 2012;58:682–689. [PMC free article] [PubMed] []
627. Yu XM, Phan T, Patel PN, Jaskula-Sztul R, Chen H. Chrysin activates Notch1 signaling and suppresses tumor growth of anaplastic thyroid carcinoma in vitro and in vivo. Cancer. 2013;119:774–781. [PMC free article] [PubMed] []
628. Patel PN, Yu XM, Jaskula-Sztul R, Chen H. Hesperetin activates the Notch1 signaling cascade, causes apoptosis, and induces cellular differentiation in anaplastic thyroid cancer. Ann. Surg. Oncol. 2014;21:S497–504. [PMC free article] [PubMed] []
629. Li K, et al. Modulation of Notch signaling by antibodies specific for the extracellular negative regulatory region of NOTCH3. J. Biol. Chem. 2008;283:8046–8054. [PubMed] []
630. Demitrack ES, Samuelson LC. Notch as a Driver of Gastric Epithelial Cell Proliferation. Cell Mol. Gastroenterol. Hepatol. 2017;3:323–330. [PMC free article] [PubMed] []
631. Real PJ, et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat. Med. 2009;15:50–58. [PMC free article] [PubMed] []
632. Luistro L, et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res. 2009;69:7672–7680. [PMC free article] [PubMed] []
633. Govaerts I, et al. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia. J. Hematol. Oncol. 2021;14:97. [PMC free article] [PubMed] []
634. Ito T. Intratumoral heterogeneity of Notch1 expression in small cell lung cancer. J. Thorac. Dis. 2018;10:1272–1275. [PMC free article] [PubMed] []
635. Marx V. Method of the Year: spatially resolved transcriptomics. Nat. Methods. 2021;18:9–14. [PubMed] []
636. Joutel A. Prospects for diminishing the impact of nonamyloid small-vessel diseases of the brain. Annu. Rev. Pharm. Toxicol. 2020;60:437–456. [PubMed] []
637. Matsuda M, et al. Recapitulating the human segmentation clock with pluripotent stem cells. Nature. 2020;580:124–129. [PubMed] []
638. Simpson MA, et al. Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and progressive bone loss. Nat. Genet. 2011;43:303–305. [PubMed] []
639. Isidor B, et al. Truncating mutations in the last exon of NOTCH2 cause a rare skeletal disorder with osteoporosis. Nat. Genet. 2011;43:306–308. [PubMed] []
640. Fukushima H, et al. NOTCH2 Hajdu-Cheney Mutations Escape SCF-Dependent Proteolysis to Promote Osteoporosis. Mol. Cell. 2017;68:645–658.e5. [PMC free article] [PubMed] []
641. Luxán G, et al. Mutations in the NOTCH pathway regulator MIB1 cause left ventricular noncompaction cardiomyopathy. Nat. Med. 2013;19:193–201. [PubMed] []
642. Towbin JA, Lorts A, Jefferies JL. Left ventricular non-compaction cardiomyopathy. Lancet. 2015;386:813–825. [PubMed] []
643. Stittrich A-B, et al. Mutations in NOTCH1 cause Adams-Oliver syndrome. Am. J. Hum. Genet. 2014;95:275–284. [PMC free article] [PubMed] []
644. Hassed SJ, et al. RBPJ mutations identified in two families affected by Adams-Oliver syndrome. Am. J. Hum. Genet. 2012;91:391–395. [PMC free article] [PubMed] []
645. Nus M, et al. Diet-induced aortic valve disease in mice haploinsufficient for the Notch pathway effector RBPJK/CSL. Arterioscler Thromb. Vasc. Biol. 2011;31:1580–1588. [PubMed] []
646. MacGrogan D, et al. Sequential ligand-dependent notch signaling activation regulates valve primordium formation and morphogenesis. Circ. Res. 2016;118:1480–1497. [PubMed] []
647. Wang Y, et al. Notch-Tnf signalling is required for development and homeostasis of arterial valves. Eur. Heart J. 2017;38:675–686. [PMC free article] [PubMed] []
648. Ikeda M, et al. Genetic evidence for association between NOTCH4 and schizophrenia supported by a GWAS follow-up study in a Japanese population. Mol. Psychiatry. 2013;18:636–638. [PubMed] []
649. Zhang Y, et al. Convergent lines of evidence support as a schizophrenia risk gene. J. Med. Genet. 2021;58:666–678. [PubMed] []
650. Morris HE, Neves KB, Montezano AC, MacLean MR, Touyz RM. Notch3 signalling and vascular remodelling in pulmonary arterial hypertension. Clin. Sci. 2019;133:2481–2498. [PMC free article] [PubMed] []
651. Li X, et al. Notch3 signaling promotes the development of pulmonary arterial hypertension. Nat. Med. 2009;15:1289–1297. [PMC free article] [PubMed] []
652. Zhang Y, et al. Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease. Blood. 2011;117:299–308. [PMC free article] [PubMed] []
653. Siveke JT, et al. Notch signaling is required for exocrine regeneration after acute pancreatitis. Gastroenterology. 2008;134:544–555. [PubMed] []
654. Golson ML, Loomes KM, Oakey R, Kaestner KH. Ductal malformation and pancreatitis in mice caused by conditional Jag1 deletion. Gastroenterology. 2009;136:1761–1771.e1. [PubMed] []
655. Zhang X, et al. Inhibition of Notch activity promotes pancreatic cytokeratin 5-positive cell differentiation to beta cells and improves glucose homeostasis following acute pancreatitis. Cell Death Dis. 2021;12:867. [PMC free article] [PubMed] []
656. John GR, et al. Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation. Nat. Med. 2002;8:1115–1121. [PubMed] []
657. Seifert T, Bauer J, Weissert R, Fazekas F, Storch MK. Notch1 and its ligand Jagged1 are present in remyelination in a T-cell- and antibody-mediated model of inflammatory demyelination. Acta Neuropathol. 2007;113:195–203. [PubMed] []
658. Zhang Y, et al. Notch1 signaling plays a role in regulating precursor differentiation during CNS remyelination. Proc. Natl Acad. Sci. USA. 2009;106:19162–19167. [PMC free article] [PubMed] []
659. Mu X, et al. The role of Notch signaling in muscle progenitor cell depletion and the rapid onset of histopathology in muscular dystrophy. Hum. Mol. Genet. 2015;24:2923–2937. [PMC free article] [PubMed] []
660. Vieira NM, et al. Jagged 1 rescues the Duchenne muscular dystrophy phenotype. Cell. 2015;163:1204–1213. [PMC free article] [PubMed] []
661. Tracy MR, Dormans JP, Kusumi K. Klippel-Feil syndrome: clinical features and current understanding of etiology. Clin. Orthop. Relat. Res. 2004;424:183–190. [PubMed] []
662. Karaca E, et al. Rare variants in the notch signaling pathway describe a novel type of autosomal recessive Klippel-Feil syndrome. Am. J. Med. Genet. A. 2015;167A:2795–2799. [PMC free article] [PubMed] []
663. Petruccelli E, et al. Alcohol activates Scabrous-notch to influence associated memories. Neuron. 2018;100:1209–1223. [PMC free article] [PubMed] []
664. Rosati E, et al. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood. 2009;113:856–865. [PubMed] []
665. Papayannidis C, et al. A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood Cancer J. 2015;5:e350. [PMC free article] [PubMed] []
666. Peereboom DM, et al. A phase II and pharmacodynamic Trial of RO4929097 for patients with recurrent/progressive glioblastoma. Neurosurgery. 2021;88:246–251. [PMC free article] [PubMed] []
667. Krop I, et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J. Clin. Oncol. 2012;30:2307–2313. [PubMed] []
668. Schott AF, et al. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin. Cancer Res. 2013;19:1512–1524. [PMC free article] [PubMed] []
669. Mir O, et al. Notch pathway inhibition with LY3039478 in soft tissue sarcoma and gastrointestinal stromal tumours. Eur. J. Cancer. 2018;103:88–97. [PubMed] []
670. Azaro A, et al. Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer. Invest N. Drugs. 2021;39:193–201. [PubMed] []
671. Borthakur G, et al. Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma. Cancer. 2021;127:372–380. [PubMed] []
672. Azaro A, et al. A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors. Invest N. Drugs. 2021;39:1089–1098. [PubMed] []
673. Rudin CM, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18:42–51. [PMC free article] [PubMed] []
674. McKeage MJ, et al. Phase IB trial of the anti-cancer stem cell DLL4-binding agent demcizumab with pemetrexed and carboplatin as first-line treatment of metastatic non-squamous NSCLC. Target Oncol. 2018;13:89–98. [PubMed] []

Articles from Signal Transduction and Targeted Therapy are provided here courtesy of Nature Publishing Group